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Abstract
The unrivalled specificity with which an antibody binds to the antigen that has 
stimulated its production, forms the basis for the development of a multi-million euro 
biotech industry based on mammalian cell culture.
However, the large-scale production of monoclonal antibodies, (MAb) is faced with a 
number of major problems. These include the poor yield of hybridised cells and the low 
productivity of MAb in culture.
This thesis investigates aspects of the latter of these problems by attempting to design 
optimised culture conditions for growth and antibody production for a number of 
hybridoma producing cell lines namely the hybridoma producing anti-topoisomerase Il­
ex MAb, 4/2D (IgGi), the hybridoma producing MAb 1/11C (IgGi), the hybridoma 
producing MAb to a novel complex of cytokeratin 6 and 9, 5C3 (IgGi) and the 
hybridoma producing anti-mdr-1 MAb 6/1C (IgGi).
Assay techniques such as Radio Immunodiffusion and ELISA were investigated to 
determine their reliability in quantifying monoclonal antibody in cell culture 
supernatant. The effect of commercially available serum free and protein free media on 
growth characteristics and productivity of the hybridoma producing cell lines were also 
examined. Finally, the environmental aspects of cell culture conditions (temperature 
and mixing) were considered.
A new system for quantifying MAb in supernatant was evaluated. This system, 
involving nephelometry (a turbidity-based system) was compared with the commonly 
used methods of ELISA and RID. The main advantage of such a system is that it gives 
real time analysis of antibody productivity whereas the RID method takes 2-3 days and 
the ELISA takes approximately 4 hours complete.
After evaluation on small-scale runs, a number of 10L fermentation runs were designed 
and executed to examine MAb production in two of the hybridoma producing cell lines 
4/2D and 5C3 at large scale.
As a result of varying temperature and agitation, the culture conditions of 37 C and 
lOOrpm were found to be the most efficient for cell growth and antibody productivity in 
all cases except the culture of 4/2D in PFHM II. In this case, the most efficient culture 
conditions in terms of MAb production were found to be 34 C and 200rpm. This result 
highlights the fact that each cell line has its own customised culture conditions.
Using the optimised culture conditions at large scale, it was found that quantities (mg/L) 
of antibody similar to those observed at small scale were being produced. The main 
difference however was that peak antibody productivity was occurring at day 3 and then 
decreasing thereafter. The exception to this was the culture of the hybridoma producing 
MAb, 5C3 in protein free conditions. Not only were antibody quantities increasing 
throughout the culture but also the levels of antibody produced were 10-15 fold in 
excess of the other cell line in both SSM and PFM. The results are discussed in detail 
and recommendations are made for future work.
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Section 1 Introduction
1.1 The Industry
The unrivalled specificity with which an antibody binds to the antigen that stimulated its 
production forms the basis of its use. If monoclonal antibodies are produced against an 
antigen unique to a particular type of cell, these antibodies should selectively bind only 
at the surface of these cells. In this so called "magic bullet" effect, binding of the 
antibody could potentially trigger destruction of a particular cell, be it cancer cells, 
virally infected cells or microbial cells at the site of an infection (Walsh, 2001; Little et 
al, 2000).
By the end of 2001, 13 monoclonal antibody based therapeutic agents had gained 
regulatory approval by the FDA (Table 1.1). A further 59 are currently undergoing 
evaluation. The most common of these are in the area of cancer treatment (32 
products).
Table 1.1 FDA approved therapeutic antibodies (adapted from Borrebaeck, 2001)
Product Specificity Indication Year Approved
Orthoclotne OKT®3 
(muromonab-CD3)
CD3
Acute kidney transplant 
rejection
1986
ReoPro® abcixiMAb GpIIb/IIIa Prevention of blood clotting 1994
Rituxan® (rituxiMAb) CD20 Non Hodgkin’s lymphoma 1997
Zenapax (DaclizuMAb) CD25 (IL2R)
Acute kidney transplant 
rejection
1997
Remicade (InflixiMAb) TNFa Crohn's disease 1998
Simulect® (basilixiMAb) CD25 (IL2R)
Acute kidney transplant 
rejection.
1998
Synagis® (palivizuMAb) RSV Respiratory syncytis virus 1996
Thymoglobulin® Polyclonal abs
Acute kidney transplant 
rejection
1998
Herceptin (TrastuzuMAb) Her2 Metastatic breast cancer 2000
CroFab® Snake Venom Rattlesnake antidote 2000
Campath® (alerntuzuMAb) CD52 Chronic lymphocytic leukaemia 2001
Mylotarg®
(gemtuzuMAbozogamicin)
CD33 Acute Myeloid leukaemia 2000
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Due to the increased interest in the development of monoclonal antibodies (Mabs), the 
large-scale manufacturing sector of the industry is expanding rapidly. Volumes of 
commercialised antibodies are expected to increase from a production volume of 257kg 
in 1999 to 558kg in 2002. It is expected within the next year or two, that the average 
volume of monoclonal antibody produced by an individual manufacturer will increase 
by 20%, (from present averages of 75kg to 100kg by the end of 2002). Currently there 
are approximately 235 MAbs in development and by 2010, it is expected that 100 of 
these will be commercialised (Dutton, 2001; Kelley, 2001; Reichert, 2001).
Approximately half of the $5 billion annual turnover of the biotech industry is based 
upon large-scale mammalian cell culture processes. Table 1.2 shows examples of the 
revenue growth rates expected for some of these products over a five-year period.
Currently Ireland plays host to approximately 31 biotech companies (Bioresearch 
Ireland, 2001). Among them is the successful indigenous company Trinity Biotech pic, 
(formed in 1992) that specialises in the development, manufacture and marketing of 
diagnostic products which utilise immunoassay technologies. Trinity Biotech markets 
over 120 products through distributors in 80 countries worldwide. Numerous 
international companies have set up business in Ireland in the last few years many of 
which have experienced significant revenue growth over the past five years. Amongst 
these companies are Genzyme, Genemedics and Wyeth.
Table 1.2 Antibody and IgG fusion proteins presently on the market and expected 
growth figures for 2005.
Estimated Sales 
($ million)
2000
$
2005
$
OKT3 30 35
Panorex 43 69
ReoPro 418 500
Rituxan A ll 778
Zenapax 21 43
Simulect 30 70
Synagis 427 650
Remicade 371 900
Enbrel 652 1225
Her cep tin 270 559
Myelotarg 20 144
Campath 0 110
Total $2710 $5803
(Plus in Development $7383)
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1.1.1 Antibodies
When the body is challenged against a foreign substance (antigen), it responds by 
producing high affinity binding proteins, called antibodies (Mader, 1996). These 
proteins vary in terms of function, cell surface density, tissue distribution, specificity,
avidity and isotype (Breedveld, 2001).
Antibodies are Y shaped molecules, which are composed of a basic four-chain (two 
heavy and two light chains) structure linked together by disulphide bonds (Figure 1.1). 
When the sequence of an antibody is examined closely it is clear that there are regions 
of extensive homology and regions of dissimilarity. The latter region is called the 
variable region and the homologous area is known as the constant region. The variable 
region is the critical site for antigen binding and is the distinctive feature that is unique 
to each individual antibody molecule (Soloski, 2000).
The main site of attachment to the epitope on the antigen-binding sites is called the 
complementarity-determining region (CDR). Different isotypes of immunoglobulins 
are defined by the structures of immunoglobulin CDR regions (Breedveld, 2000). There 
are five different classes of antibody: IgG, IgM, IgA, IgE and IgD. The most common 
and useful immunoglobulin is IgG due to its’ 
long biological half-life (>20 days) and its’
ability to interact with the human immune system 
(van Dijk & van de Winkle, 2001).
Antigen binding sices, 
Com plem entarity D eterm ining Region
Light chain '  '  Light chain
 ^ C o n sta n t
The antibody molecule
Figure 1.1 Structure of an antibody molecule
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1.1.2 Antibody mechanism of action
Antibodies operate via a number of potential mechanisms. The most commonly known 
method of destruction is by blocking or sterically hindering the function of the target 
antigen. A prime example of an antibody operating like this is in the use of anti-tumour 
necrosis factor a  (TNF-a) MAb. This MAb is used in the treatment of rheumatoid 
arthritis and Crohn’s disease. The MAb binds and blocks the action of the pro- 
inflammatory cytokine (Glennie & Johnson, 2000). Similarly, MAb can prevent cell­
cell interactions by blocking receptor ligand interaction. Antibodies may also kill cells 
by activating the complement cascade at the cell surface, with consequent lysis; or by 
binding to receptors on the surface of specialised effector cells, (such as phagocytes or 
killer cells) and triggering phagocytosis or antibody-dependent cell-mediated cytolysis 
(Gorter & Meri, 2000).
With the human immune system in mind, researchers wanted to replicate the operation 
of the immune system outside the human body. Here they could control the steps that 
were occurring and they could harvest the production of a single source of specific 
antibody. It was clear that every plasma cell derived from a B cell secretes antibody 
against a specific antigen. They believed that if  a way could be found of harvesting 
these B cells and culturing them in vitro, then they could possibly develop therapeutics 
against a number of diseases and thus develop diagnostic kits for quicker identification 
of disease. This eventually, led to the creation of monoclonal antibodies.
1.1.3 Monoclonal Antibodies
In 1975, George Kohler and Cesar Milstein published a paper describing their new 
method for producing monoclonal antibodies (Kohler & Milstein, 1975). This paper 
described fusing two types of cells to form a hybridoma. The partner cells used were an 
antibody secreting B cell and a myeloma cell (continuously dividing B cell tumour). 
The resulting hybridoma combined the properties of each constituent, continuously 
secreting a single type of antibody when cultured in the ascities fluid in a mouse 
abdomen. This new method had a profound effect on immunology as it provides a 
powerful new method to search for cancer antigens due to their ability to recognise
4
minute differences between molecules and so scientists could at last produce defined 
antibodies in sufficient quantities to put antibody-based therapies to use. In 1984, 
Kohler and Milstein received the Nobel Prize for their discovery.
1.1.4 Monoclonal Antibody Production
To produce MAbs, mice are immunised by injection with the antigen to which the MAb 
is required. When an immune response has been raised, the B cells are harvested from 
the rodent, usually the spleen, and these are fused with immortal myleoma cells by 
fusion of the cell membranes with polyethylene glycol (PEG). This fusion procedure 
results in the production of immortalised hybrid cells or hybridomas. The remainder of 
the process is then one of isolation and production of hybridoma cells, which have 
retained the ability of the B cell to produce the desired antibody and the growth 
characteristics of the myleoma cell. The process of MAb production can therefore be 
considered in three parts: immunisation, fusion and selection of the required hybridoma 
(McCardle, 1998). In Figure 1.2 a pictorial representation of the procedure involved in 
MAb production can be seen.
Monoclonal Antibody Production
Antibody-form ing cells are fused w ith 
cultivated tumor cells to form  hybridon
H
antibody production
Antibody-producing 
hybridom as cloned
Monoclonal antibodies 
isolated for cultivation
Figure 1.2 Monoclonal Antibody Production.
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1.1.5 Humanised Antibodies
Murine monoclonal antibodies although widely used in the area of clinical diagnostics, 
have not had the amount of success originally expected in human therapy. Two major 
problems in the therapeutic use of murine monoclonal antibodies were identified at an 
early stage. Firstly, the specificity associated with monoclonal antibodies for their 
therapeutic targets did not always trigger the appropriate therapeutic response. 
Secondly, when murine antibodies were identified to work in vivo, the human immune 
system recognised them as foreign and a human anti-murine antibody immune response 
(HAMA) occurred (King, 1998). The OKT3 antibody used in the prevention of organ 
rejection overcame this problem by administering only single shot or via multiple use 
within a short period of a week to ten days before the antibody response developed. 
This antibody achieved FDA approval in 1986 (Clark, 2000a; Sgro, 1995; Goldstein et 
al., 1985).
In an attempt to reduce and even eliminate the immunogenicity of murine monoclonal 
chimeric antibodies, recombinant DNA technology was applied. These methods 
involved splicing the gene sequence that codes for the mouse variable regions (at the 
antigen-binding site, the Complementary Determining Region) to the constant regions 
of a human antibody (Clark, 2000b; Jones, 1986). The resultant hybrid structures were 
more than 70% human and they contained the desired antigen-binding specificity of the 
parent murine monoclonal but were also less immunogenic when administered to 
humans.
The generation of human MAbs has proven to be problematic. Firstly, it is not 
appropriate to immunise humans for particular antigens; hence a suitable source of 
immune lymphocytes is not readily available. To overcome this problem, a system 
involving in vitro immunisation of human B cells was developed. The major drawbacks 
with these techniques were that MAbs generated are often of the IgM subclass, with low 
to intermediate affinities for the antigen (King, 1998). Although reports exist from the 
early 90's attempts at using human myeloma cell lines were problematic (Nilsson, 
1971). In recent times Karpas et al. (2001) described a human myeloma cell line 
suitable for the generation of human monoclonal antibodies a technology, which was a 
major step away from the use of murine cell lines.
Humanised antibodies are also prepared by antibody engineering. In this instance, the 
antigen binding CDR’s are grafted into human V region framework regions. The 
resultant antibodies are entirely human in nature except for these short sequences and 
should therefore have the same characteristics as a native human antibody (Walsh, 
2001; Glennie & Johnston, 2000; Little et ah, 2000; Berkower, 1996). Hundreds of 
fully humanised antibodies have been produced using this technology. Clinical trials 
have been carried out on some but to date no significant immune response has been 
elicited.
Early Monoclonal Antibodies
Chimeric 
33% mouse protein
“Humanized”
~ 10% mouse protein
HuMAb Antibodies
100% HumanMurine 
100% mouse protein
Figure 1.3 Evolution of antibodies
An alternative approach to the generation of human MAbs is the genetic manipulation 
of mice to disable the production of mouse immunoglobulin and to functionally replace 
them with human antibody producing genes. These transgenic mice like the 
“xenomouse” developed by Abgenix (CA, US) can then produce MAbs in response to 
immunisation to a variety of diverse antigens. A lot of success has been achieved with 
such technology, several high affinity antibodies have been generated (Fishwild et ah, 
1996, Green, 1999, Yang et ah, 2001). MAbs from Xenomouse ™ animals have been 
shown to have therapeutic potential and both in vitro and in vivo, and appear to have the 
pharmacokinetics of normal human antibodies based on clinical trials. Thus this 
Xenomouse ™ technology should be possible to generate high affinity, fully human 
MAbs.
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1.1.6 Applications of monoclonal Antibodies
Monoclonal antibodies have a large role to play in the diagnosis and treatment of life 
threatening diseases. Such as cancer and autoimmune disease, hi recent years, major 
advances have been made in the areas of drug discovery, diagnosis and delivery to the 
target organ (Reff & Heard, 2001; Govindan et al., 2000; Khaw, 1999; Cragg et al.,
1999)
1.1.7 Diagnostics
Monoclonal antibodies have been used in the design of sensitive detection assays such 
as Enzyme Linked Immunosorbent Assays (ELISAs). These tests have been used to 
detect normal and auto antibody levels, determine the presence and levels of auto 
antigens, viral/bacterial and other environmental antigens as well as assessing the levels 
of normal components in bodily fluids e.g. pregnancy testing kits (Borrebaeck, 2000). 
MAbs have also made an impact on the isolation and purification of molecules. In 
some applications a given MAb can be coupled to an insoluble surface and used to 
affinity purify a molecule of interest. This approach allows a several-fold purification 
to be performed in one step.
Cancer Imaging
Radioimmunodetection (RAID) is another diagnostic method that takes advantage of 
tumour specific or tumour associated radiolabeled monoclonal antibodies or other 
biological molecules, which bind to malignant tissue to diagnose the extent of disease in 
cancer patients.
RAID was introduced into clinical practice in an effort to provide a more accurate 
means of determining the extent of the malignant process in cancer patients. Two 
researchers, Pressman and Keighly (1948) were the first to demonstrate the use of 
radiolabelled antibodies in the targeting of a specific organ or tissue. They showed that 
the immunoglobulin fraction containing antibodies to normal rat kidneys could be
radiolabelled with l31I (Iodine-131) and used to specifically target the kidneys in vivo. 
This work suggested the potential of antibodies for tumour imaging and therapy.
Initially however, a number of problems were encountered with this new technology. 
There was a lack of specific targets associated with various tumours used in in vivo 
trials and appropriate radiolabels for tagging the available antibodies. However, recent 
advances in monoclonal antibodies and improved radiolabeling methods have enabled 
investigators to image a host of cancers related to the breast (Burak et ah, 1998), lung, 
cervix and pancreas (Gold et ah, 2001).
Radioimmunotherapy has advantages over other typically used methods such as the 
computed tomographic scans (CT). CT scans depend on a change in size and 
architecture of organs. Radiolabeled monoclonals have the ability to detect abnormal 
cells at an early stage because of the expression of tumour antigens. Once cancer is 
diagnosed, accurate staging is important in deciding the most appropriate therapy. 
Later, during follow up surgery, levels of tumour antigens such as carcinoembyronic 
antigen for colon cancer or prostate specific antigen in prostate cancer, may indicate 
reoccurrence of the cancer long before conventional methods can reliably identify the 
disease material (Berkower, 1996).
1.1.8 Quantifying Monoclonal Antibodies
Radial Immunodiffusion (RID)
Radial Immunodiffusion evolved by Mancini et ah, (1965) and Fahey & McKelvey 
(1965), is a classical diagnostic method to determine the levels of IgG subclasses. This 
assay is widely used and is very easy to perform. However, when monitoring large and 
frequent samples the relatively long incubation times (approximately 72 hours) are a 
disadvantage.
The method involves antigen diffusing rapidly from a cylindrical well through an 
agarose gel containing an appropriate monospecific antibody. Antigen-antibody 
complexes, are formed, which under the correct conditions will form a precipitation 
ring. The ring size increases until equilibrium is reached between the formation and
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breakdown of these complexes this point is termed “completion”. A linear relationship 
exists between the square of the ring diameter and the antigen concentration. By 
measuring the ring diameters produced by a number of samples of known concentration, 
a calibration curve can be constructed. The concentration of the antigen in the unknown 
sample may be determined by measuring the ring diameter produced and reading it off 
the calibration curve.
ELISA (Enzyme Linked Immunosorbent Assay)
The basis of the ELISA method is that enzymes can be attached to antibodies without 
the loss of activity. The subsequent addition of a suitable substrate leads to colour 
development, which, can then be quantitated spectrophotometrically. Enzyme detection 
has become the standard method for most laboratory immunoassays and the most 
commonly used is the ‘sandwich’ ELISA. This involves immobilising an antigen to a 
solid support and incubating with the sample-containing antibody (primary antibody). 
After binding of the primary antibody, excess enzyme labelled secondary antibody is 
added. Commonly used enzymes are horseradish peroxidase (HRP) and alkaline 
phosphatase (AP). These convert substrate to product with a high turnover rate to allow 
the generation of a large amount of coloured product, which can be quantified 
(Crowther, 2001; King, 1998).
Nephelometry
Nephelometry is used to determine IgG concentrations in cell culture supernatants. The 
MININEPH (Binding Site, UK) used in this work is an endpoint nephelometer that uses 
the measurement of light scattered by an antibody/antigen complex to determine protein 
concentrations.
The light source is a diode laser that emits at 670nm. The focused light passes through 
a cuvette containing the reaction mixture, where the antibody/antigen complexes cause 
light to be scattered. The scatter is proportional to the amount of anti gen/ antibody 
complexes that have formed, and is detected by a photodiode.
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Advantages of nephelometry are the relatively short incubation time and ability to 
measure small concentrations of antibody. Another advantage is that nephelometry 
assays may be readily automated and are therefore suitable for the routine measurement 
of IgG subclasses in large numbers of samples (Baker et al., 2002).
1.2 Large Scale Mammalian Cell Culture
1.2.1 Introduction
The increased demand for animal cell derived products has stimulated the development 
of newer and more efficient apparatus and processes, in which manufacturers are able to 
harvest higher concentrations of cells.
With regards to the production of monoclonal antibodies, there are two major 
bottlenecks that must be overcome, these include the poor yield of hybridised cells and 
the low cellular productivity of monoclonal antibodies in culture (Kundu, 1998). These 
problems can be overcome by improving the design of available methods of culturing 
cells at large scale and involves the use of more efficient high-density culture methods.
The theory behind scale up is to take a process, producing a product at small scale and 
to increase the scale of production using a variety of means (Chisti, 1993; Resiman, 
1993). It should be noted that when dealing with scale up it is important to adhere as 
closely as possible to the parameters established in the initial production phase. A 
typical scale up procedure normally involves taking a 1 ml vial of cells from the working 
cell bank (WCB) and scaling up to a maximum of 30,000 litres depending on the 
requirements of the process (Freshney, 1994). This is usually achieved by one of two 
methods:
■ Increasing the number of units already in operation
■ Increasing the size of the culture system without increasing the number of 
vessels involved (McGlinchey et al., 1998).
The latter method is probably the most commonly used when a high concentration of 
product is required.
Scaling up a process can be fraught with problems and there are a number of criteria, 
which must be taken into consideration. Firstly, mammalian cell lines are classified as 
either anchorage-dependent or anchorage-independent based on their growth 
characteristics in culture. Cells that can grow in suspension are easily scaled up through 
to production level using fermentation vessels of increasing size.
Anchorage-dependent cells tend to prove more difficult to scale-up. They require a 
surface for attachment in order to proliferate. Due to this, they are normally grown in 
hollow fibre reactors or in stirred tank reactors using microcarriers which act as a 
substratum for growth.
Mixing rates and aeration are major parameters that affect the growth of cells in culture 
(Section 1.2.4 and 1.2.5). In a stirred tank reactor cells require constant agitation for 
purposes of acquiring appropriate quantities of oxygen and nutrients. The main aim of 
mixing and aeration is to achieve non-turbulent, streamlined bulk flow patterns within 
the culture fluid so that mechanical stress damage on the cells is minimised (Griffiths,
1988).
The choice of medium used in culture is another critical parameter in the growth of 
cells, antibody productivity and downstream processing (Section 1.2.2).
1.2.2 Choice of Medium
1.2.2.1 Serum-supplemented Medium
Serum is defined as the "black box” of mammalian cell culture. It is composed of a 
complex mixture of more than 100 poorly defined biomolecules with different growth 
promoting and inhibiting activities. These components include hormonal factors, 
attachment factors, growth factors, proteins, lipids, and inorganic trace elements 
(Jayme, 1991; Griffiths, 1987). The exact composition is not entirely known and its 
constituents can vary in concentration from batch to batch. Serum is considered to be a 
very important component of any culture medium typically constituting 5-10% (v/v) of 
the growth medium for cells. There are a number of disadvantages when culturing cells 
in serum.
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■ Serum may contain selective inhibitors, bacterial toxins, lipids and polyamine 
oxidases, which form cytotoxic polyaminoaldehydes upon reaction with 
polyamines such as sperimidine (Cartwright & Shah, 1995).
■ Serum screening is necessary due to the large batch to batch variation. This is a 
costly and time-consuming process. Also one serum type will not satisfy all cell 
types due to the different cellular requirements of cells depending on their origin 
either in the body, species specificity or depending on whether cells are normal 
or transformed. Separate screening has to be carried out for each cell line.
■ The supply of serum is not always guaranteed. In times of biological drought 
and disease, social or economic downturns, it may be difficult to obtain a 
particular serum from a particular country. This may also result in an increase in 
cost of other serums due to the increased demand (Mizrahi & Lazar, 1988).
■ Serum also tends to interfere with the production of monoclonal antibodies, 
resulting in more and complicated downstream processing steps. Often affinity 
column chromatography, gel filtration and ion exchange steps are required. 
These steps are time consuming and labour intensive, with extra purification 
steps required to remove traces of serum, leading to a costly downstream process 
and reductions in final MAb yield (Cartwright & Shah, 1995).
■ Outbreaks of disease such as CJD and foot and mouth in livestock has been 
making it harder to source and use foetal calf serum safely.
Because of these reasons, regulatory authorities do not allow the use of serum during 
the harvesting of human therapeutic proteins.
1.2.2.2 Serum-free Medium
Serum-free Media (SFM) consist of basal media supplemented with a series of serum- 
free additives. The most commonly used basal media are: Dublecco’s modified Eagle’s 
medium (DMEM), Hams F-12, Roswell Park Memorial Institute (RPMI-1640) and 
Iscove’s Modified Dubleccos Medium (IMDM). These can be used in combination 
with each other or singly. Differences have been observed between basal media in 
terms of the growth promoting effects, hence careful consideration should be taken 
when choosing a basal media (Kitano et al., 1986; Murakami et a l, 1982a).
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Each cell line will have different requirements for cell growth and productivity. 
Generally, additives are divided into the following groups:
Energy Sources
Carbohydrates are the main energy source for cultured cells with glucose, glutamine and 
glutamax (alanine-glutamine dipeptide) being the most commonly used. The 
concentration of specific carbohydrate sources used can vary in the range 5-20mM. 
When added at a high concentration, it is rapidly converted to lactate, which lowers the 
pH to inhibitory levels. Glutamine is another important energy source. The amino acid 
L-glutamine is sometimes added in conjunction with glucose to reduce the degree of 
conversion of glucose to lactate (Mizrahi and Lazar, 1988). Other sources that may be 
used include fructose (Mochizuki et al., 1993) sucrose, maltose, galactose and mannose.
Amino Acids
Animal cells have a requirement for non-essential amino acids such as arginine, lysine, 
cystine and histidine. Other amino acids are often added to compensate for a particular 
cell lines’ inability to make them. Blasey et al. (1989) found that hybridoma cells 
instantly started dying once amino acids were limited. When L-glutamine was depleted 
both cell growth and MAb production was halted.
Vitamins
Vitamins of the B group are necessary for cell growth and replication. Many vitamins 
act as co-factors. The vitamins most commonly added to basal media include biotin, 
choline, folic acid, pantothenic acid, thiamine, inositol and ethanolamine (Kovar & 
Franek, 1985; Murakami et al., 1982b).
Lipids
Lipids, especially unsaturated fatty acids, are well known nutrients of serum-free media 
for animal cell cultivation in vitro. Requirements for these substances are mainly 
associated with their role as membrane components. In certain cases they are linked
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directly with the control of cell growth (Kovár, 1987). Typical examples of lipids in 
culture media include the fatty acids linoleic acid, cholesterol and lipoproteins (Darfler, 
1990b; Sato, 1984).
Transporter Proteins
Typical transport proteins include transferrin and albumin. Transferrin functions in 
acting as an iron transporter. The functions of iron include, acting as a co-factor in 
enzymatic reactions and it is closely associated with DNA synthesis and cell growth 
(Kovár and Franék, 1987; Kovár and Franék, 1984). Flowever, in the development of 
protein-free media it is desirable to find an alternative to transferrin because of its high 
cost and the difficulty in removing it from culture media during downstream processing.
• o_i_ t
The effect of replacing transferrin with ferric chloride (FeCl ) on two hybndoma cell 
lines was examined (Sanfelieu et al., 1994). The results showed comparable cell 
growth characteristics and antibody productivity in one cell line. In the other cell line, 
growth was less but MAb production was similar to the control media containing 
transferrin. In another study Metcalf et al. (1994) examined the effect of replacing 
transferrin with 2-hydroxy-2,4,6-cycloheptarin-l-one (tropolone). This showed that 
tropolone could also replace transferrin in a large-scale culture system.
Hormones and Growth Promoters
Growth factors are termed mitogenic polypeptides capable of promoting DNA synthesis 
in resting cells and keeping cycling cells from entering the resting phase (Go) (Mizrahi 
& Lazar, 1988). The most well know examples of growth promoters include insulin 
and hydrocortisone. Insulin is considered essential in the serum-free culture of 
hybridoma cells. The functions served by insulin include the stimulation of uridine and 
glucose uptake and the syntheses of RNA, protein and lipid. Insulin is generally added 
to the culture medium in the concentration range 5-10p,g/mL (Zhou & Hu, 1997; Martial 
et al., 1994; Glassy et al., 1988; Kovár, 1986b). Other factors such as NGF (nerve 
growth factor) and EGF (epidermal growth factor) are added depending on the cell line.
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Trace Elements
This group generally includes additives such as iron, zinc, copper and selenium. Many 
function as enzyme co-factors. Selenium is thought to have a special function in 
protecting cells from the toxic effects of peroxides (Kovar, 1988; Kovar & Franek, 
1986). Their role in cell culture cannot be underestimated. Cleveland et al. (1983) 
developed a protein-free medium (PFM) replacing insulin, transferrin, albumin, and 
liposomes with the trace elements Al, Ag, Ba, Br, Cd, Co, Cr, F, Ge, I, Rb, Zr, Cu, Mn, 
Ni, Sn, Zn, Mo, V, Fe, Si, and Se. Immunoglobulin production was comparable for all 
cell lines tested between serum supplemented medium (SSM) and protein free medium 
with ten out of the eleven cell lines having comparable growth rates.
Numerous serum-free media have been developed, which have the ability to maintain 
the growth of mammalian cell lines in culture. Selected reviews, which deal with the 
development of SFM include the following: (Chua et al., 1994; Simonson et al., 1994; 
Chen et al., 1993; Federspiel et al, 1991; Lang, et al., 1991; Mariani et al., 1991; 
Merten and Litwin, 1991; Morrow, 1990; Blasey & Winzer, 1989; Clark et al., 1989; 
Wolfe et al., 1988; Shacter 1987; Tharakan et al., 1986a; Kovar and Franek, 1986; 
Kawamoto et al., 1986; Tharakan et al., 1986b). Commercially available serum-free 
media differ widely in terms of their protein concentration, price and ability to maintain 
the growth and productivity of specific hybridoma cell lines. In the commercial arena, 
two other types of specific serum-free media exist:
1.2.2.3 Protein-free Medium (PFM)
This medium does not contain any quantifiable levels of protein. The development of 
protein-free media is a major step forward in the research and development of 
hybridoma culture and MAb production. Protein-free media allows easier purification 
of antibody because the culture supernatant is devoid of any background external 
macromolecules (Fran k and Dolnikova, 1991, Tarleton, 1991). Numerous 
investigators have developed protein-free media replacing protein-based additives with 
trace elements, vitamins and other agents (Voigt and Zintl, 1999; Nagira et al., 1995; 
Bertheussen, 1993; Darfler, 1990a; Cleveland et al., 1983).
16
1.2.2.4 Chemically Defined Medium (CDM)
The use of chemically defined medium for the cultivation of hybridoma cells provides 
several advantages over the classical serum-supplemented medium. The use of defined 
media allows a quantitative study of the influence of each individual constituent and its 
concentration on cell growth and on monoclonal antibody synthesis and secretion. 
Other advantages include a reduction in the risk of contamination from protein-based 
products and higher antibody purity (Stoll et al., 1996; Schneider, 1989)
1.2.2.5 Advantages of Serum-free Media
“ Serum-free media reduces the risk of viral and endotoxin contamination often 
associated with serum.
■ A growth media which eliminates any uncertainty regarding the identity and 
concentration of its constituents, is a major advantage when attempting to obtain 
product approval from the relevant regulatory authority.
■ It has been shown that cells adapted to grow in SFM can have a product 
secretory capacity more than that obtained in SSM (Darfler, 1990a; Clark et al., 
1989; Tharakan et al., 1986a)
■ Monoclonal antibody purification is more efficient and economical compared to 
the separation of MAb cultured in SSM or ascitic fluid. In excess of 90% purity 
can be obtained (Graf et al., 1991). Large volumes of supernatant can be 
applied to the chromatographic columns due to the low protein concentration of 
the serum-free media.
1.2.2.6 Disadvantages of SFM
■ The process of adapting cells to serum-free media from serum-supplemented 
media is a slow time consuming process. It involves taking cells cultured in 
SSM and “weaning" them into SFM over a number of passages, slowly 
reducing the quantity of serum been used.
" In some cases the cost of adding the various growth factors and hormones
required may result in the cost of the media being greater than that of SSM.
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■ SFM lacks the protection against shear forces previously obtained from SSM. 
This leads to difficulties in maintaining cell viability in scale up (Ramirez & 
Mutharasan, 1992; Ozturk & Palsson, 1991b).
■ Cells cultured in SFM are less tolerant to changes in the environment such as pH 
and carbon dioxide fluctuations. Ultrapure reagents such as water are required 
and pH and temperature need to be carefully controlled.
■ Cells in SFM are extremely fastidious and there is no universal SFM for growth 
thus identifying the optimum medium for a particular cell line can be time 
consuming (Simonson et al., 1994; Barnes & Sato, 1980).
1.2.3 Culture Vessels
1.2.3.1 Static Culture Flasks
These flasks range in size from 12.5cm2 to 175cm2. They provide a substratum for 
growth of anchorage-dependent cells and they can maintain the growth of anchorage 
independent cells. They are generally used in the early stages of scale-up to inoculate 
roller or spimier bottles.
1.2.3.2 Roller bottles
In the beginning, the manufacturing of animal cell derived products was primarily 
carried out using glass roller bottles. Since then animal cell bioreactors have evolved 
extensively.
The effort behind the development of these bioreactors was stimulated by the desire to 
overcome some potential problems in scaling up of animal cell processes. Among the 
major drawbacks of the roller bottle systems are its labour-intensive nature, utilisation 
of valuable space and most importantly the unavailability of pH and dissolved oxygen 
control. On the other hand, the roller bottle system is very flexible as it allows rapid 
expansion or reduction in the production capacity. Hybridoma cells which are 
anchorage-dependent, can be grown on roller bottle apparatus. The major limiting 
factor however has been the fact that a maximum of 106cell/ml only, can be maintained 
in a healthy state within the culture. The MAb produced must then be concentrated by
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methods such as ammonium sulphate precipitation. This method of growing hybridoma 
necessitates the use of large quantities of media, serum and ammonium sulphate.
An adaptation of the commonly used roller bottle method is the bubble chamber dialysis 
roller apparatus. This system involves the growth of cells inside dialysis tubing within a 
modified roller bottle. The roller bottle is modified to enable harvesting of the produced 
antibody. The cells within the dialysis tubing are maintained in suspension by an 
oscillating bubble. The media is stored on the outside of the tubing where nutrients may 
diffuse into the cells. Monoclonal antibody yields up to 0.5g during 20 days of culture 
have been reported (Pannell & Milstein, 1992).
1.2.3.3 Spinner Flasks
Spinner flasks are miniature bioreactors which are used in the scale-up of cells. They 
generally range in size from 50ml to 1L. They facilitate the growth of both anchorage 
independent and anchorage-dependent cells. Anchorage dependent cells require the 
addition of microcarriers for optimum growth. Spinner flasks need to be siliconised 
prior to use to prevent attachment of cells to the glass surface. The flasks consist of a 
glass vessel with two side arms and a top cap. The side arms facilitate the addition and 
removal of media and cells. Suspended from the top cap are a glass rod and a magnetic 
stirrer. Mixing occurs when the flask is placed upon a specific magnetic base, which 
can control the spinning speed of the magnetic stirrer. Spinner flasks provide excellent 
vessels for the scale-up of cells to 1 OL-bioreactor scale.
1.2.3.4 Stirred Tank Bioreactors
For producing large quantities of both anchorage-dependant and anchorage independent 
animal cells, stirred tank bioreactors (STB) and adaptations have become the method of 
choice. STB’s have the capability to support the growth of high biomass cell culture 
fermentations in a sterile environment. STB’s can be modified to provide in vitro cells 
with adequate supplies of aeration, agitation, temperature and pH. This is accomplished 
through computer operated control systems, which allow real time monitoring and 
control of the system (Liitkemeyer el al, 2000). The provision of services such as 
sterilised compressed air, water supply comprising both hot and chilled sources of
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water, facilities for the drainage of waste products/exhaust gases and addition of fresh 
products are necessary to carry out efficient mammalian cell culture fermentation.
Traditional impeller driven apparatus such as the stirred tank bioreactors are available in 
a range of sizes from 1L up to tens of thousands of litres. Other types of bioreactors 
exist such as airlift reactors, in particular the draft tube intemal-loop airlift devices, 
which are known to be one of the largest reactors for free suspension cultures 
(Meisenholder, 1999; Grima et al., 1997). Airlift bioreactors are the preferred means of 
growing cells at large scale because this system provides a relatively mild and 
homogenous field of shear stress compared with the stirred tank reactor and bubble 
column fermenters. In some systems the turbulence has a focus and dissipates with 
distance from the impeller or sparger, having more of a damaging effect on the shear 
sensitive mammalian cells.
Smaller bioreactors are generally composed of a glass reactor vessel with a stainless 
steel head-plate. Larger bioreactors are usually composed of stainless steel 316, which 
is very expensive as it contains corrosive resistant material necessary for mammalian 
cell culture. For the production of animal cell derived products and MAb, the 
biotechnology industry takes advantage of the size of these bioreactors for the 
production of their products. However, there are a number of criteria which tend to 
have an effect on the growth of the cells and these must be considered at every stage in 
the development of a new process.
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1.2.4 Aeration
The capability of a cell culture to propagate can be limited if oxygen is not supplied 
efficiently throughout the system. The aeration and agitation system should ensure that 
oxygen delivery is not a growth-limiting factor. Cellular functions utilising oxygen 
include cell maintenance, respiratory oxidation for growth and substrate oxidation into 
metabolic products (Bailey & Ollis, 1986). Oxygen consumption rates of animal cell 
cultures are low compared to bacterial cell cultures. This is due to their lower growth 
rates and cell densities. However, animal cells are more sensitive to vigorous mixing 
and gas sparging. Therefore, maintaining a sufficient oxygen supply to cell cultures is a 
principal consideration in large-scale and high-density mammalian cell cultures.
The most common and efficient means of delivering oxygen to the cells is via a process 
know as sparging. Sparging is described as the process of bubbling air or another gas 
e.g. through a relatively deep pool of the culture broth, usually through a device called a 
sparger which is normally located at the bottom of the bioreactor (Chisti, 2000).
However, mammalian cells lack the outer cell wall associated with bacterial and yeast 
cell; which leaves them more sensitive to mechanical agitation and aeration via sparging 
(Hu & Peshwa, 1991). The bubbles that form from the sparging effect carry oxygen up 
through the suspension culture dispersing air to the cells. The adverse effect of this 
method is that cells can attach to the bubbles and thus are drawn up to the liquid-gas 
interface (Reiter & Bliiml, 1994; Jobses et al., 1991). At this point the bubbles escape 
into the gas phase leaving the cells on the surface of the suspension culture where they 
cannot escape the foam that forms as a result of escaping bubbles breaking through a 
thin film of serum and proteins (Handa-Corrigan et al., 1988). In addition, cells may be 
subjected to hydrodynamic forces as a bubble approaches the air liquid interface as 
Figure 1.3 demonstrates.
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Figure 1.4 The hydrodynamic mechanism of bubble rupture at the air liquid 
interface. A) When a bubble approaches the air liquid interface, its upper 
part protrudes out of the interface, forming a hemispherical liquid film 
cap. Its lower part depresses the liquid below the interface B) Before the 
bubble collapses, the rupture starts at the thinnest apex of the film cap 
where a hole is formed and the liquid film thins to a critical thickness C) 
When this high-speed flow reaches the liquid layer surrounding the 
bubble cavity it pushes the liquid to flow inward under the bubble cavity 
D) When this symmetric flow meets at the bottom of the bubble cavity, a 
stagnation point is created and high pressure is resulted. This high- 
pressure results in bubble break up.
The high speed induced by bubble rupture is enough to severely damage animal cells.
The high speed flow creates intense hydrodynamic stresses in liquid close to the
■ 2 •bursting bubbles. The shear stress is estimated to be in the region of 95N/m in the
receding film and 200-3OON/m in the boundary layer surrounding the bubble cavity.
■ • 9Hybridomas are said to be sensitive to shear stresses beyond l-5N/m (Jobses et al.,
1991).
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In addition, bubble escape can also lead to foam formation. Foaming results in a layer 
of bubbles forming over the surface at the top of the culture media. This prevents gas 
gaining entry into the culture media via headspace aeration. In addition, cells will 
attach to this layer of bubbles during mixing. This results in an increase in cell death 
and loss of productivity in the culture (Jobses et ah, 1991; Handa-Corrigan et ah,
1989). Bubble damage can also occur in agitated non-sparged bioreactors due to the 
entrainment of air through the culture fluid surface. In experiments on surface aerated 
cultures it has been found that cell damage begins when cell entraimnent is initiated at 
stilting speeds between 150-200rpm (Kunas et ah, 1990).
In order to combat the adverse effects of sparging, other techniques must be employed 
to transfer oxygen to the cells. Common methods employed include:
■ Headspace oxygenation
* External oxygenation
■ Direct oxygenation using gas permeable silicone tubing or hydrophobic 
membranes
The simplest method of bubble-free oxygenation is transfer of oxygen from the 
headspace. This method is widely used in small-scale applications such as T-flasks and 
spinner flasks, at large scale production if foaming occurs gas delivered into the 
headspace will not be able to pass through the foam effectively thus reducing the gas 
supply to the cells.
Silicon aeration tubing enables bubble-free oxygenation of animal cells in culture. To 
prevent the formation of bubbles, the reactor headspace is connected to gas input tubes, 
which automatically adjust the pressure between the gas in the membrane and the 
liquid. The major problem with using silicone tubing for direct oxygenation is that the 
diffusion rate of oxygen through the tubing is very low and large amounts of tubing 
(approximately 10 metres for a 10L bioreactor) are required for dense cell culture 
systems. Scalability of such a process design would be a major problem involving huge 
quantities of materials. External oxygenation involves refreshing culture medium 
outside the culture vessel with new oxygen. This is usually achieved using an external 
arm from the bioreactor into which medium from the culture vessel can be pumped and 
fresh oxygen is supplied before being pumped back into the reactor vessel.
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1.2.5 Agitation
The aim of agitation is to obtain uniform culture conditions in the bioreactor in order to 
obtain maximal gas transfer to the cells, to avoid gradients of nutrients, temperature and 
pH and to keep the cells in suspension. In a stirred tank reactor mixing is achieved 
using an impeller. There are a number of different types of impeller available which are 
specific for particular processes. The most commonly used impeller in mammalian cell 
culture is the marine impeller, which together with its angled blades enables efficient 
axial pumping capacity. Axial flow impellers produce higher flow per unit input 
characteristics compared to radial flow impellers. Thus they produce lower shear 
conditions suitable for the cultivation of animal cells compared to radial flow impellers. 
This ensures complete mixing of the reactor medium and improves refreshment of the 
upper most layer of liquid to achieve higher oxygen transfer rates without sparging.
Low agitation rates result in clumping. Clumping of cells can give rise to inaccurate 
cell counting. The cells inside of the clump are being starved of nutrients and air, which 
results in their early death and reduces overall antibody productivity. However, 
excessive agitation results in increased physical forces being exerted on the animal 
cells. Since animal cells are quite large (10-100pm) and lack an outer protective cell 
wall, they are rendered quite fragile. Therefore, large hydrodynamic forces are liable to 
result in the death of cells early on in the cell cycle (Elias et al., 1995).
Attempts have been made to quantify detrimental hydrodynamic forces in terms of shear 
stress (x), shear rate (y) and turbulence intensity. Shear has two components. Shear 
stress is the force per unit area acting on a body and shear rate, is a measure of how the 
velocity changes as we move away from that body (Doran, 1995). They are related to 
each other by the following equation:
x = p,y (Equation 1)
p = viscosity of the solution (Nsm'2) 
x = shear stress (Nmf2) 
y = average shear rate (s'1)
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Shear can be visualised as liquid flow lines moving at different speeds and directions. 
Such velocity fluctuations occur in turbulent eddies. The smaller the eddy and the 
greater the velocity fluctuation then the greater will be the level of shear. There are two 
forms of shear:
■ Localised shear, which occurs around objects moving in the culture media 
e.g. impeller and bubbles
■ Shear in the bulk liquid arising from turbulence within the reactor. As the
The type of fluid flow is important when looking at the effect of agitation on the growth 
of hybridoma cells. There are three main types of flow (Figure 1.4):
Laminar flow tends to be unidirectional and is visualised as "flow lines". There is very 
little movement between the fluid lines, which results in inefficient mixing of cells, 
culture media and oxygen in the bioreactor. Transient flow is a state that exists in 
between laminar and turbulent flow. In this state, fluid flows randomly between 
laminar and turbulent flow resulting in poor mixing of the culture components. During 
turbulent flow the fluid flow lines breakdown to form eddies. These eddies carry the 
fluids away from the fluid lines leading to a mixing of materials throughout the 
reactor. Turbulent flow conditions are required for good mass and heat transfer and 
are hence the most desired mixing state (Scragg, 1991).
level of turbulence increases, the eddy size will decrease and the level of 
shear will increase
■ Laminar
■ Transient
■ Turbulent
Laminar flow Turbulent flow
Fluid stays in ordered flow As the fluid moves turbulent eddies 
lines. There is no significant are formed. These eddies break
mixing between the flow lines down forming smaller eddies. On a
microscale, liquid moves in random 
directions, leading to mixing.
Figure 1.5 Diagrammatic representations of laminar and turbulent flow.
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Along with turbulent flow conditions come the hazard of eddies. Eddies are best 
described as whirlpools; hence, the liquid rotates instead of following distinct flow 
lines. These whirlpools are unstable and continuously breakdown in a phenomenon 
referred to as a turbulence "cascade" (Aloi & Cherry, 1996). Eventually eddies 
breakdown to a size where they have insufficient energy to form smaller eddies. The 
smallest eddy size that is found is defined by the "Kolomogrov eddy size (e)". Under 
normal stirring conditions the average size of the turbulent eddies is considerably 
larger than the average cell diameter. The resultant effect is that the cells are able to 
"ride" between eddies and thus are not affected by shear forces. However, at increased 
stirring speeds the Kolomogrov eddy size decreases resulting in collision with and 
damage to the cells.
1.2.5.1 Reducing the effects of Shear
Foetal Bovine Serum (FBS) and other common surfactants such as Pluronic F-68 are 
routinely used in addition to the culture media because they show protective effects 
against excessive agitation (van der Pol et al., 1992; Velez et al., 1986). Their 
protective nature has been related to surface active properties, which affect bubble-gas 
formation and bubble burst characteristics (Ozturk & Palsson, 1991b; Oh et al., 1989, 
Handa-Corrigan et al., 1989). Michaels et al. (1991) concluded that the protective 
effect afforded by FBS was both physical and biological where as that afforded by 
Pluronic F-68 was physical only. However, it is unknown if the FBS yields a 
significant protective effect under conditions of excessive turbulent shear. Others have 
reported Pluronic F-68 as having a fast acting biological effect, by interacting directly 
with the hybridoma cell membranes modifying the plasma membrane and making it 
more shear resistant (Ramirez & Mutharasan, 1992; Jobses et al., 1991).
Other methods commonly used to avoid the foaming effect include liquid oxygen 
vectors such as perfluorocarbons (Lowe et al., 1998; Deshusses et al., 1997), surface 
aeration and the use of bubble free oxygenation through microporous or diffusion 
tubing made of silicone rubber (Chisti, 2000).
A number of studies have demonstrated no significant effect of high-speed impeller 
agitation on hybridoma cultures in the absence of sparging. Oh et al. (1989)
26
successfully cultured hybridoma cells at 450rpm in RPMI (+10% FBS). Kunas & 
Papoutsakis (1990) attributed decreased hybridoma growth rates at agitation levels in 
excess of 800rpm, to interactions of cells with Kolmogoroff microscale eddies of 
approximately 13|jm in diameter. This is in agreement with the findings of Smith & 
Greenfield (1992) where in a study using serum-supplemented media cultures agitated 
at 200rpm yielded 26(jg/mL, where as agitation at 600rpm yielded 27)0,g/mL. Growth 
characteristics showed a shorter growth period and decreased cell viabilities early in the 
culture.
High levels of viable cells decline at higher agitation rates in serum-free cultures. These 
have been linked to high metabolic rates in the exponential growth period and 
subsequent nutrient limitations (Kunas & Papoutsakis, 1990). Apparent exponential 
growth rates (fiapp) were independent of agitation conditions implying that instantaneous 
death events which are typical of physical disruption, did not result from cell 
interactions with turbulent eddies. The turbulence intensity however was sufficient to 
have subtler biological interaction with the cells resulting in increased glycolysis rates. 
This increase in glycolysis was required to provide energy either to satisfy a deficiency 
in other energy production pathways or to increase overall energy production. Also 
increased energy may be required for maintenance of internal cell structures or repair of 
membranes that are affected by turbulent fluid forces. Increased rates of viable cell 
decline were precipitated by limitation of glucose and glutamine rather than essential 
amino acids as found with SSM (Passini and Gouchee 1989; Lee et al., 1988).
It has been proven that at increased agitation speeds there is a corresponding increase in 
the number of dead and damaged cells (Dodge & Hu, 1985). For example, it has been 
reported that the decreased cell viability at 200rpm resulted in a lower monoclonal 
antibody concentrate (140ug/ml) than in T-flasks (250jj,g/ml) (Lee et al., 1988). In 
addition, the components of damaged cells are usually secreted into the cell culture 
suspension, which results in a reduction of the intrinsic growth rate of the cells. This in 
turn can affect the quality and quantity of product that is reaped from the cell culture. 
Furthermore, if  the damage includes lysis of the cells the increased protein in the 
medium makes product purification difficult (Aloi & Cherry, 1995).
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To date in the pharmaceutical industry, there have been numerous examples of large- 
scale operation of stirred tank bioreactors employing suspension cultures or 
modifications thereof for increased and more efficient production of cells and their 
products. It has been observed that agitation and sparging have had a more adverse
effect on smaller scales than on larger scales. Therefore, excessive sparging and
agitation should be avoided at smaller scales. However at larger scales successful 
employment of many relatively large-scale bioreactors demonstrates that agitation and 
aeration are not the biggest obstacles to overcome.
1.2.6 Growth Limitations
The major growth limiting factors associated with mammalian cell cultures are:
■ Ammonium and lactate inhibition
■ Depletion of energy sources, (glucose and glutamine)
■ Amino acid deficiency
■ Exhaustion or inactivation of growth factors
■ Lipid, vitamin and trace element deficiency
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Figure 1.6 A cell and its environment (Fu & Barford, 1994; Spier, 1992).
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Glucose and the amino acid L-glutamine have been proven to be extremely important in 
various proliferation and production mechanisms in culture (Jenkins et al, 1992). 
Glutamine is thought to be the more important of the two for the efficient culture of 
hybridoma cells. Ozturk & Palsson (1991a) observed that hybridoma cultures ceased to 
grow upon exhaustion of glutamine and that glutamine could substitute for depleted 
glucose but not vice versa.
The by-products of these energy sources are growth and product inhibitory if allowed to 
accumulate above a certain limit (Ljunggren & Haggstrom 1995; Kromenaker & Srienc, 
1994; Omasa et al., 1992; Reid & Greenfield, 1990). Accumulation of lactate and 
ammonia destroys the buffering capacity of the medium and therefore shifts the culture 
to a lower and undesirable pH environment. This increase in lactate and ammonia alters 
the cell growth rate and specific productivity of antibody in hybridoma culture (Chen et 
al., 2000; Bibila & Robinson, 1995). In order to try and control the build up of these 
metabolic waste products, attempts have been made to supply glucose to the culture in a 
controlled manner such as using fed-batch routines. Maximisation of the fed-batch 
process is achieved by periodic supplementation of the culture with nutrients that are 
quickly consumed or exhausted. Hence the concentration of glucose can be maintained 
at a lower but appropriate level. This technique has been successful in keeping the 
lactate and ammonia concentrations below inhibitory levels.
Other avenues followed involved the manipulation of metabolic pathways. For example 
in the case of lactate, lactate dehydrogenase (LDH) has an isozyme form and functions 
as a tetramer and converts cellular pyruvate to lactate. By removing this gene it aids in 
reducing the build up of lactate in the culture medium (Chen et al., 2000). Gene 
targeting is a powerful tool for inhibition of gene expression on a permanent basis, or 
for systematic alteration of the mammalian genome. Another method used to reduce 
ammonia build up in culture involves the enzyme GS (glutamine synthase), which is not 
normally found in hybridoma cultures.
The incorporation of an immobilised glutamine synthase (GS) within hybridoma cell 
cultures slows down the accumulation of ammonia and replenishes glutamine by 
reversing the metabolism of glutamine (Okeson & Riley, 2001).
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1.2.7 Temperature
The most frequently used temperature for the cultivation of mammalian cells is 37°C. 
However, it has been shown that cultivation at lower temperature results in slower 
growth and enhances specific productivity in cells (Suzuki & Ollis 1989; Reuveny, 
1986). It is thought that the reason for this effect is related to the hybridoma cell cycle. 
The hybridoma cell cycle comprises four consecutive phases: DNA synthesis (S-phase), 
a gap (G2 -phase), a mitotis phase and a second gap (Gi-phase). An additional phase 
identified as the resting phase Go, occurs when cells in the Gi phase are no longer 
committed to enter the S phase. Synthesis and secretion of immunoglobulins by 
different cell lines have been reported to be restricted to the late Gi and S phases. 
Hence, MAb productivity could be improved by methods which favour accumulation of 
cells in the Gi phase. A decreased specific growth rate is reflected in a prolonged Gi 
phase. Since MAb synthesis is assumed to take place in the Gi phase, a prolonged stay 
of the cells at this stage may be responsible for the enhanced antibody productivity 
levels (Ramirez &Mutharasan, 1992; Suzuki, 1990).
Blomkolk & Gray (1994) reported highest cell density and MAb yield from non­
agitated cultures at 37°C. In agitated culture, the highest cell yield was achieved at 
34°C, with an increased lag phase recorded. The highest MAb productivity was 
achieved at 34°C and 37°C. At the upper scale of the temperature range, (39°C) 
Blomkolk & Gray reported no growth. This contrasts with the findings of Mutharasan 
& Sureshkumar (1991). They found that maximum cell density was recorded at 33"C, 
maximum cell yield at 35°C and maximum specific antibody yield at 38°C. The 
difference between maximum cell density and cell yield is that density pertains to the 
stage in the growth curve that most cell growth was recorded. On the other hand, cell 
yield is related to the total number of cells produced over the whole growth period.
The sharp contrast between the results obtained between the two researchers at the 
upper end of the temperature range 38°C and 39°C, has been attributed to the fact that 
38°C is the upper limit for growth and small changes in temperature above this, may 
have had a serious detrimental effect on the growth and productivity of the cells.
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1.3 Cell Culture Methods
Depending on the equipment available, it is possible to perform batch, fed-batch or 
continuous perfusion cultures. The choice of system and the operation mode allows the 
production of short or long term cultures, low or high density of cells and high or low 
concentrations of product. The following is a brief description behind each of the most 
common methods of producing the desired products and their applications in industry.
1.3.1 Batch Cultures
A batch culture is a closed system in which cells are inoculated into a quantity of 
nutrient medium contained within a suitable vessel. Cells are cultured to death and the 
antibody harvest is collected at a specific time point.
Traditionally, animal cells have been cultivated in batch culture either as suspension or 
monolayers. In a batch reactor, cells are inoculated into a system that contains the right 
nutrients, the required temperature, pH and dissolved oxygen levels. As the cell 
numbers increase, nutrients are consumed and waste products accumulate (Katinger & 
Scheirer, 1985). This process has an adverse effect on the environment of the culture 
which usually leads to a cessation of cell metabolism and the production of the desired 
product.
Simplicity in process control and operation, resulting in process consistency, low 
contamination rate and low operating costs are some of the advantages of batch culture 
(Tovey, 1985). On the other hand, the low product titre and productivity are major 
disadvantages associated with batch culture (Moro et al, 1994). The desired product is 
generally secreted by viable cells, hence product formation is directly proportional to 
the integrated viable cell concentration with time. Therefore, a high viable cell density 
maintained for a long time is required for maximum efficiency (Xie and Wang, 1997).
31
1.3.2 Fed-batch Culture
In fed-batch systems, nutrients are kept at appropriate concentrations by controlled 
feeding. Waste products and cells are not withdrawn. The culture is fed at intervals 
with fresh medium and there is a corresponding increase in the volume of the culture. 
As a result the overall cell densities and cell yields are increased per litre of media 
(Tovey, 1985).
Fed-batch is ideal for the production of substances such as MAb’s, where the synthesis 
is maximal after the cells have reached the stationary phase. For example, it has been 
reported that a fed-batch culture operated for 5 5 Oh reached a total cell concentration of 
nearly 5 x 107cell/ml and a peak viable cell concentration of over 1.5 X 107cells/ml (Hu 
& Aunins, 1997). Cell culture longevity in fed-batch culture of hybridomas is often 
limited by elevated medium osmolarity caused by repeated nutrient feeding. The use of 
a hypoosmolar medium can delay the onset of severe cell death resulting from the 
increased osmolality of the culture and in return increase the MAb productivity (Ryu & 
Lee, 1999).
If this system was to be modified to allow the addition of nutrients and removal of 
waste products, the resultant effect would be an increase in culture time and an 
improvement in the cell densities produced. This type of system is termed perfusion 
culture of cells.
1.3.3 Perfusion culture
Perfusion culture provides an in vivo like environment where suspended cells are 
retained by filters or are immobilised on beads. Perfusion cultures have been described 
as being advantageous for non-propagating cells, when cells of a limited life span are 
used and when the kinetics of product formation are typically non-growth related as is 
in the case of MAb’s. The main aim of perfusion cell culture is to maintain the cells in 
the ideal culture environment for a longer period of time in order to increase 
productivity. The essential parameter in perfusion culture is the rate at which medium 
is replaced. By intensifying the replacement rate there is an increased provision of 
nutrients, which in turn leads to an increase in the viable cell density (Mercille et al.,
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2000). A number of mechanical devices have been developed increasing the efficiency 
of perfusion cultures of animal cells with fresh medium. Such devices include 
membrane filtration systems, dialysis reactors, devices which use gravitational settling 
(Wen et al., 2000), spin filters (Deo et al., 1996; Yabannavar, 1992) and ultrasonic 
filters (Bierau, 1998; Gaidi et al., 1996). The major limitation with the type of systems 
mentioned here are that they are closed systems, where small amounts of waste products 
are retained and this ultimately leads to the demise of the culture, hi order to overcome 
this problem, the use of an open system such as a continual-flow culture system is 
necessary.
On reviewing the current processes used in large-scale cell culture production of 
recombinant proteins and antibodies it is clear that the industry has converged on using 
suspension cultures in stirred tank bioreactors with some form of controlled feeding 
system like batch or fed-batch (Chu & Robinson, 2001).
1.3.4 Hollow Fibre Bioreactors
Originally developed in 1972, the hollow fibre bioreactor (HFB) was designed to mimic 
the in vivo capillary system (Rnazek et al., 1972/ The reasoning behind this was to try 
and maintain a more physiological environment for culturing cells with regard to 
nutrient supply, metabolic waste removal, and pH control while providing a stable 
microenvironment without shear (Jackson et al., 1996).
A typical HFB system is composed (Figure 1.6) of a gas exchange unit, a bioreactor 
composed of capillary membranes made of cellulose, a media supply and waste bottles. 
The factors that may cause variations in the operation of hollow fibre bioreactors 
include pH, temperature, IC (Intracapillary) recirculation rate, bioreactor composition 
gas mixture, harvest rate and IC media feed rate (Czirbik, 1996; Lowrey, 1993).
Hollow fibre bioreactors vary from supplier to supplier in terms of their arrangement 
and composition of the hollow fibres. The fibre material may be composed of one of a 
range of materials including cellulose, acetate, cuprammonium, rayon and 
polyethylmethanacrylate (PAMA). In general it has been found that for adherent cell 
lines cuprammonium and cellulose are largely undesirable due to their hydrophobic
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nature. Typically, the membranes will have a molecular weight cut off less than or 
equal to 45-50kDa. This is to prevent loss of immunoglobulin (IgG), which is 
approximately 150kDa (Lipman & Jackson, 1998).
Also included in a HFB are pH probes, dissolved oxygen probes and media reservoirs 
for the extracapillary space (ECS) and Intracapillary space (ICS) (Dhainaut et al 
1992).
Figure 1.7 Diagrammatic representation of the production of monoclonal antibody 
in a hollow fibre bioreactor.
The ECS of the hollow fibre reactor is used for cell growth. The ECS is both 
compartmentally and physiologically separate from the intracapillary space. Cells are 
provided with nutrients from the culture medium, which is continuously circulating 
through the ICS. Small molecular weight metabolic waste products diffuse from the 
ECS to the ICS, while secreted immunoglobulins can be retained in the ECS for 
periodic collection.
Oxygen is provided by aerating the ICS stream. Recycle flow is analogous to blood 
flow through capillaries embedded in tissue hence the configuration of a hollow fibre 
bioreactor mimics, to a certain extent the human in vivo system. The two fibre-free 
regions at either end of the cartridge are used to introduce cells and fresh media into the 
ECS and to harvest the protein product.
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Hollow fibre bioreactors have been reported to consistently produce concentrations of 
products in the range 0.7-2.3mg/ml (Altshuler et al., 1986). Dhainout et al., (1992) 
reported a total culture harvest of approximately 3.0-3.1g over a 25 day culture period. 
Piret & Cooney (1990) using an ultrafiltration hollow fibre bioreactor, have reported 
MAb production in excess of 17mg/ml. This system provides advantages over a 
conventional hollow fibre bioreactor as it retains growth factors and selectively 
concentrates high molecular weight protein products, which reduces the need for 
extensive and sometimes invasive downstream processing.
This system also offers a support medium for the growth of many cell types. The 
continuous perfusion system enables the constant supply of essential nutrients and 
removal of metabolic waste products necessary for optimal production (Omasa et al.,
1995). Cells are protected from shear, which is often a common fault found in standard 
stirred tank reactor systems where aeration via sparging can lead to damage of the 
sensitive cell membrane of an animal cell. Typical cell densities in the HFB can reach 
in the range of approximately 107-108cells/ml and cell viability and production can be 
maintained for extended periods.
The ability to frequently harvest the antibody from the bioreactor during production 
decreases the potential for degradation, which normally results from prolonged 
exposure to cellular proteases in the culture media (Graner et al., 1999; van Erp el al., 
1991b). Downstream processing of the products from hollow fibre bioreactors has been 
made easier with the successful introduction of serum-free and protein-free media to 
cells (Dhainanut et al, 1992; van Erp, et al., 1991a; Heifetz et al., 1989; Klerx et al., 
1988). This important breakthrough has led to a decrease in downstream processing 
and production costs. HFB's also have their disadvantages. They have the potential for 
microbial contamination and mechanical failure, therefore technical expertise is 
required to avoid these complications. In addition, the materials and equipment used for 
production of MAbs in hollow fibre bioreactors are very expensive (Jackson et al.,
1996).
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1.4 Validation
During the past 50 years, there has been an increasing awareness of the safety concerns 
surrounding the manufacturing of medical products. This is due to the occurrence of a 
number of tragic accidents in the past; for example in the 1930’s in the USA a mistake 
was made in the formulation of children’s syrup and in Europe in the 1960’s the 
thalidomide tragedy led to the death of a number of people. These and other similar 
tragedies have contributed to the establishment of regulatory agencies such as the Food 
and Drug Administration (FDA) in the USA.
These regulatory agencies established guidelines and standards for industry which they 
have to adhere to. The growing awareness for the high levels of safety required and the 
resultant higher quality standards also led to several technical improvements in the 
manufacture of pharmaceuticals. In line with this there have also been improvements in 
the organisation of manufacturing processes leading to the implementation of Good 
Manufacturing Practice (GMP). The aim of GMP is to clearly define the system that is 
used to manufacture a specific product in a reproducible and documented manner, in 
order to ensure the highest possible quality, safety, and efficacy of the product. This 
can only be achieved if all the components and steps involved in the manufacturing 
process are thoroughly documented and validated. Today, the establishment of 
manufacturing processes for new biopharmaceuticals is only possible under GMP 
conditions (Hesse & Wagner, 2000).
The term validation describes the provision of documented evidence that assures a high 
degree of confidence that a system or process performs its intended function accurately 
and reliably, is under control and at all times reproducible (FDA, 1997). Validation is 
an important process for a number of reasons; firstly, it leads to an assurance of 
confidence in procedures and methods carried out by a lab. Secondly, it results in a 
more efficient system of documentation and recording within the lab, which makes the 
process of transferring methods or scale-up much easier in the long term. It also acts as 
a bench mark for comparison of methods in different studies and laboratories. Included 
in a labs overall validation policy should be documented information on all aspects of 
production processes, cleaning procedures, analytical methods, in process control test 
procedures, computerised systems and persons responsible for design, review, approval
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and documentation of each validation phase. Prior to starting process validation 
activities appropriate qualification of critical equipment and ancillary systems should be 
completed and critical documentation collected as described below. It is also advised 
that the product life cycle described in Figure 2.6 is used as a guide when a new process 
is initiated.
1.4.1 Standard Operating Procedures
Standard operating procedures are a written tool, which are important for a number of 
reasons. Firstly, they define how a task is to be performed to achieve a specified 
outcome, and they standardise the way a task is to be performed to minimize variation. 
They also form the basis for training task performers, provide an informational tool that 
supports the performers, and, of course to fulfil a regulatory compliance. There are a 
number of different types of SOP’s including administrative tasks, which are generally 
rule based such as who has permission to enter a particular area. Cognitive tasks are 
procedures relating to decision making activities for instance reviewing decision 
making activities and motor tasks which generally refer to tasks such as setting up a 
fermenter (Vesper, 2001).
1.4.2 The product life cycle
The product life cycle (Figure 2.6) is an essential guide for ensuring that the user is 
completing each step of the validation process before moving onto the next section. 
The following explanations will define what is involved at each step in the product life 
cycle.
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Figure 1.8 The Product Life Cycle.
User requirement specification (URS) This specification defines the intended 
functionality of the process. It should always be completed first as it can be used as a 
request for tender. This specification ascertains to what degree, quality has been built 
into the product. This is combined with the functional specification, which in the end 
produces a system specification.
Functional specification (FS) The functional specification describes the 
operational and performance functionality of the system. It provides 
information regarding hardware and software to comply with the URS. It should 
always be completed prior to designing a process. Once the system becomes 
operational it acts as a version-controlled description of the system FS should 
always include the following details:
System Attributes 
Operational environment 
Maintenance requirements 
Other Specifications 
Training Requirements 
Reference documents 
Appendices
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■ Hardware and Software design the design specification defines how the 
functionality described in the functional specification will be implemented. It 
usually contains a description of the following:
■ System design Overview
■ System description.
■ Input/Output instrumentation
■ Hardware operating environment
■ Electrical supplies
Qualification of the process is usually carried out by conducting the following activities, 
individually or combined:
■ Design Qualification (DQ) Included in this section is documented verification 
that the proposed design of the facilities, equipment, or systems ARE suitable 
for their intended purpose (EMEA, 2000).
■ Installation Qualification (IQ) This section contains documentation that 
ensures that all the system components are present and correctly installed and 
are capable of operating consistently within established limits and tolerances in 
compliance with the appropriate design and user requirements (EMEA, 2000; 
FDA, 1987). Typical documentation found in this section include:
■ System Overview
■ Installation Methodology
■ Description of all connections, e.g. piping and electrical
■ SOP’s
■ Testing documentation
■ References
■ Operational Qualification (OQ) This section contains information
pertaining to the verification that the equipment or systems installed or 
modified, perform as intended throughout the anticipated operating ranges. 
Typical documentation included in this section includes:
39
* System Overview
■ Responsibilities
■ Testing Methodology
* Testing Structure
The OQ report describes conclusions of the testing and makes recommendations 
regarding implementation of system (FDA, 1987).
■ Performance Qualification (PQ) This section includes documented 
verification that the equipment and ancillary systems, as connected together, can 
perform effectively and reproducibly based on the approved process method and 
specifications. This section will also include discrepancies found during testing 
(EMEA 2000; FDA, 1997).
1.4.3 Process Validation of a MAb Production Procedure
When undertaking process validation a manufacturer must evaluate all the factors that 
may affect product quality and ensure that they can repeatedly produce the desired level 
and quality of biological product. These factors vary considerably from process to 
process and may include all or some of the following criteria; raw materials, personnel, 
facilities and equipment. Process validation studies should be commenced early on in 
the research and development (R&D) stage. At this time extensive studies should be 
carried out on the product in order to chemically, physically and electrically characterise 
it. All aspects of the product, which impact on safety and effectiveness, should be 
considered. Examples of these aspects include performance, reliability and stability. 
Acceptable ranges or limits should be established for each characteristic to set up 
allowable variations (FDA, 1987).
An example of the steps undertaken to define set points and limits and ensure product 
quality are included in the following scenario: A cell line producing a recombinant 
protein at an optimum pH of 7.5 is chosen. The proven acceptable ranges from a 
validation study may vary between pH 7.1-7.9. A control parameter may then be 
selected between pH 7.3-7.7, providing 0.2pH units of process "safety" outside this 
range. As these criteria are being decided a series of physio-chemical and functional
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assays are carried out to ensure that the product produced at any of the pH values within 
this range are of acceptable quality (Moran et al., 2000; Federal Register, 1998).
A typical Process Validation Protocol would require the developer to include the 
following information (PDA, 1999):
■ Short description of the process.
■ Summary of the critical processing steps to be investigated.
■ Finished product specification for release.
■ In-process controls proposed with acceptance criteria.
■ Additional testing carried.
■ Sampling Plans.
■ Departmental functions and responsibilities.
■ Proposed timetable.
There are four different types of manufacturing process validations in the 
pharmaceutical industry prospective, concurrent, retrospective validations, and 
revalidation. The type used depends on the particular process and what stage it is at.
Prospective Validation This validation includes considerations that need to be 
made before a product is introduced or when there is a change in the manufacturing 
process which may affect the product characteristics, such as uniformity and identity. 
The following are described as the key elements of prospective validation.
■ Equipment - Installation (Installation Qualification) and process (Performance 
Qualification)
■ Revalidation -  when there is a change in the process
■ Documentation -  It is essential to have documented evidence of each step in the 
validation program (EMEA, 2000; FDA, 1987)
Retrospective Validation This validation document provides evidence based on 
review and analysis of historical information. This method of validation is useful when 
there is a stable process with a large historical database. The main objective of this type 
of process validation is to support confidence in the process (EMEA, 2000)
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Concurrent Validation This evaluates the process based on information generated 
during the actual implementation of the process. Typical situations in which one would 
use concurrent validation are (EMEA, 2000):
■ When a step of the process is modified.
■ The product is made infrequently.
■ A new raw material is introduced in to a process/system.
Revalidation A manufacturing process would have to be revalidated when changes are 
made to critical components such as raw materials, changes or replacements in 
equipment and changes in the production facility (EMEA, 2000).
Validation is very important to ensure that strict guidelines and controls are 
implemented. For example, European sera have been banned from use in the 
production of biopharmaceuticals due to the known presence of transmissible 
spongiform encepha-lopathies (TSE’s). However, serum that is certified to be from 
New Zealand is free from these contaminating agents. In 1994, 30,000 litres of so 
called New Zealand serum was sold world wide when only 15,000 litres had been 
produced. This is where vendor certification alongside quality control testing with 
validation elements, such as assay cross-validation, change controls and other contract 
procedure, to provide the maximum possible safety and quality level of raw materials 
comes into action (Hesse & Wagner, 2000).
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1.4.4 Analytical Method Validation
"Validation o f an analytical method is the process by which it establishes, by 
laboratory studies, that the performance characteristics o f the method meet the 
requirements for the intended analytical applications ”
(USP Chapter 1225)
Validation is an important process, which ensures that a procedure is fit for the purpose 
intended in that it ensures confidence that the correct results are obtained. It also 
identifies crucial aspects that are susceptible to change and can affect results. The 
following list details the parameters that should be considered when carrying out a 
validation procedure on an analytical method (ICH guidelines, 1994; ICH guidleines, 
1995; Chow, 1997).
■ Specificity -  The ability to assess unequivocally the analyte in the presence of 
components which may be expected to be present. Typically, these might include 
impurities.
■ Accuracy -  This is the closeness of agreement between the value, which is accepted 
either as the conventional or true value or an accepted reference value, and the value 
found.
■ Precision -  The precision of an analytical procedure expresses the closeness of 
agreement between a series of measurements obtained from multiple sampling of 
the homogenous sample under the prescribed conditions. Precision is often termed 
inter assay variation.
■ Repeatability -  This expresses the precision under the same operating conditions 
over a short interval of time. Repeatability is also termed intra-assay precision.
■ Reproducibility -  This expresses the precision between laboratories.
■ Limits of detection -  This is the lowest amount of analyte in a sample, which can be 
detected but not necessarily quantified to an exact value.
■ Measurement range -  The range of an analytical procedure is the interval between 
the upper and lower concentration of analyte in the sample for which, it has been 
demonstrated that the analytical procedure has a suitable level of precision, accuracy 
and linearity.
■ Limitations of the method (e.g. types of sample that are unacceptable).
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■ Linearity -  o f  an analytical procedure is its ability to obtain test results, which are 
directly proportional to the concentration (amount) o f  analyte in the sample.
By carrying out these procedures and following guidelines set by the ICH, one can 
ensure that a validation method is robust and fit fo r the purpose intended.
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1.5 Aims of Thesis
■ It was the aim of this thesis to adapt a number of hybridoma cell lines to protein- 
free/serum- free culture conditions and to scale their productivity up to a 10L 
fermenter under optimised culture conditions. This involved looking at the effect of 
a number o f commercially available serum-free and protein-free media on the 
growth and productivity of four hybridoma producing cell lines namely 4/2D, 5C3, 
1/11C and 6/1C. Cell lines which adapted to and performed most efficiently in 
culture, were chosen for further scale up and optimisation studies.
■ Optimisations studies involved measuring the environmental aspects of cell culture 
conditions (i.e. temperature and mixing) on the growth and productivity on two of 
the chosen hybridoma producing cell lines, 4/2D and 5C3. The most efficient 
culture conditions were chosen and used in the batch culture of these cell lines at 
10L. The ability of the hybridoma cell lines to maintain growth and productivity at 
large scale was determined.
■ A series of hollow fibre operations were performed using the hybridoma cell line 
5C3, both in serum-free and serum-supplemented culture conditions. Antibody 
productivity from this system and cost efficiency were compared with that achieved 
in the 10L bioreactor.
■ For the purpose of this thesis, it was necessary to use a method of quantifying MAb 
from culture supernatant that was efficient, reliable and easy to operate. 
Nephelometry was the method chosen. The main work involved validation of the 
nephelometer in order to ensure that the procedure was fit for the purpose intended 
in that it ensured confidence that the correct results were obtained when assaying the 
test samples. This validation work involved carrying out assays for precision, 
accuracy, reproducibility and specificity.
■ The initial validation on the bioreactor and control systems, which involved carrying 
out both an Installational and Performance Qualification were performed.
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Section 2 Materials and Methods
Addresses of suppliers are provided in Appendix III.
2.1.1 Water
Ultrapure water was used in the preparation of all media and solutions. This water was 
purified to a standard of 12-18QM/cm resistance by a reverse osmosis system 
(Millipore Milli-RO 10 Plus and Maxima UF water system, ELGA).
2.1.2 Glassware
Most solutions pertaining to cell culture and maintenance were prepared and stored in 
sterile glass bottles. All glassware including these bottles, used for cell culture work 
were soaked in a 2% (v/v) solution of RBS (Chemical Products) for at least one hour 
after which, they were scrubbed and rinsed several times in tap water. The glassware 
was washed in an industrial dishwasher, using Neodisher detergent (an organic, 
phosphate-based acid detergent), and rinsed twice with UHP. The materials were 
finally sterilised by autoclaving as described in Section 2.1.3.
2.1.3. Sterilisation
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121°C 
for 20 minutes at 15p.s.i. Thermolabile solutions were filtered through a 0.22pm sterile, 
low protein-binding filter (Millipore, Millex-GV SLGV025BS). Large volumes, (up to 
10 L) of thermolabile solutions were filter sterilised through a micro-culture bell filter 
(Gelman, 12158).
2.1.4. Media Preparation
The basal medium used during routine cell culture was prepared according to the 
formulations shown in Table 2.1. 10X media were added to sterile ultrapure water, 
buffered with NaHC0 3  and adjusted to a pH of 7.45-7.55 using sterile 1,5M NaOH and 
1.5M HC1. The medium was then filtered through a sterile 0.22pm bell filter (Gelman,
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G1423S) and stored in 500ml bottles at 4°C or in the case for large scale culture in 10L 
sterile bags until the expiry date recorded on each individual 10X medium container 
was reached (up to three months from production date). Prior to use, 100ml aliquots of 
basal media were supplemented with 2mM L-glutamine (Gibco 25030-024) and 5-15% 
foetal calf serum (FCS). This was then used as routine culture medium. This was 
stored for up to 2 weeks at 4°C after which time fresh culture medium was prepared. 
Hybridoma cells were grown in a basic basal medium, the commercially available 
DMEM. DM EM with Glutamax I (Glutamax is L-Amyl-L-Glutamine, high glucose 
concentration - 4.5mg, Gibco 61965-026) supplemented with 10% heat inactivated FCS 
(Myoclone, Gibco 10082-147) was used in these experiments. This was further 
supplemented for hybridoma growth and hybridoma cloning with 1% Penicillin 
streptomycin (Gibco, 15070-022).
Table 2.1 Preparation of basal media
DMEM (IX)
(Gibco 52100-039)
Ultrapure H20 10 L
7.5% NaHC03
(Riedel-de Haen, 31437)
49.3ml
2.2.1 Cell culture procedures
All cell culture work was earned out in a class II down-flow re-circulating laminar 
airflow cabinet (Nuaire Biological Cabinet). Strict aseptic technique was adhered to at 
all times. The laminar flow cabinet was swabbed with 70% industrial methylated spirits 
(IMS) before and after use, as were all items brought into the cabinet. Each cell line 
was assigned specific media and waste bottles. At any time, only one cell line was used 
in the laminar air-flow cabinet, and upon completion of work with any given cell line 
the laminar air-flow cabinet was allowed to clear for at least 15 minutes. This was to 
eliminate any possibilities of cross contamination between the various cell lines. The 
cabinet itself was cleaned weekly with industrial disinfectants (Virkon, Antec
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International or TEGO, TH Goldschmidt) as were all incubators used in the culture of 
cell lines and hybridomas. These detergents were alternated every month.
2.2.2 Subculturing cell lines
During routine subculturing or harvesting of adherent cell lines, cells were removed 
from their flasks by enzymatic detachment. Waste medium was removed from the cells 
which were then rinsed with pre-warmed trypsin-versene/EDTA (TV) solution (0.25% 
(w/v) trypsin (Gibco 043-05090), 0.01% (w/v) EDTA (Sigma) solution in PBS (Oxoid, 
BR14A). This ensured that any naturally occurring trypsin inhibitor in residual serum 
was deactivated. Fresh TV was then placed in the flask and incubated until the cells 
were seen to have detached (2-10 minutes). The TV solution was deactivated by the 
addition of pre-warmed basal medium containing serum. The entire solution was then 
transferred, to a sterile universal tube (Sterilin, 128a) and centrifuged at lOOOrpm 
(Allegra™ 6KR Centrifuge, Beckman, USA) for 5 minutes. The resulting pellet was 
then re-suspended in pre-warmed growth medium, cells counted and tissue culture 
flasks re-seeded at the required density.
Hybridoma cells are loosely adherent. Cells were passaged by tapping the flask lightly 
and/or gentle pipetting with a 10ml sterile pipette (Elkay, Ireland). Cell suspensions 
were pooled and centrifuged at lOOOrpm for 5 minutes. The cell pellet was then re­
suspended in culture medium and a cell count performed (Section 2.2.4) and the cells 
re-seeded at the required density. Cells were grown in 5% CO2 .
2.2.3 Sequential adaptation of hybridoma cells to protein-free and serum-free 
conditions
The cells were inoculated at double the normal seeding density, approximately 2xl05 
cells/ml in a 75:25 (v/v) mixture of serum-supplemented: serum-free/protein-free 
medium. The culture was monitored until the density reached 1 x 106cells/ml. At this 
stage cell were subcultured in to a 50:50 (v/v) mixture of serum-supplemented: serum- 
free/protein-free medium. Again, the culture was monitored until it reached 
lx l0 6cells/ml and subcultured in a 25:75 (v/v) mixture of serum-supplemented: serum-
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free/protein-free medium. When the culture reached lx l0 6cells/ml it was sub-cultured 
in to a 100% serum-free/protein-free medium.
2.2.4 Cell counting
Cells were trypsinised, pelleted and re-suspended in media as described in section 2.2.2. 
Cell counting and viability were earned out by using trypan blue (Gibco, 15250) dye 
exclusion technique. An aliquot of Trypan blue was added to a single cell suspension at 
a ratio of 1:2. After 3 minutes incubation at room temperature, a sample of the mixture 
was applied to the chamber of a Neubauer haemocytometer over which a glass cover 
slip had been placed. Cells in the 4 outer comer grids of the chamber were counted 
microscopically, an average per comer grid was calculated with the dilution factor taken 
into account and the final number multiplied by 104 to determine the number of cells per 
ml. Non-viable cells were those, which stained blue while viable cells excluded the 
trypan blue dye and remained unstained.
2.2.5 Cell freezing
Cells of various passage numbers were frozen and cryo-preserved to serve as master 
stocks. Vials could then be thawed and cultured for study. Cells to be frozen were 
harvested in the log phase of growth and counted as described in Section 2.2.4. The 
pellets were re-suspended in foetal calf semm (pre-cooled to 4°C) and an equal volume 
of freezing medium (DMSO (Sigma, D-5879)/serum 1:9 (v/v)) was added drop-wise to 
the cell suspension to give a final concentration of at least 5xl06 cells per ml. 1.5ml of 
the cell suspension was quickly placed in a cryovial (Greiner 122278), which was 
placed in the vapour phase of liquid nitrogen container for 2.5-3.5hr. After this, the 
cyro-vials were stored in liquid nitrogen until required.
2.2.6 Cell thawing
The cryopreserved cells were removed from the liquid nitrogen and thawed at 37°C. 
Immediately prior to removal of a cryovial from the liquid nitrogen, a sterile universal 
tube containing growth medium was prepared for the rapid transfer and dilution of 
thawed cells (thus reducing the exposure time to DMSO, which is toxic at room
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temperature). Following the addition of the thawed cell suspension to the growth 
medium, the suspension was centrifuged at l,000rpm for 3 minutes, after which the 
pellet was re-suspended in fresh growth medium. A viability count was carried out 
(Section 2.2.4) and the thawed cells were placed in tissue culture flasks with a quantity 
of medium and allowed to attach over-night. The following day the cultures were re-fed 
with growth medium to remove any residual DMSO.
2.3.1 Hybridoma cell lines
Details of the cell lines used for the experiments detailed in this thesis are provided in 
Table 2.2. Cell lines were maintained in 25cm2 (Costar 3056), 75cm2 (Costar 3376) or 
175cm2 (Nunclon, NUNC 178883) tissue culture flasks at 37°C and fed every 2-3 days. 
Confluent hybridoma cell lines were grown for at least 6 days with no change of growth 
media when antibody was being harvested.
Table 2.2 Source description and media requirements of cell lines used in 
experiments described in this thesis.
Cell line Subtype Cell type description Basal Medium Source
6/1C TgG! Hybridoma producing 
anti-mdr-1 MAb
DMEM (Glut I)* NCTCC (Moran et 
al., 1997)
4 2D IgGt Hybridoma producing 
anti Topoisomerase II- 
alpha MAb
DMEM (Glut 
I)*/SFM/PFM*
NCTCC (Moran et 
al., 1996)
1/11C IgG! Hybridoma producing 
MAb (unknown kidney 
antigen)
DMEM (Glut I)*/ 
SFM/PFM*
NCTCC (Moran et 
al., 1998; Lalor, 
2001)
5C3 IgGi Hybridoma producing 
MAb to a novel complex 
of cytokeratin 6 and 
cytokeratin 9
DMEM (Glut 
I)*/SFM/PFM*
NCTCC (Larkin, 
2002)
*Inc icates other media were used in conjunction with this ce 1 line and are descri
section 2.3.2.
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6/1C
The anti- mdr-1 MAb (IgGi) producing clone 6/1C was produced following a 
combination of in vivo and in vitro immunization regimes in Balb/c mice with a 
synthetic 12-amino acid peptide that corresponds to amino acids 21-32 of P- 
glyocprotein (P-170).
P-Glycoprotein is an integral plasma membrane protein involved in the active efflux of 
cytotoxic materials from the cell and is consistently associated with multidrug resistance 
in cultured cell lines selected for multidrug resistance and in certain tumours (Moran et 
a l, 1997).
4 2D
The anti-topoisomerase Il-a antibody (Clone 4/2D) was produced against a synthetic 
amino acid peptide conjugated to BSA. The peptide was chosen from the entire Topo 
II-a amino acid sequence for its apparent specificity to Topo II- a. The isotype of this 
antibody is IgGj. Antibodies specific for topoisomerase II- a or topoisomerase II-P are 
valuable tools for investigating the exact physiological roles played by each isoform. 
Monoclonal and polyclonal antibodies have been utilised to quantitate and visualise the 
level of each of the enzymes within the nucleus of specific cells (Robinson et al., 1993).
1/11C
The antibody producing hybridoma 1/11C (IgG,) was generated employing a novel 
approach i.e. using dewaxed formalin fixed paraffin embedded archival tissue as an 
immunogen (Moran et al., 1998). The use of dewaxed formalin fixed paraffin 
embedded archival tissue was employed in an attempt to identify novel antigens with 
possible diagnostic and/or prognostic value. Antibodies directed against archival 
normal kidney were generated as proof of principle that this method was feasible (Lalor, 
2001).
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5C3
As with the 1/11C, 5C3 (IgG,) was also generated using dewaxed formalin fixed 
embedded archival tissue as an immunogen. In this case, formalin fixed paraffin 
embedded breast tumour tissue was employed as an immunogen. Internal sequencing 
revealed that the 5C3 reactive antigen was recognising a novel complex of human 
cytokeratin 6B and cytokeratin 9. Cytokeratin 6 has been detected in malignant and 
benign tumours. This cytokeratin in a complex with cytokeratin 5 has been previously 
detected in invasive breast cancers (Otterbach et al., 2000).
2.3.2 Hybridoma Media
DMEM:
PFHM II: 
UltraDoma:
HyQADCFMab:
CD Hybridoma:
HTM20CTH:
PFM:
HyQ®SFX-MAb: 
Hybridoma SFM:
Ex-CELL™620:
SFM:
TCH:
OptiMab:
with Glutamax I supplied as a IX stock (Gibco, 61962-026).
protein-free media supplied as a IX stock (Gibco, 12040-051)
protein-free media supplied as a IX stock (Biowhittaker, 12- 
723F)
protein-free medium supplied as a IX stock (HyClone 
SH30043.02)
protein-free chemically defined medium supplied as a IX stock 
(Gibco, 11279).
protein-free mediun supplied as a IX stock (JRH, 14610) 
protein-free media, supplied as a IX stock (Sigma, S2897) 
serum-free medium supplied as a IX stock (HyClone SH30206) 
serum-free low protein medium supplied as a IX stock (Gibco, 
12045).
serum-free medium supplied as a IX stock (JRH, 14620) 
serum-free media, supplied as a 1 X stock (Sigma, H4281) 
serum supplement supplied as a IX stock (Celox, 2010026) 
protein-free supplement supplied as a IX stock (Gibco, 11910) 
OptiMAb is a defined protein-free concentrate. The product 
consists of alternate carbon sources, a monoclonal antibody 
inducer, and essential nutrients which, have been shown to be 
significantly depleted during the high-density culture phase. In 
addition, this product has been formulated to shift culture
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osmolarity into a range known to be optimum for antibody 
production (Mercille & Maisse, 1998; Jayme, 1991).
DMEM: with Glutamax II, supplied as a IX stock (Gibco, 041-21661M)
Glutamine is well known for its vital role in cellular metabolism, 
both as an energy source and as a precursor for nucleic acid 
synthesis. However its instability in culture media, which 
involves spontaneous deamination to pyrrolidone carboxylic acid 
(PCA) and ammonia makes it an unfavorable energy choice in 
culture medium. Glutamax II is a heat stable derivative of 
glutamine. Glutamax II used in conjunction with hybridoma 
cells, is a poor stimulator of cell division and growth due to its 
inability to travel through the cell especially the mitochondrial 
membrane. For this reason, the optimum time to add Glutamax II 
to the cells is when the culture is reaching the plateau phase of 
growth thus enhancing antibody production in the maximum 
number of cells (Hosoi et al., 1988).
2.3.3 Mycoplasma analysis of cell lines
Mycoplasma examinations were carried out routinely (every 3 months) on all cell lines 
used in this study.
2.3.3.1 Indirect staining procedure for Mycoplasma analysis
Mycoplasma negative NRK cells (Normal Rat Kidney fibroblasts) were used as 
indicator cells for this analysis. The cells were culturcd with supernatant (harvested 
from test cell lines after 2-3 days confluency) from test cell lines for 4 to 5 days, fixed 
and stained with Hoescht 33258 fluorescent stain (bisbenzamide) which binds 
specifically to DNA, thus it would stain the nucleus of the cell and any Mycoplasma 
infection, which can be seen as small fluorescent bodies in the cytoplasm of the NRK 
cells. Positive controls consisted of NRK cells infected with Mycoplasma enriched 
supernatants.
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2.3.3.2 Direct staining procedure for Mycoplasma analysis
The direct procedure for Mycoplasma involved inoculating test samples onto an 
enriched Mycoplasma culture broth (Mycoplasma broth base, Becton-Dickinson, 
255420) to optimise the growth of any contaminants and incubated at 37°C for 48h. 
Samples of this broth were then streaked onto plates of Mycoplasma agar base and 
incubated for 3 weeks at 37°C and 5% CO2 . Plates were checked microscopically every
7 days for the growth of small oval shaped colonies, which were indicative of 
Mycoplasma i nfect i on.
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2.4 Antibody Detectioii
2.4.1 Mouse IgG ELISA
The purpose of the Mouse-IgG ELISA, was the quantatitive determination of mouse 
IgG in mouse hybridoma supernatants and ascities (Figure 2.1). The Elisa plates were 
coated with an anti mouse IgG (Fc specific), F (ab') fragment o f goat antibody (Sigma 
M0284), 2(j,g/ml per well in 100 (j.1 in carbonate buffer (1.378g NaHCOa and 0.382g 
Na2 CC>3 dissolved in 160ml distilled H20 , the pH is calibrated to 9.5 +/'0.1 with NaOH 
and finally the buffer is brought to a final volume of 20mls) and incubated overnight at 
4°C. The plates were washed once in TBST (Tris Buffer Saline 0.1% (v/v) Tween 20 
(Merck)) and then incubated with blocking buffer (1% (w/v) BSA (Sigma A3803), 0.1% 
Sodium Azide, PBS) for 1.5 hours at room temperature. The plates were then washed in 
1%. 100^1 of standards and sample was added to the antibody-coated plates and
incubated at 37°C for 1 hour. This solution was then discarded and the plates washed 3 
times in wash buffer, 1 % TBST. 1 OOjil of secondary antibody, alkaline-phosphatase- 
linked rabbit anti mouse immunoglobulin, IgG (Sigma, diluted 1/2000 in TBST) was 
added to each well and incubated at 37°C for 1 hour. The secondary antibody was then 
removed and the plates washed three times in TBST as before. Plates were then 
incubated with the substrate solution (1 mg/ml p-nitrophenyl phosphate (PNPP, Sigma 
N-9389) in 0.1M glycine, 0.001M MgCl2, 0.001 M ZnCl2, pH 10.4) at 37°C for 0.5-1 
hour or until a yellow colour appeared in the wells. The reaction was stopped by the 
addition of 1M NaOH, which also enhanced colour. Absorbencies were read on a 
Titerex ELISA plate reader at 405 nm. Positive reactivity was determined by 
comparing the supernatant containing wells with the standard curve.
55
Substrate
IgG culture supernatant 1° Antibody
2° Antibody Rabbit anti-mouse
Capture Antibody goat anti-mouse
Figure 2.1 Representation of a Sandwich ELISA.
2.4.2 Nephelometry
The MININEPH (The Binding Site, UK) was used to determine IgG concentrations in 
cell culture supernatants. The MININEPH is an endpoint nephelometer that uses the 
measurement of light scattered by an antibody/antigen reaction to determine protein 
concentrations.
The light source is a diode laser that emits at 670nm. The focused light passes through 
a cuvette containing the reaction mixture, where the antibody/antigen complexes cause 
light to be scattered. The scatter is proportional to the amount of antigen/antibody 
complexes that have formed, and is detected by a photodiode (Figure 2.2).
The User Prepared Chemistry mode (UPC) was the program used. A stirring bar was 
initially added to the cuvette (ZK501.R). lOpl of the sample (neat or diluted) was 
carefully added to the bottom of the cuvette. The cuvette was then placed into the 
cuvette chamber. Using an electronic pipette 400 pi of reaction buffer (SN041) and 
40pl of antiserum (PC272) are added to the cuvette. The assay settings included a blank 
time of 15 seconds and a read time of 900 seconds. Measurements of scatter were 
recorded at regular intervals to generate a curve of concentration versus scatter from 
which unknown samples may be determined.
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The standard used in the generation of the standard curve was that used in conjunction 
with the RID plates (G272.3) (Section 2.4.3). The standard had a neat concentration of 
1200 mg/L. The control used in these experiments was the c-myc MAB (IgGi). 
Controls were examined at varying dilutions to ensure sample results lay in the linear 
region of the graph.
lamp
photocell
Figure 2.2 Representation of nephelometric process.
Validating the nephelometer involved performing inter and intra variation assays, along 
with determining the linearity of the standard curve, the specificity and accuracy of the 
assay.
The intra assay variation involved measuring a sample from the same specimen for 
approximately ten separate assays and comparing the average %CV (Coefficient of 
variation) of all the samples. The inter variation assay involved assaying samples from 
the same specimen in triplicate over four separate working days and comparing the 
results by measuring the average %CV.
The linear range and upper/lower limits of detection of the standard curve were 
determined by carrying out a range of standard curves and identifying these parameters 
The linear part of the curve was the region from which sample concentrations could be 
determined.
The specificity of the assay was determined by employing a variety of standard IgG and 
IgM samples and by measuring their concentration on the nephelometiy. Results 
obtained were compared to their actual concentrations. The accuracy of the standards
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was determined by comparing the theoretical value with the actual value (Section
2.10.4).
2.4.3 NanoRID
Radial Immunodiffusion (RID) using the NANORID detection kit (The Binding Site, 
GT272.3) is a technique that is routinely used for measuring the concentrations of 
various soluble antigens in biological fluids. It is principally derived from the work of 
Mancini et al., (1964) and Fahey & McKelvey (1965). The method involves antigen 
diffusing rapidly from a cylindrical well through an agarose gel containing an 
appropriate monospecific antibody. Antigen-antibody complexes are formed, which 
under the appropriate conditions will form a precipitation ring. The diameter of the ring 
can be measured and compared to a list of RID references (Figure 2.3).
Calibrator and unknown samples of 10pl were added to each of the wells and allowed to 
diffuse for 72 hours.
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’ma» MTiblo
Figure 2.3 RID Reference table for mouse Immunoglobulins. Concentrations in 
mg/L (Adapted from The Binding Site Ltd product information sheet)
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2.5 MAb Purification
2.5.1 Purification
The NAb™ Protein L Spin Kit (Pierce, 20530) was used to purify IgG from culture 
supernatants. Initially protein L beads were used but it appeared that the antibody was 
not binding, so the beads were changed and protein G beads were used.
0.2ml of immobilised Protein G gel slurry was washed by adding 0.3ml of PBS, mixing 
gently and then spinning down at maximum speed using a centrifuge (14000rpm). 
0.4ml of supernatant was added to the protein G beads and gently mixed for 30 minutes. 
Non-specifically bound antibody was removed using 0.4ml of PBS and spinning for 1 
minute. This was repeated three times.
The protein of interest was removed by adding 0.4ml of elution buffer and mixing for 5 
minutes. Eluate was collected by spinning at maximum speed for 1 minute. This was 
repeated three times. Eluted samples were neutralised by adding immediately 40pl of 
1M sodium phosphate, pH 8.0.
2.5.2 Dialysis
Culture supernatants were transferred to a Slid-a-lyser dialysis cassette (Pierce, 66406) 
and dialysed against two changes of PBS (10 L) overnight at 4°C.
2.5.3 Isotype analysis
The mouse MAbs were isotyped using an isotyping kit specific for mouse MAbs, i.e. 
Isostrip Mouse Monoclonal Antibody Isotyping Kit (Boehringer Mannheim, 1493027). 
The isotyping strip bears immobilised bands of goat anti-mouse antibodies 
corresponding to the common mouse antibody isotypes and to kappa and lambda light 
chains. The development tube also contains anti-mouse lambda and kappa chain 
antibodies immobilised on latex beads, which bind to all mouse monoclonal antibodies 
regardless of isotype. Upon addition of the test strip to the development tube containing 
the test antibody/latex bead complex, the complex travels up the strip until it binds to
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the goat anti-mouse antibody specific for the monoclonal isotype. Results appear as a 
blue band in two sections corresponding to the subclass and light chain type.
Hybridoma supernatants were diluted 1/100 and ascities 1/20,000 in PBS and incubated 
for up to 10 minutes at room temperature. Once the positive control bands were 
suitably developed, the black strip and the base of the isotyping strip was removed to 
prevent any further band development.
Mouse MAbs were also istoyped using an ELISA based mouse MAb isotyping kit, (The 
Mouse Typer®Sub-Isotyping Panel, BIO-RAD, 172-2055).
For the ELISA method, ascities was diluted 1/100 and 1/1000 in carbonate buffer, pH 
9.5. 100pl of this ascities solution was added to each well of a chosen column and 
plates were incubated for 1 hour at 37°C and then overnight at 4°C. Mouse 
immunoglobulins were included as a positive control. Plates were washed with wash 
buffer (0.1% (v/v) Tween 20 in PBS (phosphate buffer salts)). Non-specific sites were 
blocked with 1% (w/v) BSA in PBS for 1 hour at 37°C. The blocking buffer was then 
discarded and washed as before. lOOpl of appropriate rabbit-anti-mouse 
immunoglobulin (i.e. anti-IgG 1, 2a, 2b, 3, anti-IgM, anti-kappa, and anti-lambda chain 
etc.) from the kit was added to each row (each column containing immobilised test 
antibody or standards). Plates were incubated at 37°C for 1 hour. Plates were then 
washed as previously described. 100pl of goat anti-rabbit immunoglobulin-alkaline 
phosphatase conjugated antibody diluted in blocking buffer was then added to each well 
and incubated at 37°C for 1.5 hours. Following the washing, 1 mg/ml p-nitrophenyl 
phosphate (PNPP, Sigma 104-0) in substrate solution was added to each well and 
incubated for 0.5-1 hour at 37°C. Colour enhancement was achieved by the addition of 
0.2M NaOH. Plates were read on a Titerex ELISA plate reader at 405nm.
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2.6 Immunocytochemical Analysis
Table 2.3 Source description and media requirements of cell lines used in 
immunocytochemical experiments described in this thesis.
Cell line Cell type description Basal Medium Source
1)1. KP
Human non-small-cell
lung carcinoma.
ATCC
NCTCC 
Law e/ a/., 1992
DLKPA
Human Non-small-cell 
lung carcinoma. Drug- 
selected (Adriamycin)
ATCC
NCTCC 
Clynes et al, 
1992
Zr-75-1
Human ductal breast 
carcinoma
RPMI-1640 
(Gibco, 52400-025)
ECACC 
Engel et al., 1978
NCTCC: National Cell and Tissue Culture Centre, Dublin City University,
Glasnevin, Dublin 9, Ireland.
ECACC: European Collection of Animal Cell Cultures, Salisbury, Wiltshire, SP4
OJG.
ATCC: basal media consists of a 1:1 mixture of DMEM and Hams F12.
RPMI 1640: RPMI 1640 media supplied as a IX stock (Gibco, 52400-025).
2.6.1 Preparation of cytospins
Glass slides were coated with poly-l-lysine (Sigma, P-8920) prior to all 
immunocytochemical procedures (Huang et al, 1983). Glass slides were washed in
0.5% Tween 20, rinsed thoroughly, immersed in 70% IMS for 10 minutes and dried at 
37°C. Approximately 10|il of poly-l-lysine was applied to one end of slides and spread 
into an even film over whole surface of slides. Coated slides were stored at RT until 
required.
Cells from actively growing cultures were trypsinised (Section 2.2.2), washed 3 times 
for 10 minutes in PBS and diluted to a final concentration of lx l0 6cells/ml in PBS. 
Cytospins were allowed to air dry over night. Approximately 100pl aliquots of cell 
suspension were spotted directly onto coated slides, air-dried for 20 minutes after which
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excess liquid was tapped off. Again, slides were allowed to air-dry overnight. All 
slides were foil wrapped and stored at -20°C until required.
2.6.2 Immunocytochemistry
All immunocytochemical studies on cell lines were performed according to the method 
of Hsu et al., (1981) using an avidin-biotin horseradish peroxidase (HRP) conjugated kit 
(ABC) plus an appropriate secondary antibody.
Cytospin preparations were fixed for optimal time in ice-cold acetone (6/1C: 1 minute; 
5C3: 4 minutes, 4/2D: 10 minutes; 1/11C: 4 minutes) and allowed to air dry for at least 
15 minutes prior to immunostaining. Endogenous peroxidase activity was quenched by 
placing cytospins in 0.6% (v/v) H202/methanol. All slides were blocked for non­
specific staining with 20% (v/v) normal rabbit serum for 20 minutes. Primary 
antibodies were applied to each sample optimally diluted in 1% TBST (Tris Buffer 
Saline 0.1% (v/v) Tween 20 (Merck)) (dilutions ranged from neat, 1 in 2 and 1 in 10). 
Primary antibodies were incubated overnight at 4°C or for 2 hours at RT, which was 
followed by a 30 minute incubation with biotinylated rabbit anti-mouse IgG (1/300 
dilution in TBS/ 0.1% (v/v) Tween 20). Finally, Vectastain Elite ABC reagent (HRP 
conjugated)(Vector Laboratories, UK PK-7100) was applied for 25 minutes and the 
peroxidase substrate 3’-3-diaminobenzidine tetrahydrochloride (DAB) peroxidase 
substrate kit (Vector Laboratories, UK SK-4100) was then applied for 5-7 minutes. All 
incubations were carried out at RT and slides were washed after each incubation in 3 
changes of (TBS/0.1% (v/v) Tween 20 over 15 minutes). Cells were lightly stained 
with haematoxylin, differentiated in 1% (v/v) acid alcohol and ‘blued’ in Scott’s tap 
water. Following dehydration in graded alcohol, slides were cleared in xylene and 
mounted in DPX (BDH, UK). Negative control slides in which primary antibody was 
replaced by control mouse immunoglobulins (1-2000, Vector Laboratories, UK) (used 
within the manufacturers recommended concentration range) were included in all 
experiments.
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2.7 SDS PAGE
2.7.1 Gel electrophoresis
Proteins were separated by SDS-PAGE (Laemmli et al., 1970). Gels were prepared as 
outlined in Table 2.4 and poured into clean 10cm x 8cm gel casting cassettes (Mighty 
Small™ SE 245, Hoefer, US) which consisted of one glass plate and one aluminium 
plate separated by 0.75cm2 plastic spacers. The resolving gel was poured first and 
allowed to set. A layer of saturated isobutanol (50ml isobutanol: 5ml dH20) was gently 
layered over the resolving gel to prevent drying out. When the resolving gel was set the 
layer of isobutanol was washed off with several changes of dEkO. The stacking gel was 
then poured and a comb was fitted allowing the formation of wells for sample loading. 
Once the gels had set (at RT) they were wrapped in tinfoil and stored at 4°C if not used 
immediately. Approximately 15-30pg of protein was applied to each well of the 
polyacrylamide gel. Pre-stained molecular weight markers (New England Biolabs, UK) 
were also loaded onto the gel for the determination of the molecular weight of unknown 
protein samples. Gels were run at 250 volts and 45 milliamps. (Atto power pack, Atto 
Corp., Japan) for 1-1.5 hr or until the bromophenol blue line reaches 1cm from the end 
of the gel (values were halved if only one gel was being run), with IX 
Tris/Glycine/SDS running buffer (Biorad, 161-0732). When the gel had run fully, 
electrophoresis was stopped. The gel was then placed in Coomassie stain for 
approximately 10 minutes and destained until the protein bands become visible. The 
composition of destain was: methanol 30%, glacial acetic acid 10%, H2 O 60%.
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Table 2.4 P rep a ra tio n  o f  e lec tro p h o res is  gels
Component Resolving Gel (12.5% Acrylamide)
Stacking Gel 
(5% Acrylamide)
Acrylamide/Bis-acrylamide
(code A-3574, Sigma, USA) 6.08ml 0.84ml
Distilled H20 4.95ml 2.84ml
1.5M Tris/HCL, pH 8.8
(code 161-0798, Bio-Rad, USA) 3.75ml
0.5 M Tris/HCL, pH 6.8
(161-0799, Bio-Rad, USA) 1.25ml
10% SDS
(code 161-0416, Bio-Rad, USA)
150|o,l 50|al
10% Ammonium Persulphate
(code A-3678, Sigma USA)
60(j.l 20fj.l
TEMED
(code T-9281, Sigma, USA)
lOfal 5(xl
2.7.2 Protein Concentration Determination
Microtitreplate method
Protein concentration was determined by the BCA method (Smith et al., 1985) using a 
kit obtained from Pierce (Pierce, 23225). Protein samples (crude cell lysates) were 
diluted to a final volume of IOOjj.1 in PBS. BSA protein standards of known 
concentration were also prepared from a 2mg/ml stock solution in PBS in borosicilliate 
test tubes. Negative controls consisted of PBS only. lOOpl of the BCA reagent 
(prepared according to the manufacturers instructions) was added to each protein 
sample, mixed and incubated at 60°C for 30 minutes. Following a brief cooling period, 
samples were transferred to plastic cuvettes (Elkay) and the absorbence read on a 
spectrophotometer (Titertek, Multiscan Plus) at 562nm. A standard curve of absorbance 
versus protein concentration of the BSA standards was constructed. The protein 
concentration of the test samples was then calculated.
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2.8 In Vitro Propagation of Hybridoma Cells
2.8.1 Hollow Fibre Bioreactor
All experiments with hollow fibre cultures were performed in the cellmax artificial 
capillary module (Cellco Inc, 400-011). Both serum-supplemented and the protein-free 
medium PFHM II were used during the course of these experiments.
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Figure 2.4 Longitudinal section through a typical hollow fibre cartridge. The terms 
upstream and downstream indicate axial position with respect to the bulk 
ICS flow. ICS = Intracpaillary space, ECS = Extracapillary space. 
(Adapted from http://www.iam.ubc.ca/~marek/Chauterl.pdf)
The cellmax system comprises of a pump station and artificial capillary module. The 
pump station compresses the pump tubing on the artificial capillary module forcing the 
culture medium to flow through the artificial capillary cartridge. The artificial capillary 
module is comprised of an artificial cartridge, oxygenation tubing, and a positive 
displacement pump on a plastic-flow-path stand. It is connected to a medium reservoir 
bottle by a short length of silicon tubing. Medium is oxygenated during its passage 
through the coils of silicone tubing on the flowpath.
A pre-culturing step was initially performed. This involved draining the ECS of fluid 
by flushing pre-warmed medium through the cartridge approximately five times (Figure
2.4). The inlet and outlet tubes from the artificial capillary cartridge were connected to
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a bottle containing 100ml of pre-warmed culture medium. This system with medium 
flowing through the cartridge was set up at a high flow rate for 48 hours. At least two 
hours prior to inoculation, the system was refreshed with pre-warmed medium.
Cells were inoculated at a density of 5xl07cells/ml directly into the artificial capillary 
module via the side port tubing. The outlet and inlet tubing were closed with slide 
clamps to prevent ultrafiltration during inoculation. The flow rate of medium through 
the cartridge was set to low to enable maximum attachment of the cells to the hollow 
fibres.
The following settings were used for the operation of the Cellmax: 5% CO2 , 
temperature 37°C, for the first seven days flow-rate was set at 5ml/min to enable an 
environment where cells could attach to the hollow fibres. On subsequent harvests, 
depending on the degree of antibody production the flow-rate was increased to 
25ml/min and 50ml/min. Each run in the hollow fibre lasted for 21 days. Supernatant 
was harvested every two days after day 7 for cell viability and productivity analysis. 
Medium was replaced at each harvest. Glucose and lactose analysis was performed 
using a glucose sensor kit (G2, MediSense).
2.8.2 Spinner Flask Culture
2.8.2.1 Spinner flask suspension culture
500ml and 1L glass spinners from Bellco (New Jersey) and 10L fermenter vessels from 
FT Applikon (Flolland) were used for scale-up and growth of MAbs. Before glass 
vessels could be used for cell culture experiments they needed to be treated to prevent 
cells adhering to the glass.
After sterilisation flasks were rinsed with pre-warmed medium and incubated at 37 C 
ready for use. Hybridoma cells in the exponential phase of growth were collected in the 
manner described in Section 2.2.2. Cell counts were carried out using the method 
described in 2.2.4. A total working volume of 50ml of medium containing cells diluted 
to the required density were inoculated into the spinner. Flasks were incubated at 37°C 
on a magnetic stirrer spinner unit (Bellco).
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Sampling was carried out in the laminar flow cabinet making sure to keep the agitator 
rotating to ensure a representative sample from the spinner flask was been obtained. A 
lml sample was taken and centrifuged at lOOOrpm for 5 minutes. The pellets were 
resuspended in 10ml of the appropriate media. Cell counts were carried out as 
described in section 2.2.3. Cells were re-seeded at the desired inoculation density using 
fresh media.
2.8.2.2 Depyrogenation
The glass vessels were steeped in 0.5M NaOH overnight to remove any pyrogens that 
may have attached to the vessel. The NaOH was removed and the vessel was washed 
thoroughly with purified H20. Prior to siliconisation the vessel was dried overnight at 
37°C.
2.8.2.3 Siliconisation of Spinner Flasks:
A small amount (approximately 10-15ml in the case of the 500 spinner flasks, 20-25ml 
in the case of the 1L flask and 60-75ml in the case of the 10L vessel) of 2% 1,1,1- 
dimethyldichlorosilane solution (BDH 331644V) was added to the flasks, which were 
then rotated by hand to ensure even coating of all the surfaces (including the agitator). 
This procedure was carried out with care in the fume hood. The flasks were allowed to 
air-dry for approximately 1 hour after which time they were rinsed three times in UHP. 
A small amount of UHP water was left in the spinner flask after the final rinse and the 
two side arms caps were not fully tightened to prevent steam ventilation during 
autoclaving. Flasks were then loosely covered with tin foil and sterilised at 121°C at 
lbar absolute pressure for 20 minutes.
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2.8.3 10 L Bioreator
2.8.3.1 System Background
The ADI Bio Controller ADI 1060, the ADI 1035 Bioconsole and the ADI 1040/25 
were used in unison for the process control of the 10L Applikon bioreactor. The 
purpose of the ADI 1060 was to control and monitor mammalian cell culture systems in 
a controlled environment where pH, temperature, dissolved oxygen and mixing can be 
controlled.
The ADI 1035 Bioconsole was an actuator console that was used in combination with 
the ADI 1060 Bio Controller. It supports gas flow regulation, stirrer speed, pH control, 
dissolved Oxygen control, level control, temperature control, and liquid 
addition/withdrawal via pumps.
The ADI 1040/25 functions by connecting the ADI 1060 Bio Controller with the 
bioreactor and their actuator consoles. The measured sensor signals were amplified in 
the 1040/25 and were transmitted to the Bio Controller through serial communication. 
Depending on deviation from the set point, a controller output value was sent to an 
analog or digital output that would activate the actuator in the ADI 1035 in order to 
decrease the deviation from the set point. The control system is shown below (Figure
2.5) and outlines the roles played by each component of the process system. The 
associated 10L Bioreactor was a glass stirred tank reactor.
Bioreactor
I/O  In te rface  
1
A ctu a to r
r  oncnlp
A D I
IMS
ADIin^ n
Biocontroller
S cada (B ioexpert 
system )
Figure 2.5 Schematic overview of the Applikon “bioprocess” system.
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2.8.3.2 Preparation of the glass vessel
As per sections 2.8.2.2 and 2.8.2.3.
2.8.3.3 Preparation of the headplate
(See appendix IV for head-plate description). The ports in the bioreactor are numbered 
from 1 to 19. The parts associated with the head-plate are mounted in accordance with 
the diagram in appendix IV. All silicone O-rings were inspected for damage and, if 
necessary were replaced. When bioreactor parts were mounted in the head-plate, 75cm 
of C-flex tubing was connected to the bioreactor lid (see Figure X) in the following 
ports; 2 (a -c), 5 (a - c), 10,12, and 13. A Whatman filter gas exhaust system was added 
to the C-flex tubing at the following ports; 2a and 10. A Millex FG 50 filter was 
attached to the c-flex tubes on ports 2 (b+c) and 5(a, b,+ c). The rest of the tubes were 
folded at the end and tied off with a cable ties
All tubes, which were connected to the bioreactor lid, were secured with the aid of cable 
ties. This also applied to the connectors and the glassware connected to the silicone 
tubing.
2.8.3.4 Integrity Testing
2.8.3.4.1 Aeration tubing Test:
The vessel was filled with 10L of water ensuring that all silicon aeration tubing and 
connections were completely covered. While the baskets were in the water filled 
bioreactor, air was passed through the tubing. Leakage was signified by the visualisation 
of bubbles arising from any point in the tubing. A pressure holding gauge test using the 
Sartocheck was carried out. A digital pressure gauge was attached to one end of the air 
tubing and air was pumped into the tubing until a 0.6bar pressure was obtained. The 
other end of the tubing was clamped off. The pressure was not allowed to drop more 
than 250mbar over 15 minutes to enable successful completion of the test.
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2.8.3.4.2 Bioreactor Testing:
The lid of the bioreactor was clamped tightly to the glass vessel. An integrity test was 
initiated using the Sartocheck by passing air under pressure (0.5bar) into the system 
ensuring that the pressure drop over 15 minutes was less than 50mbar.
2.8.3.5 Calibration
2.8.3.5.1 Temperature
A water bath was heated to 37°C. The bioreactor temperature probe was removed from 
its holder and was inserted into the bath until it recorded a stable temperature. A digital 
thermometer was used to measure the temperature of the water. The temperature 
recorded on the digital thennometer was entered into the ADI 1060 as the calibrated 
value for the temperature probe.
2.8.3.5.2 pH
A sample of media was removed aseptically from the bioreactor. The pH was 
determined using a calibrated pH meter. The value obtained is entered in to the ADI 
1060 as the exact pH value of the medium.
2.8.3.5.3 Dissolved Oxygen Concentration
In order to generate a calibration curve to determine the dissolved oxygen concentration
at any point during the culture, two points were chosen, an upper and lower limit.
Initially nitrogen was gassed into the system. This resulted in a drop of dissolved 
oxygen concentration to approximately zero. Zero was entered as the first point of the 
curve in the ADI 1060. Air or oxygen was then gassed into the system until a stable 
reading of 100% was obtained. At this stage 100 was entered as the upper point of the 
calibration curve in the ADI 1060.
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2.8.3.6 Inoculation
The vessel was filled with 10L of the appropriate medium and supplements. The 
contents were allowed to adjust to the required pH, temperature and dissolved oxygen 
levels for a period of approximately 2 hours. The appropriate inoculation density of 
cells was added as soon as the process conditions had stabilised. Sterility checks were 
carried out after the addition of each substance to the culture media.
2.8.3.7 Sampling
10ml samples were taken daily to calculate cell number, viability, and glucose/lactate 
concentrations. Using a welder, a sterile sample bag was connected to the outlet tubing 
from the culture medium and the sample medium was extracted and analysed.
2.8.3.8 Product Collection
At the end of a culture run, the agitator was switched off in order to allow the cells to 
settle out of suspension. The remaining culture medium was aseptically siphoned into 
1L glass bottles. The medium was subsequently spun down and the supernatant frozen 
at -20°C until required.
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2.9 10 L Validation
2.9.1 Performing an Installation Qualification (IQ)
The puipose of this IQ was to provide documented evidence that the Applikon 10L 
Bioreactor and control units were installed as per design intent and to the
manufacturer’s recommendations where applicable.
The IQ was the documentation process, which verified that the physical components of 
a system have been installed according to design specifications. The IQ also served as a 
final equipment audit prior to equipment operation. The installation of the system was 
verified by reviewing the equipment installed and using the check sheets provided in 
this protocol to document that the system components conformed to design 
specifications. In addition, where applicable, engineering documentation were reviewed 
and compared to the installed system.
The following list incorporates the headings used and explanations for each step in the 
validation process. These are only an outline, a full description is given in Appendix
Specification & Documentation Review
This section identified a list of all specification and purchase documentation 
associated with the bioreactor and verifies that this documentation was complete 
and accurately describes the installed equipment.
Engineering & Safety Documentation Review
This section identified a list of all engineering documentation associated with 
the bioreactor and verifies that this documentation was complete and accurately 
describes the installed equipment.
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Equipment List
A list of all installed process and ancillary equipment based on information from 
the purchase orders and equipment specifications were included here.
Instrument List
A complete list of instruments designated critical or non- critical was included 
in this section.
Critical instruments pertain to those whose performance will affect the operation 
of the system or the quality attributes of the process material.
Non-critical instruments were those provided for information or convenience 
purposes only. The information provided included an ID number, manufacturer, 
location, and description of each item.
Utilities Verification
A complete list of utilities supplied to the equipment based on equipment 
specifications.
Materials o f construction % Lubricants list
A complete list of materials of construction of equipment components and 
lubricants used was included in this section.
Control o f System Hardware
A complete list of major control hardware including installed boards and 
communications cabling based on information from purchase orders and 
equipment specifications. Verification that the items have been installed as 
specified was included. Indication of hardware identification, location,
manufacture and description for each item as was applicable was also included.
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Input/Output List/Loop check Documentation
Verification of existence and adequacy of loop checks performed by the 
installing contractor.
Setpoints & Software Parameters
Documented set points and other operating parameter data installed in the 
control panel or on local instrumentation
Software Documentation
The revision of installed software was recorded. Installation location, including 
hardware model Number, serial Number, manufacturer, reference specifications, 
printed copy of annotated applications code (ladder logic etc.), including date 
and version, software functionality flowcharts and documentation of any 
modifications made to the software.
Factory Acceptance Testing
Listed all audit and testing documentation including vendor audit report, test 
procedures and results of any testing performed on the system, including 
commissioning and Factory Acceptance Tests (FAT). Verified completeness of 
documentation and satisfactory resolution of any deviations or failed tests.
Standard Operating Procedures
Listed all applicable SOP’s including procedures for operation, cleaning, 
maintenance, change control and calibration. Verified that these were in place, 
that they accurately describe the applicable equipment and that they were 
implemented by appropriate personnel. Training records should be available for 
all personnel operating the bioreactor.
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Installational Qualification Discrepancy Summary
Documented any discrepancies or variations noted during the execution of the 
IQ protocol. Included the resolution of these items and/or any item outstanding 
that would require resolution in the future.
Once each section in the Validation Qualification has been completed it needs to be 
checked and signed off by at least three personnel. In this case these were the 
fermentation manager, the validation supervisor and the QA manager.
2.9.2 Operational Qualification
The purpose of the Operational Qualification (OQ) was to demonstrate that the 
Applikon 10L Bioreactor and control units operated according to the design intent and 
manufacturers recommendations.
The Performance Qualification provides documented evidence that the Applikon 10 L 
bioreactor and Control Units consistently function in accordance with the design 
specification and were effective in maintaining the growth of mammalian cells over a 
period, free from contamination. The PQ was the testing process, which evaluates the 
effectiveness and consistency of the Applikon 10 L bioreactor and Control Units during 
routine production as defined by the relevant Standard Operating Procedures (SOP's). 
The PQ verified that the equipment will consistency meet its predetermined 
specifications. The 10L bioreactor and Control Units were challenged during the PQ 
stage to determine the ability of the system to maintain adequate culture conditions.
Configuration Table ADI 1060
This section involved recording the sensor card settings for each of the following 
functions:
■ pH
■ D 0 2
■ Digital Output
■ Analog Output
■ Serial Communications
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These were default values and should not change over the course of the fermentation 
run.
The next part of an operational qualification involved looking at the temperature, pH, 
DO2 , and level controls and how they reacted when asked to perform a function.
Temperature
To examine the ability of the temperature control system to maintain temperature at a 
constant the following test was set up and results were recorded.
Cultivation Mode
Control Temperature inside bioreactor at 37°C during cultivation, with a stirrer speed of 
lOOrpm for at least 3 hours.
To test the response of the temperature control system to various commands, the 
following experiment was initiated and results were recorded.
Test Mode
■ The temperature controller on ADI 1060 was initiated.
■ "Stepresponses" were created by changing the temperature setpoint using a profile 
as seen in Table 2.5.
■ The criteria for overshoot during cooling and heating were +/-2°C and within an 
hour after reaching the set-point the temperature must be stable (+/- 0.2°C). 
Periodical data was recorded.
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Table 2.5 List of temperature “stepresponses”
SETPOINT CHANGE DATE SIGN INSPECTOR CHECK: PASS/FAIL
37°C---- > 31°C
31°C---- > 3 5 °C
35°C---- >  37°C
37°C---- >  32°C
32°C >  31°C
31°C 37°C
pH
To test the response of the pH control system to various commands the following 
experiment was initiated and results were recorded (Table 2.6)
Test Mode
■ The pH control on the AD 11060 was initiated.
■ The pH simulator (setpoint 7.0 pH) was connected to the system.
■ The value on CO (control output) was measured.
Table 2.6 List of pH commands
SET POINT 
CHANGE
CO/VALUE
(CO %)
CHECK
ACTUATOR
PASS/FAIL
SET
POINT
CHANGE
CO/ PUMP
BASE
CHECK
ACTUATOR
PASS/FAIL
4 4
7 5
8 6
9 9
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d o 2
To test the response of the DO2  control system to various commands the following 
experiment was initiated and results were recorded (Table 2.7).
Test Mode
■ The DO controller in the ADI 1060 was initiated.
■ A DO-simulator (setpoint 25%) was connected.
■ The CO (control output) was checked.
Table 2.7 Dissolved Oxygen control values.
SIMULATOR
AIR
VALVE
(CO%)
CHECK
ACTUATOR
PASS/FAIL
ST IRRER SPEED
(CO%)
CHECK
ACTUATOR
PASS/FAIL
0
50
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2.10 Statistical Analysis
All data was expressed as the mean of the number of replicates being analysed +/- 
standard deviation (sd)
Samples from the suspension culture of the hybridoma producing cell lines 4/2D and 
5C3 (Section 3.4, 3.5, 3.6, 3.7, 3.8, 3.9) were recorded in duplicate and readings shown 
on graphs were an average of the two readings.
2.10.1 Specific Growth Rate
The growth of cells in batch suspension culture may be represented by the following 
equation:
dV—  = fj.V (Equation 1)
dt
V = viable cell density (cells/mL) 
p. = specific growth rate (1/t) 
t = time (d)
The equation (1) above implies that the increase in the cell population (dV) at a certain 
time interval was proportional to the amount of biomass present (V). The symbol \i was 
the specific growth rate and represents the growth rate of a unit amount of cells.
If p. was constant, then equation (1) may be rearranged:
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Time(C6ys
——  = /u (Equation 2)
Integrated this gives:
In V = In V0 + /.it (Equation 3)
Where V0 was the viable cell concentration (cells/ml) at time = 0.
The plot of In V versus time will be a straight line with a slope of p, the specific growth 
rate. It was important to remember that this equation holds true only when p. was 
constant i.e. p = pmax. The maximum specific growth rate, p = pmax, occurs during the 
period of exponential growth.
Sample Calculation
Calculation of the specific growth rate
Days Cell No. Ln
(xlO6 cells/ml) (Cell number)
3 0.57E+06 13.25
4 1.18E+06 13.98
5 2.38E+06 14.68
i i  =  u ( m a x ) =  0 .7 1 7 2  ( f !
V o  = 6 .6 0 E + 0 4  ( S t a r t in g  c o n c . o f  c e lls )
Figure 2.8 Sample calculation for the determination of specific growth rate p.
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1. A normal growth curve was tri-phasic with a maximum growth rate between the lag 
phase and the onset of the stationary phase (days 1-4).
2. Calculate the natural log (In) of each viable count for days 1-4 and plot against time 
(days).
3. The slope of the best-fit linear regression line was equivalent to the specific growth 
rate and the intercept at the y-axis was equivalent to the natural log of the starting 
concentration of cells, Vo. In the example shown \x = |xmax = 0.7172 d'1 and Vo = 6.6 
x 104 cells/ml.
4. If sufficient data was available within the time periods 0-1 days (lag or adaptation 
phase and days 4-6 (stationary phase), then these growth rates can be determined in 
a similar fashion.
2.10.2 Doubling Times/Number of Generations
The doubling time (td) simply represents the time taken for a cell population to double 
in number i.e. to proliferate from Vo to 2Vo cells/ml. By substituting these into equation 
(3) we get:
ln2F0 = ln V0 + /utd (Equation 4)
and rearranging:
ln2---- = td (Equation 5)
The number of doublings or generations, n, may be calculated by:
1 v rn = ---- In—  (Equation 6)
In 2 V0
Where Vo was the starting viable cell density and Vf the final cell density. If calculating 
the number of generations for the lifetime of a cell in culture, simply total the number of 
generations calculated at each sub-culture.
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Sample Calculation:
Using data from the example shown above, the doubling time was determined as 
follows:
In  9
t,, = ---------= 0.996 d~l or 23.19hours (Equation7)
0.7172
The number of generations, n, using measured data yields:
1 , 0.579X106 .  _  A. oxn = ---- In------------ — = 3.127 (Equation 8)
In 2 0.66^10
2.10.3 S ta n d a rd  D e via tio n
Standard deviation tells how spread out numbers were from the average, calculated by 
taking the square root of the arithmetic average of the squares of the deviations from the 
mean in a frequency distribution.
It was calculated as follows:
a  N
X = Sample.
H = Mean.
N  = Total Number of Samples.
Coefficient o f Variance (CV):
_ Standard Deviation 
Mean
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This is the closeness of agreement between the value, which is accepted either as the 
conventional or true value or an accepted reference value, and the value found. It is 
determined as follows:
r Theoretical Re suit -  Actual Re suit ^
[--------------------------------------------- ] * 100
Theoretical Result
2.10.4 Accuracy
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S e c t io n  3  R e s u lt s
3.0 Hybridoma 6/1C
3.1 C u ltu rin g  a n ti-m d r-1  p ro d u c in g  h yb rid o m a , 6 / IC  in  serum  free  and p ro te in  
fre e  m edia
A seven-day growth curve and subsequent passaging assays of the cells were carried out 
to monitor growth characteristics and antibody productivity of the cell line, 6/1C.
The 7-day growth curve was performed to identify the time of maximum cell density 
and viability of the cells when harvesting cells for scaling up purposes. It was also used 
to compare the growth characteristics of the cell line in each of the different media in 
order to identify which media supports the most efficient growth of the cells. The three- 
day passaging assay looked at the ability of the cells to achieve consistent cell density 
levels. This is important when looking at the stability of cell lines in culture over time.
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2.5
Time (Days)
—•— EX-CELL620 —A— SSM —X— HytxxJoma SFM Sigma SFM HyQSFXMAB
Figure 3.1 Shows comparison of the growth curves of the cell line 6/1C in SSM and 
SFM growth media. The cell line was cultured in six different media for 
a period of 7 days and cells counts were taken daily. Samples on day 6 
were retained for further analysis of antibody productivity.
Time (Days)
ExCell 620 -* -S S M  Hybridoma SFM * Sigma SFM ♦- HyQSFXIMb
Figure 3.2 Shows comparison of the growth rates of the cell line 6/1C in SSM and 
SFM during routine passaging. Cells were re-seeded at lx l0 5cells/ml 
and fed with fresh medium every three days.
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Figure 3.3 Shows comparison of the growth curve of the cell line 6/1C in SSM and 
PFM growth media. The cell line was cultured in six different media for 
a period of 7 days with cells counts taken daily. Samples on day 6 were 
retained for further analysis of antibody productivity.
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Figure 3.4 Shows comparison of the growth rates of the cell line 6/1C MAb in SSM
and PFM during routine passaging. Cells were re-seeded at 1x105 
cells/ml and fed with fresh medium every 3 days.
87
Note: For clarification in Figure 3.2 T d passage data for Sigma in SFM is 
superimposed on data for HyQSFXMAb hence it is not to completely visible to the eye. 
The same applies to Figure 3.4 where Sigma PFM is superimposed behind 
HyQADCFMAb in the 3rdpassage.
The results in Figures 3.1-3.4 indicate that the media, which best sustains the growth of 
the 6/1C cell line are, in the case of SFM, ExCell 620 and Hybridoma SFM. In terms of 
the performance of the PFM, both HTM20CTH and CD Hybridoma, achieved higher 
and similar cell densities respectively, to that achieved with the positive control, SSM. 
The rest o f the media were able to sustain some growth of the 6/1C cell line except for 
the Sigma supplied SFM, which yielded very poor results in terms of growth.
Cell density in each of the media peaked at day 4 with the exception of the serum free 
HYQSFX-MAb and the protein free ADCFMAb, both from Hyclone, which achieved 
maximum cell density at day 5.
In the stationary phase, multiple passage growth assays ExCELL 620, Hybridoma SFM, 
CD Hybridoma media all performed better in comparison to the serum-supplemented 
control (DMEM supplemented with 10% FCS). In addition over the assay growth 
periods the maximum cell density achieved for the cell line in each of the media was 
consistent.
Overall, the media that performed well in terms of growth were the ExCell 620, 
Hybridoma SFM and CD Hybridoma media.
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3.2 Antibody Detection
3.2.1 ELISA
The ELISA method has proven to be unreliable and inaccurate as a method for 
quantifying antibody concentrations throughout the course of this work. The standard 
curve developed was reliable and reproducible but the results obtained for quantifying 
anti mdr-1, antibody from 1/11C cell line, antibody from 5C3 cell line and anti 
topisomerase II-a, (4/2D) antibody production in various media and in the ascites across 
a range of dilutions was never linear or reproducible. This was considered unusual as 
there were four cell lines producing varying quantities of antibody, and in the case of 
the antibody 5C3 large amounts of antibody were been produced in culture. This 
antibody was detected by other means but detection using the ELISA method yielded 
minimal quantities of antibodies (ranging 0.06-0.027 ng/ml).
In addition, the anti-topoisomerase II-a, 42D ascites did however yield results indicating 
the presence of antibody in the samples but the results were never linear across the 
range of dilutions used (range 100-400ng/ml). Optimisation of the ELISA would have 
needed more work to determine the linear range.
To rule out the possibility that a component of the serum was interfering with the assay 
reading or the antibodies ability to bind two standard curves were developed, the first 
standard curve was diluted out in washing buffer and a second was diluted out in 
DMEM containing 10% FBS and 1% P/S (Table 3.1).
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T a b le  3.1 Shows comparison of the standard concentrations of IgG diluted in 
washing buffer (1% TBST) and DMEM containing 10% FBS to test for 
the presence of interfering substances. Absorbance was read at 405nm.
Standard Cone, (ng/ml) 
(In washing buffer)
Absorbance
(OD)
Standard Cone, 
(ng/ml)
(In SSM)
Absorbance
(OD)
200.43 0.720 170.36 0.693
101.28 0.604 67.156 0.534
52.15 0.482 36.081 0.396
24.52 0.300 17.658 0.247
12.55 0.195 8.134 0.131
From a subsequent paired t test carried out on this data, it was concluded that the 
calculated t value of 6.11 is greater than the known table value of 2.132. This allows 
one to reject the null hypothesis at the p = 0.05 level of significance. One can conclude 
that the results obtained comparing the standard concentrations of IgG in washing 
buffer and in serum supplemented DMEM were significantly different from each other. 
Hence, the medium and the presence of serum may have been interfering with the 
readings from the assay (Appendix V sample calculation).
An attempt was made to remove the interfering substances in the supernatant by dialysis 
and then to purify it using the Protein-L spin kit. However, any antibody that was there 
appeared to be lost in this purification step.
T a b le  3.2 Examining the effect of dialysis, purification and concentration on the 
detection of MAb in the supernatant using the ELISA method.
Sample Dilution anti- 
mdr-1 (6/1C) in SSM
Dialysis
(OD)
Protein L-Spin 
(OD)
Concentrated sample 
(OD)
Neat 0.042 0.046 0.260
1 In 2 0.027 0.010 0.136
1 in 10 0.021 0.017 0.039
90
3.2.2 R a d ia l Im m un od iffusion  (R ID ) A ssay
Typically, the presence of IgG in sample supernatant on a RID plate is signified by the 
formation of a white precipitin ring. This precipitin ring is due to the formation of 
antibody-antigen complexes. In the case of each of the anti-mdr-1 monoclonal antibody 
containing supernatants, no precipitin rings were formed indicating the absence of 
detectable quantities of antibody in the samples. Controls supplied with the RID kit 
yielded positive results validating the performance of the kit.
3.2.3 Iso typ in g
Positive IgGi bands were visualised in the positive ascites control (mdr-1 ascites). The 
bands obtained in the SSM containing mdr-1 were very faint and no bands were 
recorded for any of the protein free and serum free medium in which the 6/1C cell line 
was cultured. In order to investigate the presence of IgG in the supernatants, a Mouse 
IgG isotyping kit based on an ELISA method was used. This test was very specific as 
to the types of IgG present in the samples. The positive control of mdr-1 ascites yielded 
a colour change in each of the following wells; IgGi, IgG2A, IgG2B, IgG3 , IgA (Kappa). 
This is indicative of an antibody that is not cloned out properly. Generally, one would 
expect to see a single dominant antibody species in this case IgGi. Analysis of the mdr- 
1 in cell culture supernatant yielded a positive result for IgM in both the cases of SSM 
and PFM, which may be the reason no precipitin rings were identified as the RID kit 
was specific for IgG.
3.2.4 N ephelom etry
The nephelometry results obtained for quantifying anti-mdr-1 MAb were low in 
comparison with those achieved by the 6/lC cell line in previous tests performed in our 
laboratory. Typically, values of 30-35mg/L were obtained in the past. However these 
measurements were carried out using RID, therefore a true comparison cannot be made 
between these results (Moran et al, 1998 Unpublished).
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T a b le  3.3 Nephelometric analysis of antibody production by the anti-mdr-1 (6/1C) 
cell line when cultured in various serum-supplemented, protein free and 
serum free medium. Samples were measured after 6 days of cell growth. 
(For standard curve, refer to Section 3.10.3).
S a m p le  ( M e d iu m )
A n t ib o d y  
C o n c e n t r a t io n  ( m g /L )
S ta n d a r d
D e v ia t io n  a
D M E M  ( + 1 0 %  I  B S ) 15.56 1.44
H T M 2 0 C T H  ( 1 0 X  C o n e .) 12.27 0.60
E X - C E L L  6 2 0  ( lO X C o n c . ) 8.17 1.16
H y b r id o m a  S F M  ( 1 0 X  C o n e .) 7.90 1.69
C D  H y b r id o m a  ( 1 0 X  C o n e .) 12.01 2.28
T C H  ( 1  O X  C o n e .) 14.10 0.342
S ig m a  S F M  ( 1 0 X  C o n e .) 7.40 0.78
S ig m a  P F M  ( 1 0 X  C o n e .) 6.13 0.58
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3.2.5 Im m unocytochem ical analyses o f a n ti-m d r-1  M A b  fro m  the h yb rid o m a  ce ll 
lin e  6/1C supernatant u sin g  th e  p ositive  co n tro l ce ll lin e , D L K P A .
«
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Figure 3.5(A) anti-mdr-1 MAb (6/1C) Figure 3.5(B) anti-mdr-! MAb (6/1C) in
in ascites (+control) (1/50 dilution) ExCelI620 (10X conc.) (1/2 dil.)
-
» >
►?* * •
tv %
*
Figure 3.5(C) anti-mdr-1 MAb (6/1C)
In Hybridoma SFM (lOx conc.) (1/2 dil.)
Figure 3.5(D) anti-mdr-1 MAb (6/1C)
In SSM (1/2 dil.).
93
Figure 3.5(E) Negative control Figure 3.5(F) anti-mdr-1 MAb
(PBS). (6/1C). In HTM20CTH
(lOx conc.) (1/2 dii.).
F ig u re  3 .5 (G ) anti-mdr-1 MAb (6/1C) F ig u re  3 .5 (H ) anti-mdr-1 MAb
In CD Hybridoma medium (10X conc.) (6/1C) In Sigma PFM
(1/2 dii.) (lOx conc.) (1/2 dii.).
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Analysis of the immunocytochemical staining of DLKPA cells for the presence of anti- 
mdr-1 (6/1C) antibody in the following samples yields staining of the plasma 
membrane. In each of the following samples; ExCell 620 (B ), Hybridoma SFM (C ), 
HTM20CTH (F ) , and Sigma PFM (H )  no staining of the plasma membrane was 
observed hence the results are in agreement with those obtained using RID and 
isotyping methods reiterating the point that IgGi not being produced in the cell culture 
supernatant.
Positive staining was however obtained from the samples cultured in CD Hybridoma 
(G ) . The staining was not as strong as that obtained for the positive control (ascites 
produced using 6/1C cell line diluted 1/50) or the mdr-1 cells in serum-supplemented 
medium.
Overall, antibody production for the mdr-1 cell line shown above was below the values 
typically achieved in this laboratory in the past and in papers published on the subject 
(35-50 mg/L) (Moran et a l, 1998 Unpublished; Bibila & Robinson, 1995). In addition, 
when the mdr-1 cell line was sent for commercial analysis, it was rejected due to lack of 
antibody productivity.
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3.3 G ro w th  M edium  Supplem ents
The aim of this experiment was to characterise the growth and antibody productivity of 
the cell line, 6/1C in three supplemented media, namely OptiMAb, TCH and Glutamax 
H.
0 2 4 6 e 10 12 14 16
Time (Days)
4.0
-OptiMab — A — Glutamax II K  Glutamax I — K- T C H
F ig u re  3.6 Comparison of the ability of DMEM supplemented with OptiMab and 
Glutamax II to sustain the growth of the hybridoma anti-mdr-1 MAb 
(6/1C) over time. (Control: serum supplemented DMEM with Glutamax
I).
( ............  Indicates when Glutamax II only was added to the culture)
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3.3.1 Im m unocytochem ical analyses o f a n ti m dr-1  M A b  fro m  the h ybridom a cell 
line  6/1C supernatant u sin g  the positive  co n tro l ce ll lin e  D L K P A .
F ig  3 .7 (A ) anti-mdr-1 MAb (6/1C) in F ig u re  3 .7 (B ) anti-mdr-1 MAb
in DMEM containing Glutamax I (6/1C) in DMEM containing
(1/2 dil.). Glutamax II (1/2 dil ).
#  • «  ©. *
m #  '
*  #  *
Wt $  . *
% ® ®
«I * •  4  #
* ♦ —
f igure 3.7(C) anti mdr-1 MAb (6/1C) 
in DMEM containing OptiMab (1/2 dil.).
Figure 3.7(D) anti-mdr-1 MAb
(6/1C) TCH (lOx conc.) (1/2 dil.)
Immunocytochemical (Figure 3.7 A-D) results show positive mdr-1 staining of the 
plasma membrane for each of the three samples used here. The supernatant from the 
OptiMab supplemented culture yielding very strong positive staining further backing 
nephelometric results obtained in Table 3.4. Strong positive staining was also obtained 
in the presence of the TCH (D ) supplement.
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3.3.2 Nephelometric analysis
T a b le  3.4 Antibody concentrations obtained in the various DMEM supplemented 
media. (For standard curve, refer to Section 3.10.3).
Sam ple
A n tib o d y
C o n ce n tra tio n
(m g/L)
Standard
D evia tion
a
D M E M  G lu t a m a x  I 15.56 1.44
D M E M  +  G lu t a m a x  I I 19.21 2.01
D M E M + O p t iM a b 22.23 1.32
From Figure 3.6 the presence of the supplement OptiMab yielded a large increase in cell 
number and an increased exponential phase of growth in comparison to the control 
medium serum supplemented DMEM, and the other test medium Glutamax II 
supplemented DMEM. Feeding the cells with Glutamax II on day 5 only extended the 
culture in stationary phase for one day.
Immunocytochemical analysis shows strong staining of the plasma membrane for each 
of the supplemented samples.
The nephelometric results (Table 3.4) show increased antibody productivity for the 
culture of cells in medium supplemented with OptiMab.
However, the quantities of antibody achieved throughout the course of this work are 
lower than that previously produced by this cell line and other cell lines both in our 
laboratory and in published data. Typical quantities of antibody produced from 
hybridoma cell lines are approximately 50-60 mg/L. With this particular cell line in 
previous work concentrations in the range 34-54 mg/ml were obtained in standard static 
culture flasks (Moran et al., 1998 Unpublished; Bibila & Robinson, 1995). Work 
carried out by an independent commercial company on the cell line 6/1C concluded that 
low levels and in some cases no antibody was being produced in culture. For this
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reason, it was decided that it was not feasible to carry out further scale up and 
optimisation studies on this cell line.
Three new cell lines were chosen from the laboratory stocks, their adaptation to protein 
free conditions and subsequent scale up to large scale is detailed in the next sections 3.4,
3.5 & 3.6.
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3.4 Hybridoma 4/2D
3.4.1 C u ltu re  o f an ti-Top o isom erase  I I -a  p ro d u c in g  ce ll lin e  4/2D in  serum  
supplem ented and p ro te in  fre e  cond itions
Time (Days)
—•— DMEM (10% FBS + 1% P/S) «  PFHM II a - UltraDoma
F ig u re  3.8 Shows comparison of the growth of the hybridoma producing cell line 
4/2D in two protein free media versus the control medium serum 
supplemented DMEM. Samples were taken daily for cell viability 
analysis and on day 6 for antibody concentration determination.
3.4.2 A n tib o d y  A n a lys is
A  B
F ig u re  3.9 Isotyping analysis of A ) MAb 4/2D in SSM, B ) MAb 4/2D in PFM
Table 3.5 RID and nephelometric analysis of the hybridoma producing anti- 
Topoisomerase II-a MAb in serum supplemented and protein free 
conditions. N= 3 (For nephelometric standard curve refer to Section 
3.10.3, RID sample calculation refer to Section 2.4.3)
Medium
R I D
( m g / L )
S ta n d a r d
D e v ia t io n
a
N e p h e lo m e te r
( m g / L )
S ta n d a r d
D e v ia t io n
a
D M E M  ( + 1 0 %  F B S ) 3.84 3.64 22.5 1.45
P F H M I I 1.10 4.12 19.5 0.97
U lt r a D o m a 1.685 5.92 9.2 1.07
Figure 3.9 shows isotyping for MAb 4/2D in SSM and PFM media. Figure 3.9A shows 
a strong positive band indicating the presence of IgGu Isotyping on the PFM sample 
yielded positive bands for IgG2A and IgG3.
The results in table 3.5 show the difference in results obtained between the two 
quantitative methods used to determine antibody concentrations. It was very difficult to 
make an accurate determination of results from the RID assay as it was difficult to read 
the small precipitate bands making it less objective than nephelometry. The 
nephelometric assay would be deemed more sensitive to measuring MAb in culture 
supernatant.
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3.4.3 Im m unocytochem ical analyses o f anti-topoisom erase I I -o  M A b  from  the 
h yb rid o m a  c e ll lin e  4/2D su pernata nt on  the positive  c o n tro l c e ll line» 
D L K P A .
F ig u re  3 .1 0 (A ) anti-topo 11-a (4/2D) F ig u re  3 .10(B) anti-topo 11-oc (4/2D) in
in SSM (1/2 dil.) PFHM II (1/2 dil.).
a
*  *  •
«
«  ___
F ig u re  3 .1 0 (C ) anti-topo I I -a  (4/2D) F ig u re  3 .10(D ) Negative control
cultured in UltraDoma
(V id il.)
Immunocytochemical analysis of the supernatant from the hybridoma producing anti- 
Topoisomerase II-a cell line, 4/2D in both serum supplemented and protein free culture 
(Figures 3.10 (A-D)) conditions showed positive staining for antibody in all of the 
cases.
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3.4.4 SDS PAGE analysis
175kDa 
83 kDa 
62 kDa
47.5 kDa
32.5 kDa 
25 kDa
F ig u re  3.11 SDS PAGE (reducing gel) analysis of the hybridoma producing anti- 
Topisomerase II-a MAb (4/2D) cultured under protein free conditions 
and serum supplemented conditions. La n e  1: Markers, La n e  2: 4/2D in 
protein free medium (unconc.), L a n e  3: 4/2D in protein free supernatant 
(conc. 10X.), L a n e  4: 4/2D in serum supplemented medium (conc. 10X), 
La n e  5: 4/2D in serum supplemented medium (unconc.). Samples were 
seperated on a 12.5% SDS PAGE.
SDS-Page analysis of the supernatant from the anti-topoisomerase II-a MAb in protein 
free supernatant yielded clear bands at the 25 and 55kDa position in the concentrated 
supernatant at the expected molecular weights. Supernatant from the serum 
supplemented samples showed a band at ~55-70kDa and another band at 25kDa.
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3.4.5 Post-purification Analysis using the NAb™ Protein L Spin Kit
175 kDa
83 kDa 
fi2 kDa
47.5 kDa
32.5 kDa 
25 kDa
8
Fig 3.12 SDS PAGE (reducing gel) analysis following purification of the 
topoisomerase II-a MAb cultured in protein free and serum 
supplemented conditions (Section 2.5.1). La n e  1: Markers, L a n e  2: 
protein free supernatant, L a n e  3: Eluted protein free sample, La n e  4: 
Unbound protein free supernatant after purification, L a n e  5: Serum 
supplemented supernatant, L a n e  6: Unbound serum supplemented 
supernatant after purification, La n e  7: Serum supplemented wash after 
purification, L a n e  8: Eluted serum supplemented sample. Samples were 
separated on 12.5% SDS PAGE.
104
3.5 Hybridoma 5C3
3.5.1 C u ltu re  o f a n tib o d y p ro d u c in g  ce ll lin e  5C3 in  serum  supplem ented and 
p ro te in  fre e  m edium
Time (Days)
~•“ 5C3 in DMEM (+serum) “ * 5C3 in PFHM II 5C3 in UltraDoma
F ig u re  3.13 Shows comparison of the growth of the hybridoma producing 5C3 MAb 
in two protein free media against the control SSM. Samples were taken 
daily for cell viability analysis and on day 6-antibody concentrations 
were determined.
3.5.2 A n tib o d y  A n a lys is
a a
ii
I
■ «. OST
z  * *
■Z r t t
i l l
■  m
A  B
F ig u re  3.14 Isotyping analysis of A ) MAb 5C3 in SSM, B ) MAb 5C3 in PFM
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Table 3.6 RID and nephelometric analysis of the antibody 5C3 in serum 
supplemented and protein free conditions. N = 3 (For nephelometric 
standard curve refer to Section 3.10.3, for RID sample calculation refer 
to Section 2.4.3)
Medium
RID
(mg/L)
Standard
Dev.
a
Nephelometry
(mg/L)
Standard
Dev.
a
DMEM (+10% FBS) 4.26 3.6 18.75 0.91
PFH M II 16.2 2.8 175.64 3.21
UltraDoma 1 2.73 2.79 0.548
Figure 3.14 shows isotyping for MAb 5C3 in SSM and PFM media. Figure 3.14A and 
B show strong positive bands indicating the presence of IgGj in both the SSM and 
PFM.
The results in table 3.6 show the difference in results obtained between the two 
quantitative methods used to determine antibody concentrations. It was very difficult to 
make an accurate determination of results from the RID assay, as it was difficult to read 
the small precipitate bands making it less objective than nephelometry. The 
nephelometric assay is a more sensitive method of measuring MAb in cell culture 
supernatant.
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3.5.3 Immunocytochemical analyses of MAb from the hybridoma cell line 5C3 
supernatant using the positive control cell line, ZR-75-1
Figure 3.15 (A) 5C3 in SSM
(1/2 Dii.)
p -e *
Figure 3.15 (B) 5C3 in PFHM II 
(1/2 Dii.)
' ’ I  . 4BJ 
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Figure 3.15 (C) Negative control (PBS)
Immunocytochemical analysis of supernatant from the hybridoma cell line, 5C3 
cultured in the protein free (PFHM II) and serum supplemented medium yielded 
positive staining indicating the presence of antibody.
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3.5.4 SDS PAGE Analysis
t 2 ^ 4 5
Figure 3.16 SDS PAGE (reducing gel) analysis of antibody produced by cell line 5C3 
cultured under protein free conditions. Lane 1: Markers, Lane 2: 5C3 in 
Protein free medium (conc. 10X), Lane 3: Protein free supernatant 
(unconc), Lane 4: 5C3 in serum supplemented medium (conc. 10X), 
Lane 5: 5C3 in serum supplemented medium (unconc.). Samples were 
seperated on 12.5% SDS-PAGE.
From the SDS-PAGE analysis the results indicated the presence of heavy and light 
chains in the serum-supplemented and protein free supernatants. The aggregates formed 
in the serum-supplemented samples were probably as a result of the presence of BSA in 
serum, which has a molecular weight o f approximately 68kDa.
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3.5.5 Post-purification Analysis using the NAb™ Protein L Spin Kit
175 kDa 
83 kDa 
62 kDa
47.5 kDa
32.5 kDa 
25 kDa
Figure 3.17 SDS PAGE (reducing gel) analysis following purification of the 
hybridoma producing MAb 5C3 cultured under protein free conditions 
(Section 2.5.1). Lane 1: Markers, Lane 2: Protein free supernatant, Lane 
3: Unbound protein free supernatant after purification, Lane 4: Protein 
free wash after purification, Lane 5: Elution protein free sample (1), 
Lane 6: Eluted protein free sample (2). Samples were seperated on a 
¡2.5% SDS-PAGE.
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3.5 Hybridoma 1/11C
3.6.1 C u ltu re  o f antib od y p ro d uc in g  cell line  1/11C in serum  supplem ented and 
p ro te in  free media
Time (Days)
—•— 1/11C in DMEM (+serum) 1/11C in PFHMII a  1/11C in UltraDoma
F ig u re  3.18 Shows comparison of the growth of the hybridoma producing MAb 
1/11C in two protein free media against the control SSM. Samples were 
taken daily for cell viability analysis and on day 6 for antibody 
concentration determination.
3.6.2 A n tib o d y  A n a lys is
!33
111
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F ig u re  3.19 Isotyping analysis of A )  MAb 1/11C in SSM, B ) MAb 1/11C in PFM
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T a b le  3.7 RID and nephelometric antibody analysis of the hybridoma MAb 1/11C 
in serum supplemented and protein free conditions. (For nephelometric 
standard curve refer to Section 3.10.3, RID sample calculation refer to 
Section 2.4.3)
Medium
RID
(mg/L)
Standard 
Dev a
Nephelometry
(mg/L)
Standard 
Dev o
DMEM  
(+10% FBS)
1.94 2.11 8.12 0.58
PFHMI1 4.7 1.68 6.4 1.11
UltraDoma 1 3.24 1.89 0.8
Figure 3.19 shows that the isotyping analysis of the 1/11C antibody yielded no positive 
indication of the presence of IgG instead faint bands indicative of IgM were observed. 
Further analysis using the ELISA based mouse MAb isotyping kit (The Mouse 
Typer®Sub-Isotyping Panel) resulted in positive IgM bands being formed.
The results in table 3.7 indicate the difference in results obtained between the two 
quantitative methods used to determine antibody concentrations. It was very difficult to 
make an accurate determination of results from the RID assay, as it was difficult to read 
the small precipitate bands making it less objective than nephelometry. The 
nephelometric assay is a more sensitive method of measuring MAb in cell culture 
supernatant.
i l l
3.6.3 Im m unocytochem ical analysis o f  M A b  fro m  the h yb rid o m a  cell line 1/11C 
supernatant us ing  the positive  co n tro l ce ll line , D L K P A .
■* *  *
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«
Figure 3.20(A) MAb 1/11C
in SSM (1/2 dii)
Figure 3.20(B) MAb 1/1IC in
PFHMII (1/2 dii)
Figure 3.20(C) Negative control (PBS)
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In contrast to the results obtained from the isotyping, RID and nephelometric analysis of 
the hybridoma producing MAb l / l  1C cell line in SSM for antibody, 
immunocytochemical analysis yielded strong positive staining indicative of the presence 
of antibody.
Overall, the medium UltraDoma was unable to sustain the growth of the cell lines 
sufficiently, throughout the course of this experiment. Hence, the protein free medium 
PFHM II, which performed similarly to the positive control of serum supplemented 
DMEM was selected for further studies (Table 3.8).
As a consequence of the higher antibody and cell density levels achieved in the 
hybridoma producing cell lines 4/2D and 5C3 in both serum free and protein free 
medium these cell lines were chosen for comparison studies in further scale up 
experiments.
Ta b le  3.8 Effect o f different media on the growth of the hybridoma producing cell 
lines 4/2D, 5C3 and 1/11C.
SSM UltraDoma PFHM II
4/2D +++■ + ++
1 / U C ++ - ++
5C3 ++ - +++
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3,7 Scale up and process optim isation fo r  the p roduction  o f anti-topoisom erase 
l l - a  a n tib od y (4/2D)
Monoclonal antibody production was scaled from static flasks to a 10L-bioreactor using 
75cm2, 150cm2 static flasks, 250ml and 1L spinner flasks as intermediaries for cell 
production. In addition, 250ml spinner flasks were also used to perform process 
optimisation experiments with special attention given to temperature and agitation 
optimisation.
3.7.1 A g ita tio n
The aim of this experiment was to determine the most efficient agitation rate in terms of 
antibody productivity and cell growth in which, to produce MAb from the hybridoma 
producing cell line 4/2D both in SSM and PFM conditions. See section 1.2.5 for a 
detailed discussion on the effects of agitation.
Cells were cultured at 50, 100 and 200rpm. The effects of these agitation rates on 
growth and antibody productivity are shown in Figure 3.24.
At 50rpm in the serum-supplemented culture of the 4/2D cell line, clumping was 
observed. Culture at 100 rpm yielded cell densities in excess of 2.70xl06cells/ml. 
Antibody productivity was enhanced over that achieved at 50rpm but was very similar 
to levels achieved at 200rpm. Agitation at 200rpm resulted in a peak growth of 
2.38xl05cells/ml, one day earlier than culture at lOOrpm; cell viability rapidly declined 
after this stage (Appendix II).
The most efficient agitation rate for the growth of cells from the hybridoma producing 
cell line 4/2D in protein free medium was lOOrpm. However, in terms of the 
concentration of antibody produced it is clear that agitation of 200rpm yielded the best 
results (Figure 3.24 C & D). This may be related to the lower specific-growth rate 
observed under these conditions.
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Figure 3.24 Shows cell growth and antibody productivity data from 4/2D cells grown 
in SSM (A & B), PFM (C & D) at varying rates of agitation.
Table 3.9 Tabulated specific growth rates, doubling time and number of 
generations, data for the culture of 4/2D in SSM and PFM at varying 
rates of agitation. Each run was carried out in triplicate therefore data 
shown is an average of three (CV’s < 10%).
SSM PFM
Agitation
Rate
(rpm)
Specific 
Growth Rate
Doubling
Time
(td)
Number of 
generations 
n
Specific 
Growth Rate
Doubling
Time
(td)
Number of 
generations 
n
50 0.4624 18.20 4.37 0.987 16.80 4.56
100 0.672 24.75 2.92 0.6735 24.66 4.06
200 0.6936 23.98 2.12 0.5432 30.60 2.35
In summary, the results shown here suggest that the large-scale agitation was most 
efficient in the case of SSM at 1 OOrpm and PFM 200rpm
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3.7.2 Temperature
The aim of this experiment was to determine the most efficient temperature in terms of 
antibody productivity and cell growth in which, to produce MAb from the hybridoma 
producing cell line 4/2D in both SSM and PFM conditions. See section 1.2.7 for a 
detailed discussion on the effects of temperature.
Growth characteristics for the culture of the 4/2D cell line in serum-supplemented 
medium at 34°C and 37°C were almost identical, yielding maximum cell densities in the 
range 2.7-2.8x106cells/ml. Antibody yields were however reduced at 34°C where a 
final concentration of approximately 27mg/L was achieved compared to 37 mg/L at 
37°C. In contrast to this, growth at 39°C was very poor yielding a maximum cell density 
of approximately 0.3xl06cells/ml and an antibody concentration of 12mg/L. Specific 
growth rate, doubling time and generation values were all similar for culture at 34°C and 
37°C. However, culture at 37°C yielded better antibody productivity.
The protein free culture of the hybridoma producing 4/2D cell line yielded maximum 
cell density when cells were cultured at 37°C. A two-fold increase in cell number was 
observed over that at 34°C. Antibody productivity did not however yield the same 
trend. Final antibody concentration at 34°C was approximately 10 mg/L greater than 
that achieved at 37°C.
116
34 C 37 C
0 1 2 3 4 5 6
Time Time
Figure 3.25 Shows cell growth and antibody productivity data from 4/2D cells grown
in SSM (A & B), PFM, (C & D) at varying degrees of temperature.
Table 3.10 Tabulated specific growth rates, doubling time and number of 
generations, data for the culture of 4/2D in SSM and PFM at varying 
rates of agitation. Each run was carried out in triplicate (average of three 
with CV’s < 10%).
SIMM P FM
Temperature
(°C)
Specific 
Growth Rate
Mapp
Doubling
Time
(td)
Number of 
generations 
n
Specific 
Growth Rate
Papp
Doubling
Time
(td)
Number of 
generations 
n
34°C 0.6958 23.90 2.49 0.2139 77.75 0.462
37°C 0.672 24.75 2.92 0.6735 24.66 4.05
39°C Not enough datato compile Results 0.6198 26.83 2.76
In summary, maximum cell growth and antibody production was achieved in the serum- 
supplemented cultures at 37°C and lOOrpm. In the protein free culture, the maximum 
cell growth was achieved at, 37°C and 200rpm but antibody production reached its 
highest level when the cells were cultured at 34°C.
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The optimum process conditions described here were then used to culture cells at large- 
scale (10L bioreactor).
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3.7.3 10L Fermentation Run
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Figure 3*26 Shows cell growth and antibody production characteristics for 
4/2D cultured in SSM at the lOL-batch scale. A) Batch 1, B) 
Batch 2. C) Average glucose versus lactate concentrations. 
Samples were analysed daily for antibody, lactose, glucose and 
cell viability.
The two runs performed are shown here as the results are very different and there 
would have been a huge difference in standard deviation i f  they were compared’
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Table 3.11 Tabulated specific growth rates, doubling time and number of 
generations data for the culture of 4/2D in SSM.
Specific 
Growth Rate
Hhpii (d )
Doubling
Time
(td)
Number of generations 
n
Run 1 0.80 20.70 2.63
Run 2 0.4071 40.09 1.29
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Figure 3.27 Shows cell growth and antibody production characteristics for 4/2D 
cultured in. PFM at the lOL-batch scale. A) Cell growth and antibody 
productivity B) Glucose versus lactate concentrations. Samples were 
analysed daily for antibody, lactose, glucose and cell viability.
Table 3.12 Tabulated specific growth rates, doubling time and number of 
generations data for the culture of 4/2D in PFM.
Run Specific Growth 
Rate
M'app
Doubling
Time
(td)
Number of 
generations
N
1 0.7071 16.97 4.29
2 0.6698 19.42 3.46
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During the initial culture of the 4/2D antibody in serum-supplemented culture, antibody 
production peaked at day three to a high level and then dropped away towards the end 
of the culture. When this culture was repeated the high quantities of antibody achieved 
at day three were not repeated. However, the cell density achieved were a lot higher 
and there was no decline in antibody levels. A third run was due to be performed but 
due to commercial constraints on the equipment and laboratory space, it was unable to 
be carried out. The reasons behind why antibody levels maybe decreasing in culture are 
discussed in Section 4.4.
With regards to the culture of the hybridoma producing cell line 4/2D in PFM there was 
very little variation between the two batch culture results obtained in terms of specific 
growth rates, doubling times and number of generations. In comparison to the culture 
of the cell line 4/2D in SSM, antibody productivity also peaked at day 3 and a drop in 
antibody levels was observed after this time. The highest quantity of antibody was 
similar to that achieved at optimum conditions in the spinner flask.
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3.8 Scale-up and process optimisation for production of antibody from hybridoma 
5C3
3.8.1 Agitation
The aim of this experiment was to determine the most efficient agitation rate in terms of 
cell growth and antibody productivity in which to produce MAb from the hybridoma 
cell line 5C3 in SSM and PFM culture conditions. See section 1.2.5 for a detailed 
discussion on the effects of agitation.
Comparable cell densities were achieved in both SSM and PFM conditions at lOOrpm. 
Agitation at 200rpm under protein free conditions was deleterious to growth and 
antibody productivity. In the presence of serum however comparable levels of antibody 
were produced at 200 and lOOrpm suggesting the protective effect of serum at higher 
agitation rates.
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Figure 3.28 Shows cell growth and antibody productivity data for 5C3 cells grown in
SSM (A & B), PFM (C & D) at varying rates of agitation.
Table 3.13 Shows tabulated specific growth rates, doubling time and number of
generations, data for the culture of 5C3 in SSM and PFM at varying rates 
of agitation. Each run was carried out in triplicate (average of three with 
CV’s < 10%).
SSM PFM
Agitation
Rate
(RPM)
Specific 
Growth Rate
f*app
Doubling
Time
(td)
Number of 
generations 
n
Specific 
Growth Rate
M-app
Doubling
Time
(td)
Number of 
generations 
(n)
50 0.6090 27.13 2.90 0.3680 45.12 1.88
100 0.4450 37.37 1.32 0.6660 24.95 2.47
200 0.4257 39.00 2.36 Cells dead Cellsdead Cells dead
In summary the agitation rate, which yielded the maximum cell density for 5C3, cells 
both in serum supplemented and protein free culture conditions, was lOOrpm.
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3.8.2 Temperature
The aim of this experiment was to determine the most efficient temperature in terms of 
cell growth and antibody productivity in which to produce MAb from the hybridoma 
cell line 5C3 in SSM mid PPM culture conditions. See section 1.2.7 for a detailed 
discussion on the effects of temperature.
Maximum cell density and antibody productivity was achieved at 37°C for both SSM 
and PFM cultures. Culture at 39°C was deleterious to cell growth in SSM and PFM 
culture.
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Figure 3.29 Shows cell growth and antibody productivity data for 5C3 cells grown in 
SSM (A & B), PFM (C & D) at varying degrees of temperature.
Table 3.14 Shows tabulated specific growth rates, doubling time and number of 
generations, data for the culture of 5C3 in SSM and PFM at varying 
degrees of temperature. Each run was carried out in triplicate (average 
of three with CV’s < 10%).
SSM PFM
Temperature
(°C)
Specific 
Growth Rate
M*pp
Doubling
Time
(td)
Number of 
generations 
n
Specific 
Growth Rate
flapp
Doubling
Time
(td)
Number of 
generations 
n
34°C 0.4735 35.10 2.89 0.575 28.92 3.042
37°C 0.4450 37.37 1.320 0.6660 24.94 3.786
39°C Not enough Data to Compile results
In summary, to obtain maximum cell growth and antibody productivity the 5C3 cells 
should be grown at 37°C and lOOrpm.
The optimum process conditions described here were then used to culture cells at large- 
scale (10L bioreactor).
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3.8.2 10L fermentation run
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Figure 3.30 A: Characterising the growth rates and antibody concentration of 5C3 
cultured in SSM, B: Average glucose versus lactate cultured in SSM at 
the lOL-batch culture scale.
Table 3.15 Specific growth rates, doubling time and number of generations. Data 
for the culture of 5C3 in SSM. (Only 1 run was carried out)
Agitation Rate 
(rpm)
Specific 
Growth Rate
l*aDD id )
Doubling
Time
(td)
Number of generations
N
Run 1 0.8199 20.20 4.75
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Figure 3.31 A: Characterising the growth rates and antibody concentration of 5C3 
cultured in PFM, B: Average glucose versus lactate concentrations 
cultured in PFM at the lOL-batch culture scale.
Table 3.16 Tabulated specific growth rates, doubling time and number of 
generations. Data for the culture of 5C3 in PFM.
Temperature
(°C)
Specific 
Growth Rate
Haim (d )
Doubling
Time
(td)
Number of generations
N
Run 1 0.7724 21.50 2.97
Run 2 0.5565 29.90 2.50
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3.8.3 Comparison of antibody production in each of the cell lines
Time (Days)
Figure 3.32 Shows the comparison of antibody concentration levels achieved with 
4/2D and 5C3 in SSM and PFM
Table 3.17 Shows the comparison of antibody production and its cost for each cell 
line used in serum supplemented and protein free conditions. Antibody 
concentrations as determined on last day of the culture.
Calculations for costing can be found in the Appendix V.
10 L
(mg)
10 L  
Bioreactor 
€ /m g
5C3 in SSM 290 2.60
5C3 in PFM 2965 0.26
42D in SSM 190 3.95
42D in PFM 200 3.89
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3.9 Culture of hybridoma cell line 5C3 in the hollow fibre bioreactor
In the experiments described here, the hybridoma producing cell line 5C3 was examined 
for its ability to produce monoclonal antibody both in serum supplemented and protein 
free media in a hollow fibre bioreactor. The results were compared with those obtained 
from culture of this cell line in static flasks, spinner bottles and the 10-L bioreactor.
The results in Figure 3.33 compare the percentage viability of the culture of 5C3 in 
protein free medium and serum-supplemented medium over a culture period of 21 days. 
The results show that all three runs performed had comparable viabilities but the culture 
of cells in serum-supplemented medium had a higher viability for a longer time. With 
such a result, it is generally expected that more antibody would therefore be produced, 
as cells were kept in a viable state for longer. However, as was observed in all 
experiments comparing the MAb production of 5C3 in serum supplemented and protein 
free medium this was not the case.
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3.9.1 Serum supplemented versus protein free culture of hybridoma 5C3 in a 
hollow fibre bioreactor
Time (Days)
Figure 3.33 A: Shows the % viability of 5C3 cells cultured in SSM and PFM, B: 
Shows the antibody concentration of the 5C3 antibody cultured in 
SSM and PFM.
The culture period lasted 21 days with samples taken every two days 
for the determination of viability and antibody concentration. The 
difference between PFM (1) and (2) is that the first PFM run was 
carried out in a new hollow fibre cartridge. The second PFM run was 
performed in a cartridge that previously contained SSM medium and 
cells.
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Table 3.18 Comparisons of the final antibody concentrations obtained from the 
culture of the 5C3-cell line in a hollow fibre bioreactor. The total 
volume harvested from the hollow fibre was 485mls. The culture period 
lasted 21 days.
Total Antibody 
Produced (mg)
SSM 46
PFM (l) 119.47
PFM (2) 99.97
3.9.2 SDS-PAGE analysis
l  2
175 kDa -
83 kDa - ----- ►
62 kDa -----►
47.5 kDa - ----- ►
32.5 kDa ---- ►
25 kDa -------
Figure 3.34 Shows SDS-PAGE analysis of MAb from hybridoma 5C3 produced in a 
hollow fibre bioreactor using serum supplemented medium Lane 1: 
Markers, Lane 2: Neat supernatant from SSM. Samples were separated 
on a 12.5% SDS-PAGE..
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3.9.2 SDS-PAGE analysis
I 2 3
175 kDa ----- ►
Figure 3.35 Shows the analysis of SDS PAGE of MAb from hybridoma 5C3 
produced in a hollow fibre bioreactor with protein free medium. Lane 1: 
Markers, Lane 2: Neat supernatant from PFM (1), Lane 3: Neat supernatant 
from PFM (2). Samples were separated on a 12.5% SDS-PAGE.
The results achieved in these experiments show the superior quality and quantity of 
MAb produced from the 5C3-cell line under protein free conditions compared to serum 
supplemented conditions. How these results relate to antibody productivity in the 10L 
fermenter is discussed in section 4.5.
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3.10 Analytical Validation of Nephelometric system.
For the purpose of this thesis, it was necessary to set up a method of quantifying MAb 
from culture supernatant that was efficient, reliable and easy to operate. This method 
was to replace the more commonly used ELISA and RID methods.
Nephelometry was the method chosen. The MENINEPH (Binding Site, UK) used in this 
thesis was an endpoint nephelometer that used the measurement of light scattered by an 
antibody/antigen complex to determine protein concentrations (Section 1.1.8 & 2.4.2).
The first step required was to validate the nephelometer to ensure that the procedure was 
fit for the purpose intended in that it ensured confidence that the correct results were 
obtained when assaying the test samples.
Section 2.9.4 details the parameters that should be considered when carrying out a 
validation procedure on an analytical method.
For the purpose of this thesis, the following tests were carried out to test the validity of 
the assay (Section 2.4.2):
■ Inter-assay variation -  involved assaying samples in triplicate over four 
separate days and calculating the %CV (Section 2.9.4).
■ Intra-assay variation -  involved using the same sample carried out in 
approximately 10 assays and the results were compared (Section 2.9.4).
■ The linear range of the standard curve was defined.
■ The specificity of the assay (using IgG of various subtypes and IgM) was 
determined.
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3.10.1 Inter-Assay Variation for Nephelometer
Table 3.19 Shows Inter-assay variation. The test sample used was supernatant from 
hybridoma 5C3 cultured in PFHM II. This experiment consisted of ten 
repeat assays at one analyte concentration (N=3)
Assay 300 s 240 s 180 s 120 s 60 s 0 s
Average
Scatterò
Standard
Deviation
%CV
I 558 591 587 581 604 599 591.67 8.43 1.42
2 595 613 590 590 599 594 596.83 8.61 1.44
3 499 499 492 501 482 498 495.17 7.14 1.44
4 459 456 474 485 486 487 476.00 11.97 2.15
5 548 559 563 592 581 567 568.33 15.82 2.78
6 592 591 605 617 618 620 607.17 13.23 2.18
7 497 508 513 520 511 517 511.00 8.17 1.58
8 592 588 598 603 605 615 600.17 9,70 1.62
9 436 464 466 457 451 439 452.17 12.58 2.78
10 537 547 544 561 567 555 551.83 11.21 2.03
This inter assay variation was performed to examine precision. By definition, the 
precision of an analytical procedure expresses the closeness of agreement between a 
series of measurements obtained from multiple sampling of the homogenous sample 
under the prescribed conditions. The data in Table 3.19 measures the similarity 
between the %CV obtained for each assay carried out from the repeated assaying of a 
sample from the same source over the course of a day. By comparing the %CV 
between each assay very little variation was observed hence, validating the reliability 
of the instrument to reproduce results over the course of the day. In order to measure 
the overall precision of the assay the coefficient of variance of all ten assays was 
determined. This was achieved by obtaining the averages of each of the ten assays and 
finding their average and standard deviation. From this, a %CV of 10.2% was 
obtained. This is slightly outside the acceptable %CV of 10%.
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3.10.2 Intra-Assay Variation
Table 3.20 Shows intra-assay variation. Test sample used was supernatant from 
hybridoma 5C3 cultured in PFHM II. These data represent the average 
coefficient of variation (CV) of three within-batch measurements (N=3).
Assay 300 240 180 120 60 0
Average
Scatter
Standard
Deviation
% CV
1 606.5 617 623.5 645.5 636.5 644 628.83 15.94 2.54
2 549.5 546 548 567.5 575 574.5 560.08 14.76 2.64
3 521 525.5 531.5 546 540.5 541.5 543.33 15.15 2.84
4 418 420 418 422 4175 436 421.92 9.10 2.22
The inter-variation assay involved assaying samples from the same specimen in 
triplicate over four separate working days and comparing the results by measuring the 
%CV. Again, acceptable levels o f %CV are less than 10. The intra-assay is often 
termed the repeatability assay. By definition, repeatability expresses the precision 
under the same operating conditions over a short interval of time. This assay verifies 
the ability of the nephelometer to reproduce results over time.
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3.10.3 Determination of the linear range for the nephelometric assay
Concentraion (mg/L)
Figure 3.36 Standard Curve in the range 0-300mg/L for determining antibody 
concentrations using the nephelometer.
Initially the measurement range of the assay was determined. The standard used in the 
generation of the standard curve was that used in conjunction with the RID plates, an 
IgG antibody (G272.3) (Section 2.4.3). The standard had a neat concentration of 1200 
mg/L. The control used in these experiments was the c-myc (IgGi). Controls were 
examined at varying dilutions to ensure sample results lay in the linear region of the 
graph.
The range of an analytical procedure is the interval between the upper and lower 
concentration of analyte in the sample for which it has been demonstrated that the 
analytical procedure has a suitable level of precision, accuracy and linearity. In this 
case, it was found that although the nephelometer could measure samples at a
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concentration of 1200mg/L but they were not stable over the assay length. At the lower 
end of the curve it was found that the lower limit of detection was 9.785 mg/L
By linearity, it is meant that the analytical procedure has the ability to obtain results 
that are directly proportional to the concentration (amount) of analyte in the sample. 
From this curve, it was found that the range of the linear range of the curve was 
between 9.375-300mg/L. A number of repeat standard curves were carried out over 
time to verify this and compare values for regressional coefficients (R2) (Tables 3.21 & 
3.22).
Table 3.21 Comparison of the regression coefficients obtained for standard curve 
assays performed over 7 days.
Day
Regression 
coefficient (R2)
1 0.997
2 0.993
3 0.997
4 0.993
5 0.995
6 0.997
7 0.999
Table 3.22 Comparison of the regression coefficients obtained for standard curve 
assays performed weekly for a month.
Day
Regression 
coefficient (Rr2)
1 0.997
7 0.999
14 0.993
21 0.996
28 0.996
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The data above shows that repeated standard curves carried out over a month yielded 
very little variation. The regression coefficient is a measurement of the relationship 
between a dependent variable and an independent variable. The closer the calculated 
regression value is to one the more exact it is.
3.10.3 Determination of the specificity of the nephelometric assay
Table 3.23 Determination of the specificity of the assay -  using IgG of various 
subtypes and IgM.
Antibody Subclass
Concentration
(mg/L)
Nephelometric 
determined 
conc. (mg/L)
%
Coefficient 
of Variance
Accuracy
c-Myc IgG! (Kappa) 200.00 202.11 3.092 1.05
Anti Cytokeratin No. 
18
IgGi (Kappa) 20.00 25.33
4.985 26.65
Anti-
Bromodeoxyuridine
IgGj (Kappa) 480.00 451.51
1.055 5.93
Ki-67 IgG] (Kappa) 265.00 245.19 2.29 7.47
AntiFodrin
MAB1622
IgGi (Kappa 100.00 116.67
1.425 16.67
Negative IgM 
Control
IgM 100,00 25.35
135.6 74.65
P-glycoprotein
(MDR)
lgG2b (Kappa) 500.00 466.07
3.27 6.8
EIF-4E IgG2b (Kappa) 250.00 222.14 4.43 11.1
The purpose of this experiment was to determine the specificity and accuracy of the 
assay for varying subtypes and samples of IgG. Specificity is the ability to assess 
unequivocally the target analyte in the presence of components, which may be expected 
to be present. Typically, these might include impurities. Accuracy is the closeness of 
agreement between the value, which is accepted as either, the conventional or true 
value or an accepted reference value, and the value found.
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The specificity and accuracy obtained with relation to the IgG samples of c-myc, Ki- 
67, anti-bromodeoxyuridine, p-glycoprotein was acceptable. Results obtained for anti- 
fodrin MAB1622 and the anti-cytokeratin No. 18 were not as specific or accurate as 
those obtained for the other IgG samples. In addition, the reactivity of the anti IgG sera 
with the IgM yielded results indicative of poor binding and specificity for each other 
(Bossuyt et al, 2001).
From this, it can be concluded that nephelometry is not specific for IgM. In addition 
when determining a suitable control for the assay, a number different IgG standards of 
the specific isotype being tested for, should be analysed. This will avoid the use of a 
control, which has a high % inaccuracy, as observed in Table 3.23 whereby different 
degrees of accuracy were observed for each different control.
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Section 4 Discussion
Obtaining higher yields of monoclonal antibodies (MAb) is a challenge in hybridoma 
technology. The lack of information and detailed knowledge of animal cells and their 
microenvironment gives rise to the vast differences of productivity in vitro and in vivo. 
If a MAb producing cell line maintained the same specific antibody production rate in 
vitro as they do in vivo, they would produce 720g of IgG per day (in a 10L bioreactor at 
a density of 107cells/ml). This is not the case however, as their actual production rate is 
approximately O.lg of IgG per day (in a 10L bioreactor at a density of 107cells/ml) 
(Kundu et al., 1998).
There are three main ways of increasing MAb production in vitro:
■ Optimisation of culture conditions
■ Increasing the scale of the culture
■ Increasing the density of the culture
During the course of this thesis, each of these methods was examined. Hybridoma cells 
were adapted to grow successfully in protein-free medium and scaled up to a final 
production volume of 10L. Productivity and quality of antibody were compared with 
those obtained from utilising a high-density culture system, a hollow fibre bioreactor. 
In order to determine possible process conditions that may increase antibody 
productivity, growth of hybridoma cells using a variety of agitation and temperature 
conditions were also investigated.
141
4.1 Adaptation of hybridoma producing cell lines to protein-free and serum- 
free medium
The in vitro production of MAb in defined or low-protein cell culture medium is the 
prime objective for many biotechnology industries involved in the production of 
antibody therapeutics. The reason underlying this trend is that research has moved 
away from using serum-supplemented medium due to regulatory issues. These include 
the high protein load, which interferes with the purification and identification of 
antibody, the undefined composition of serum, the batch-to-batch variation in quality, 
the risk of contamination from viruses, mycoplasma and prions as well as the ethical 
questioning surrounding the production of foetal serum. As a consequence of these 
problems a lot of research work has been devoted over the years to searching for serum 
replacements (Chen et al., 1993; Mochizuki et al., 1993; Ramirez et al., 1990; Blasey & 
Winzer, 1989; Shacter, 1987; Barnes & Sato, 1980). The result of this research has led 
to the availability of numerous commercially available serum-free, protein-free and 
chemically defined media.
For the purpose of this thesis, commercially available media have been used to 
demonstrate that a number of MAb producing cell lines, each exhibiting unique 
characteristics in culture, can be adapted to grow and secrete MAb in protein-free,
chemically defined, and serum-free media.
All media purchased suggested an adaptation protocol, which involved either a 
sequential reduction in serum and a corresponding sequential increase in protein- 
free/serum-free medium or else a method of direct adaptation to the protein-free/serum- 
free medium. Both methods were examined. It was found that the direct adaptation 
method resulted in decreased cell viability; and visually the cells appeared to be in an 
unhealthy state. The second method, sequential adaptation gave the cells longer to 
adapt to the reduction of certain components normally found in serum (Sinacore et al., 
2000). Hence, higher cell viabilities were obtained.
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4.1.1 Adapting hybridoma 6/1C to protein-free and serum-free conditions
Having completed the adaptation of the cell lines to each of the media, stationary 
growth phase assays were performed to monitor the growth of the cells during routine 
passaging. This assay is an effective way of monitoring the cells performance in a 
particular culture environment over time. Using this method rapid identification of any 
difficulties associated with the cell line reproducing its growth during repeated sub- 
culturing was possible, thus it was a good indicator of the life span of a cell line in a 
particular culture environment. In addition, a simple growth curve was performed 
whereby cells were monitored from lag phase through to the decline phase. This allows 
visualisation of the particular growth characteristics of the cell line in a particular 
culture environment. From the growth curve it is possible to pin point the time of 
maximum cell density and viability, which is important when harvesting cells for scale- 
up purposes.
From the results of these experiments (Figures 3.1, 3.2, 3.3, 3.4) it is clear that the 
serum-free media that performed best in terms of cell number in comparison to the 
serum-supplemented control, were Excel! 620, Hybridoma SFM, the protein-free 
medium HTM20CTH and the chemically defined CD Hybridoma medium.
It is important when performing optimisation and actual cell culture processes that there 
is a system in place which can efficiently determine the quantity of antibody that is 
being produced in culture. Failure to ensure this type of system may result in loss of 
productivity due to the fact the antibody might reach its peak productivity on a certain 
date and may drop off after that due to the presence of proteases etc in the culture 
supernatant (Teige et al., 1994; Kratje et al., 1994; Enfors, 1992). Traditionally ELISA 
has been the method of choice for the quantification of monoclonal antibodies in cell 
culture. ELISA’s can be designed in a variety of formats, the most commonly used 
include the sandwich, indirect and competitive assays (Crowther, 2001). For 
quantifying antibody in the work presented in this thesis the sandwich ELISA was 
performed.
Initial quantification of the anti-mdr-1 MAb 6/1C using the ELISA method for the cell
line in serum-supplemented and various protein-free and serum-free media yielded
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unsatisfactory results. The standard curve was reproducible but the positive control i.e. 
MAb produced in ascities never yielded linear results across the range of dilutions used. 
No positive results were obtained for anti-mdr-1 MAb 6/1C cultured in the various 
media both for normal and concentrated supernatants. Daring the course of this work 
there was problem with the supply of the particular serum being used i.e. Myoclone heat 
inactivated foetal bovine serum (Gibco). This serum had been continuously used in the 
culture of this anti-mdr-1 antibody, but its supply was halted during the course of this 
research work and a number of serums were supplied as alternatives. Myoclone had 
been used because it was pre-heat inactivated. All of the new serums that were supplied 
were not heat inactivated although the supplier assured us they were at the time of 
purchase. While it cannot be said that this was the reason why antibody production was 
decreased in the hybridoma cell line 6/1C, it can be speculated that the use of different 
scrums may have caused some instability in the cells resulting in a decrease in the 
production of antibody. In order to examine the effect of serum on the quantification of 
the antibody, an ELISA was performed spiking an antibody of known concentration in 
to serum-supplemented medium and comparing results achieved with the results 
obtained from the standard curve (Table 3.1). T-test analysis of the results indicated 
that there was a significant difference between the results obtained. This result indicates 
that indeed the serum was having a significant effect on the quantification of results.
Other methods employed to determine the presence or quantify the presence of antibody 
6/1C in supernatants yielded poor results. Presence of antibody was not detected on the 
RID plates, isotyping using the isostrips yielded a very faint IgG band for anti-mdr-1 
MAb from cells cultured in serum-supplemented medium and no bands were detected 
for the samples cultured in the protein-free and serum-free media. Isotype analysis 
using the ELISA based mouse IgG, kit yielded very faint IgGi, IgG2 a, IgGm, IgGj 
results for the serum-supplemented medium and faint IgM results for the protein-free 
and serum-free media samples. The results obtained with the scrum-supplemented 
samples indicate that a non-isotype specific capture antigen was used or that sample 
over loading may have occurred.
Nephelometric analysis of these samples yielded very small quantities of antibody.
Results shown (Table 3.3) are well below the average expected antibody productivity
level, which can depending on process conditions lie anywhere between 50-100p.g/ml
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(Kundu et a l, 1998; Bibila & Robinson, 1995; Reuveny et al., 1986). In the case of 
hybridoma 6/1C, it typically produced between 35-50|ag/ml IgG in previous studies in 
the laboratory (Moran et al., 1998 unpublished data).
Tmmunocytochemical analysis is not a quantitative method. Instead, it determines the 
presence of antibody based upon staining of the plasma cell membrane of the positive 
control cell line DLKPA, in the case of hybridoma producing anti-mdr-1 cell line 6/1C.
Of the media, which induced the best growth characteristics of the hybridoma 6/1C in 
culture only the protein-free CD Hybridoma yielded positive staining as can be seen 
from Fig 3.5(G). On comparison of these results to those obtained when using 
nephelometric analysis, culture of this cell line in this medium yielded the highest levels 
of antibody.
In order to increase antibody productivity of the hybridoma producing cell line 6/1C, 
three commercially available supplements were employed. OptiMab is a defined 
protein-free concentrate, which consists of alternate carbon sources, a monoclonal 
antibody inducer and essential nutrients which, have been shown to be significantly 
depleted during the high-density culture phase (Mercille & Maisse, 1998). Glutamax II, 
the second supplement is a heat stable derivative of the amino acid glutamine. It is a 
poor stimulator of cell division and growth so the optimum time to add it to the culture 
is during late log phase of growth hence enhancing MAb production. TCH is a serum 
replacement that supports the growth of mammalian cells. As one can see from Figure 
3.6, in terms of growth, OptiMab increased the exponential phase by 4 days and reached 
higher cell densities in the range of 3.5 x 106cells/ml. Immunocytochemical staining of 
supernatants taken following addition of all three supplements showed mdr-1 positive 
staining. Notably, strong staining was recorded in the OptiMab supplemented samples. 
Nephelometric analysis also detected an increase in the levels of antibody in the 
samples containing OptiMab and Glutamax II.
Due to the difficulty in detecting quantifiable antibody using the ELISA and RID 
systems and the inability of the isotyping kits to detect strong IgG bands, it was likely 
that further studies on the 6/1C hybridoma cells would prove difficult.
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It appeared that the 6/1C cell line had a decreased rate of antibody productivity and in 
some cases had ceased antibody production altogether. In many of the adapted media, 
little or no antibody production was observed. It should also be mentioned that work 
carried out by an independent commercial company on the cell line 6/1C concluded that 
low level and in some cases, no antibody was being produced in culture. The reason 
why loss of antibody productivity was observed during the course of the work is not 
apparent, but a review of the literature suggests a number of possibilities.
As cells adapt to new environments such as the adaptation from serum-supplemented 
medium to protein-free/scrum-free medium it was noted that the cells no longer attached 
to the surface of the flask. This may have been due to a possible attachment 
enhancement factor which may be present in serum-supplemented medium and absent 
from the serum-free/protein-free medium. Alternatively, it may have been change in the 
expression of genes involved in cell adhesion, extracellular matrix or cytoskeletal 
organisation in the new culture environment. In effecting such changes, the expression 
of regulatory elements controlling their expression may also have been altered. Cellular 
events such as the cell cycle and distribution of organelles are closely linked to cell 
adhesion, cytoskeletal structure and cell shape. It is possible their expression is also 
affected when the cells are adapted to suspension growth. If the expression of such 
genes is affected it is possible that other downstream genes such as those responsible for 
antibody production are also affected (Korke et al., 2002). This is possible since stable 
production for antibody-producing cells is complex. Separate genes, which are 
integrated and regulated independently, encode heavy and light chains. Secretion of 
mature antibody into the supernatant depends on accurate assembly of these chains in 
the endoplasmic reticulum (Strutzenberger et al., 1999; Martial-Gros et al., 1999). In 
addition mycoplasma infection of hybridoma can compromise antibody production 
levels, however mycoplasma analysis was carried out on samples every 6 months and 
each time results were negative for contamination.
In summary, the inability of a cell line to secrete antibody could be due to one of the 
following factors:
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■ Genetic instability leading to modifications of the primary structure of IgG 
chains or a problem in the regulation of transcription/translation of mRNA 
(Hunkeler et al., 1989).
■ Defects in the assembly of the Heavy and Light chains -  nutritional conditions 
and growth conditions can influence assembly factors (Gardner et al., 1985).
■ Improper post-translational modification; it has been shown that the level of 
glycolysation of the protein is dependent not only on the metabolic state of the 
cell but also on the binding supplements in the medium. The protein transport 
system can be blocked until a correct configuration is achieved (Martial et al., 
1994; Hendershot, 1990)
4.1.2 Adaptation of the hybridomas 4/2D, 5C3, and 1/11C to protein-free 
medium.
Three cell lines were adapted to new protein-free media (UltraDoma and PFHM II) that
had been previously used and proven to work well in our laboratory (Larkin, 2002).
Growth characteristics and productivity in culture were compared between the three cell
lines. The three cell lines used were the hybridoma producing 5C3-cell line, the
hybridoma producing 1/11C cell line and the hybridoma producing cell line 4/2D.
These three cell lines were adapted to the new media using the sequential adaptation
process (Section 2.2.3). The results indicated that all three cell lines adapted most
favourably to the PFHM II medium (Figure 3.8, 3.13 and 3.18). It is also clear from the
results obtained from nephelometry, immunocytochemistry and RID and SDS-PAGE
that the cell lines with the highest antibody productivity were the hybridoma producing
cell line, 4/2D and the hybridoma producing cell line, 5C3. Average production rates in
static flask culture were 20(.ig/L for hybridoma 4/2D both in serum-supplemented and
protein-free conditions. For hybridoma 5C3, average production in static flask culture
was approximately 20(ig/L in serum-supplemented medium and 180(ig/L in protein-free
conditions. Because quantifiable and reproducible quantities of antibody were being
obtained in culture, these cell lines were chosen for further scale-up studies in the
protein-free medium (PFHM II) and the serum-supplemented medium. It should be
noted however that although SDS-PAGE was performed to determine the presence of
antibody culture supernatants it is not an exact method as the presence of serum may
interfere with the detection of bands. A more suitable method for the absolute detection
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of IgG bands is that of Western Blotting. In addition, a positive IgG control should 
have been included in these gels along with media controls. Media controls contain the 
culture medium minus the cells or product. The bands that appear could then be 
compared to the samples containing supernatant enabling an exact determination of the 
antibody bands to be made.
4.2 Effects of agitation on monoclonal antibody production from the 
hybridoma 4/2Dand 5C3 cell lines.
The use of agitation as a means of maintaining uniform growth conditions in culture 
can, if  used excessively, lead to physical damage of the cells. At large scale there is an 
increased demand to meet oxygen and nutrient requirements and to remove CO2 . The 
increased mass transfer requirement is met by an increase in the rate of agitation or by 
sparging air through the medium. These methods have the disadvantage of being 
potentially damaging to the cell. The damage can be as clear-cut as cell death or can 
manifest itself in a manner which results in a reduction of the intrinsic growth rate of 
cells, which can reduce the amount of product being formed. In addition, if  damage 
results in lysis of the cells the increased non-specific protein in the medium makes the 
process of protein purification very difficult (Aloi & Cherry, 1996). On the other hand 
low agitation rates result in cell aggregation (clumping). This leads to inaccurate cell 
enumeration and reduced antibody productivity as cells inner most in the clump are 
starved of oxygen and nutrients and hence cells die early on in the cell cycle.
In the work presented in this thesis, three rates of agitation were examined, 50rpm, 
lOOrpm and 200rpm. This range includes rates, which are generally described as low, 
normal and excessive.
As is shown in Figure 3.24, culture of the cell line 4/2D in serum-supplemented and
protein-free media shows maximum cell density was achieved at lOOrpm. Reduced cell
growth was observed at 50rpm under both culture conditions. Culture at lOOrpm in
protein-free medium yielded a three-fold increase in cell density compared to that at
200rpm. Reduction in cell number at 200rpm was most likely as a result of the
increased shear experienced by cells in protein-free medium, which lacks the protective
nature of serum (Jobses 1991, van der Pol et al., 1992). However, an increase in
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antibody production of 56% at 200rpm was recorded. This is unusual, as one would 
expect that in the absence of a shear protectant such as serum, the cells would be 
adversely damaged as was shown when the 5C3-cell line was cultured in the same 
medium. However this reiterates the point the all cell lines are different and 
productivity will vary in different culture environments.
Another noticeable characteristic concerning the culture of the line 4/2D in serum- 
supplemented medium is the fact that the maximum cell density under culture 
conditions of 200rpm was achieved one day earlier (Figure 3.24). The increased rate of 
cell growth in the exponential phase and of cell decline at 200rpm after maximum cell 
growth (Day 3) may be related to high metabolic rates in the exponential growth period 
and subsequent nutrient limitations (Smith & Greenfield, 1992). The increased 
agitation intensity may have been sufficient to have a subtler biological interaction with 
the cells resulting in an increase in the rate of glycolysis. Such increased rates of 
glycolysis at higher agitation rates may have been required to provide energy either to 
satisfy a deficiency in another energy production pathway or to increase overall energy 
production thus providing maintenance of internal structures or repair of membranes 
affected by turbulent fluid forces. To overcome such limitations in energy that occur 
after maximum cell density has been reached, the addition of energy sources such as 
glucose and glutamine in appropriate quantities and at appropriate times can be a 
solution (Abu-Reesh & Kargi, 1991; Dodge & Hu, 1985). Noticeably, there were 
comparable levels of 4/2D MAb produced at 200rpm and lOOrpm in serum- 
supplemented medium. This trend has been observed previously by Smith and 
Greenfield (1992), where culture at 200rpm yielded 27mg/L and that at 600rpm yielded 
26mg/L, suggesting no loss in cell activity at excessive rates of agitation.
The hybridoma cell line 5C3, cultured in serum-supplemented and protein-free medium 
(Figure 3.28) yielded similar results to the hybridoma cell line, 4/2D when cultured 
under various rates of agitation. Agitation at lOOrpm yielded the highest cell densities 
and antibody concentration. Culture of cells at 200rpm in protein-free medium had a 
deleterious effect on the growth and antibody productivity suggesting that these cells 
cultured in protein-free conditions are extremely fragile in shear stress. Interestingly, 
there was a substantial increase in the quantity of antibody produced by the hybridoma 
producing cell line 5C3 in protein-free medium. Results obtained at 50rpm and lOOrpm
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were five and ten fold respectively more than that achieved in serum-supplemented 
conditions.
4.3 Effects of temperature on monoclonal antibody production from the 
hybridoma cell lines 4/2D and 5C3.
The set point temperature 37°C has been so widely accepted to be most efficient culture 
temperature for mammalian cells since the beginning of cell culture procedures, that 
temperature has received very little attention as a process optimisation variable. For this 
reason, the number of reports on attempts to optimise the temperature are limited in 
comparison to those obtainable for pH, dissolved oxygen concentration and medium 
composition.
Previous research work has investigated temperatures in the range 29°C to 42°C. 
Reuveny et al., (1986) carried out work in the temperature range 28°C to 37°C with the 
view to prolonging higher cell viabilities in the decline phase.
It has been generally recognised that low culture temperatures suppress cell growth and 
enhances cell productivity. This is based on the reasoning that suppression of cell 
growth at low temperatures usually occurs in the Gi phase, which is the phase during 
which antibody production occurs. However the effect of low temperature on 
production has been reported to be cell line dependent with reports of enhanced, 
(Kauffmann et al., 1999; Furukawa & Ohsuye, 1998), decreased (Bamabe & Butler, 
1992; Sureshkumar & Mutharasan, 1991), stabilised (Merten & Litwin, 1991) or 
unaffected (Chuppa et al., 1996; Weidemann et al., 1994; Bloemkolk et al., 1994) 
specific production rates.
Reducing the temperature can, depending on the cell line, have many advantages over 
culture at the normally used temperature 37°C. Such advantages include a decrease in 
proteolytic activity (Kratje et al., 1994; Tiege et al., 1994; Enfors, 1992). This is 
essential if complex proteins prone to degradation are produced by cell lines with high 
proteolytic activity. In such cases, a reasonable decrease in the culture temperature 
might modulate the severity of any extra and intra cellular proteolytic attack.
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In general, it has been observed that there has been a decrease in cell metabolic 
activities at lower culture temperatures. This is reflected by a decrease in the specific 
glucose uptake rate, the specific lactate production rate, the specific glutamine uptake 
rate and the specific CO2 evolution rate. Reuveny et al., (1986) and Surcshkumar, & 
Muthaeasan (1991) reported a 200% decrease in specific glucose uptake rate at 33°C. If 
uptake rates of other components are affected in a similar manner it can be expected that 
at lower temperatures less medium will be required for cultivation hence there would be 
huge savings in the cost of production at large scale.
The purpose of the experiments carried out here was to examine the effects of the 
culture temperatures 34°C, 37°C and 39°C on the growth of the hybridoma cell lines 
4/2D and 5C3 in serum-supplemented and protein-free culture conditions.
Similar growth rates (Section 2.10.1 for calculation) and growth characteristics were 
observed between the culture of the hybridoma producing cell line 4/2D in serum- 
supplemented medium at 37°C and 34°C (Table 3.10). However, an increase in MAb 
productivity of 22.2% was observed.
Culture at 39°C had a deleterious effect on the growth and productivity of the 4/2D cell 
line (Figure 3.25). This result was in agreement with that reported by Blomkolk & Gray 
(1994) who observed that both cell growth and antibody productivity were reduced at 
39°C.
Maximum cell density was obtained from the hybridoma producing cell line 4/2D at 
37°C in protein-free medium. However, maximum antibody production occurred at 
34°C. From Table 3.10 it is clear that the specific growth rate at 34°C is lower than that 
achieved at 37°C and 39°C. According to Suzuki & Ollis (1989), a decreased specific 
growth rate is reflected in a prolonged stay of the cells in the Gi stage of the hybridoma 
cell cycle. Since monoclonal antibody, synthesis takes place in the Gi phase it is not 
surprising that a prolonged stay at this stage ultimately led to higher concentrations of 
antibody in the supernatant.
Similar growth patterns and antibody production rates were obtained when the
hybridoma producing cell line, 5C3 cells were cultured in serum-supplemented at 34°C
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and 37°C (Table 3.14). There was an observed increase of 18.75% in antibody 
production at 37°C. Culture at 39°C appeared again to be stressful for antibody 
production.
Culture at 37°C yielded the most efficient results with regards to cell number and 
antibody production (Figure 3.29). The specific growth rate at 34°C was reduced 
(0.5750d_1) compared to 37°C (0.6660d"'). Nevertheless, no increase in antibody 
production was observed. This is in contrast to the result obtained when culturing the 
hybridoma producing cell line 4/2D in protein-free medium. With a reduced specific 
growth rate, antibody production was increased by 33%. In the case of 5C3 cultured in 
protein-free medium a reduction in antibody production of 38% was observed. This 
reiterates the point made earlier during this discussion that no two cell lines are the 
same hence one camiot assume that the same operating conditions will maximise 
productivity (Weidemann et al., 1994).
In summary, the work carried out on agitation and temperature in spinner flasks has 
shown that the culture conditions of 37°C and lOOrpm are the most efficient for cell 
growth and antibody production in each of the cell lines studied.
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4.4 Production of monoclonal antibodies from hybridoma 4/2D and 5C3 in 10 L 
bioreactors
The increased demand for the production of larger quantities of vaccines and MAb 
based therapeutics in the last two decades has led to the development of larger and more 
efficient approaches to their production. These methods include a wide range and size 
of bioreactors and feeding strategies. Bioreactors, depending on the type can range in 
capacity from one to tens of thousands of litres. In the past three years, the volume of 
commercial antibody production has increased two fold (Dutton, 2001). Currently there 
are 235 monoclonal antibodies nearing clinical trials and by 2010 it is expected that 100 
of these will be commercialised (Kelley, 2001). The importance of developing efficient 
production processes cannot be underestimated.
Along with increased demand for monoclonal-based therapeutics comes the increased 
need for control systems, which can monitor the culture environment of the cells. The 
ADI control system employed for the control of the 10L fermenter, in general proved 
very straightforward to operate and set up but was not without its operational problems. 
It was found in one early calibration run that if there happened to be a surge in 
electricity causing the unit to shut down it failed to retain the original settings at start 
up. This resulted in some cases, in the temperature and dC>2 concentration rising to very 
high levels. This problem needed to be rectified before a proper run was initiated as if 
this were to happen during a culture run, all cells and product would be lost. It turned 
out that an upgrade in software rectified the problem.
For the purpose of this thesis, two of the hybridoma producing cell-lines 4/2D and 5C3 
were scaled up from a working cell bank to 10L scale. The main aim of this work was 
to show that scale up could be achieved without loss of cell activity and antibody 
productivity. The production strategy used was that of a simple batch culture, cells 
were grown for approximately six days and the product was harvested daily for further 
antibody analysis.
Duplicate runs of the culture of the hybridoma producing cell line 4/2D in serum-
supplemented medium were performed. The initial run resulted in the surprising
observation that maximum antibody production occurred at day three and antibody
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levels dropped considerably thereafter (Figure 3.26). The maximum antibody 
concentration was approximately ten-fold greater than that achieved at the spinner flask 
stage and the subsequent run. The second run yielded results similar to those achieved 
in the smaller scale studies i.e. with maximum cell density occurring at day four and 
maximum antibody productivity occurring at day six.
The duplicate runs carried out for the culture of the 4/2D cell line in protein-free 
medium were very similar. It is clear that, from the data in Table 3.12, that specific 
growth rate, doubling times and the number of generations completed were almost 
identical. The observed growth and antibody production trends were also comparable to 
those achieved at the spinner flask scale.
Noticeably, however in comparison with the first batch run of the hybridoma producing 
monoclonal antibody 4/2D, in serum-supplemented medium, antibody production 
peaked at 72 hours after which there was again a decrease in antibody levels. This 
observation suggested that the assumption that the action of acid proteases present in the 
culture medium may be leading to the denaturation of the antibody (Teige et ah, 1994; 
Kratje et ah, 1994). To examine this suggestion further, cells at small scale were 
maintained in culture for five days after maximum antibody production was reached. 
The samples were analysed to determine antibody loss but no such decrease in antibody 
concentration was observed. It appeared that factors created in the bioreactor that were 
not encountered in the spinner flask were possibly causing this loss of antibody to occur 
for instance there may have been a large build up of proteases which resulted in the 
denaturation of the antibody. There is no evidence to suggest this is the case but in 
future work section 5.2 I have detailed experiments, which could be carried out to 
monitor the protease action.
As was characteristic of the culture of the hybridoma producing cell line 5C3, larger 
quantities of antibody were observed in the smaller spinner flask in protein-free 
medium, in some cases 30 fold that achieved with the same cell line in serum- 
supplemented conditions (Figure 3.30, 3.31). Smith & Greenfield (1992) observed 
similar results with a hybridoma cell line they cultured in PFHM II. They noticed an 
increase from approximately 27(.ig/ml in serum-supplemented medium to 180(ag/mL in
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protein-free medium. They attributed this dramatic difference to the nutrient 
composition of both media.
Table 4.1 below compares the various concentrations of amino acids present in both 
media. They suggest that the non-essential amino acid alanine which is present in high 
quantities in PFHM II and not in DMEM may have an important role to play in the 
increased concentrations of monoclonal antibody being detected. Alanine is produced 
in high concentrations in hybridoma cultures as a result of both glucose and glutamine 
metabolism and it is believed to contribute to cell metabolism as a non-toxic nitrogen 
sink for glutamate amino groups. Smith & Green (1992) have postulated that alanine 
may be included as an alanine-glutamine dipeptide, which stabilises glutamine against 
spontaneous degradation. However, this dipeptide more commonly known as Glutamax
I is used in the serum-supplemented medium as the carbohydrate source and does not 
result in higher levels of antibody production.
From the Table 4.1 it is clear that nearly all of the other amino acids are present in 
higher concentrations compared to the basal medium DMEM. Hence it cannot be ruled 
out that one of these or a combination of these could be having an enhancing effect on 
the production of MAb from the hybridoma producing cell line 5C3.
In summary, high levels of antibody production where achieved when the hybridoma 
cell line, 5C3 was cultured in protein-free medium. Along with the reasonably pure 
nature of this antibody (Figure 3.16) due to its culture in protein-free medium it seems 
as if  optimum conditions for production of such an antibody have been identified.
In serum-supplemented medium the levels of antibody produced are much lower than in 
protein-free conditions. This may be due to the interference of serum when reading 
samples using the nephelometer but the fact that poor results showed up on both RID 
analysis and the isostrip analysis (Figure 3.9), leads to the conclusion that culture of 
antibody 5C3 in serum-supplemented medium resulted in very low levels of antibody 
production.
However as discussed previously, growth of 4/2D in protein-free medium did not 
produce MAb in quantities comparable to the 5C3. It could be said that this hybridoma 
producing cell line 4/2D is simply a poor producer of monoclonal antibody.
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Table 4.1 Am ino acid concentrations in DM EM  and PFHM II.
Amino Acid DMEM PFHM II
EAA mg/L mM mM
LArginine 84 1.00 1.24
L.Cysteine 48 0.40 0.14
Glutamine(Glutamax) 3.97 3.91
i_Histidine 42 0.20 0.37
L.Isoleucine 105.00 0.80 1.47
L-Leucine 105.00 0.80 2.52
L.Lysine 146.00 0.79 1.56
L.Methionine 30.00 0.20 0.45
L.Phenylalanine 66.00 0.40 0.77
L.Theroninc 95.00 0.80 1.06
.^Tryptophan 16.00 0.078 0.27
L-Tyrosine 72.00 0.40 0.50
L. Valine 94.00 0.80 1.04
NEAA
L.Alanine 0.00 0.00 5.89
[Asparagine 0.00 0.00 3.34
^Aspartate 0.00 0.00 0.10
Glutamate 0.00 0.00 1.02
i..Glycine 30.00 0.40 0.17
L.Hydroxyproline 0.00 0.00 0.19
L.Proline 0.00 0.00 3.18
L_Serine 42.00 0.40 2.86
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4.5 Antibody production from hybridoma 5C3 in a hollow fibre bioreactor
The artificial capillary cell culture provides an ideal environment for high-level 
monoclonal antibody production. Hybridomas cultured in artificial capillary systems 
generally secrete an increased amount of MAb in comparison to MAb production in 
conventional culture. This is because hybridomas cultured in hollow fibres are 
continuously bathed in a fresh supply of oxygen and nutrients from the circulating 
growth medium. At the same time lactate and growth-inhibitory secreted proteins 
diffuse out of the extracapillary space surrounding the cells and are diluted into the 
circulating medium. Hollow fibre bioreactors can consistently produce concentrated 
antibody depending on the type and size of the unit used. With some hybridomas, a 
single artificial capillary module can produce levels of MAb similar to ascities 
concentrations (~lmg/ml) (Beck et al., 1990, Altshuler, et al., 1986, Piret & Cooney, 
1990).
The culture of hybridoma producing cell line 5C3 in the hollow fibre bioreactor, yielded 
a high concentration of antibody in the protein-free medium with an average of 5.52mg 
of antibody product being produced per day, compared to that provided in serum- 
supplemented medium of 2.19mg of antibody being produced per day (Figure 3.33).
If one examines the difference in antibody production between the first and second run 
in the protein-free medium, there is a decrease in the quantity of antibody produced in 
the second run (Figure 3.33, Table 3.18). The reason could be due to the fact that 
during the second run the cells were adapted from serum-supplemented conditions into 
protein-free conditions. If one looks at the results obtained for the culture of cells in 
serum-supplemented medium they were consistently well below that achieved in the 
presence of the protein-free medium (PFHM II). It seems that in the case of the serum- 
supplemented medium used in this work that something was hindering the production of 
antibody or may be interfering with its detection. Therefore, when the cells in the 
hollow fibre were weaned off serum-supplemented into protein-free culture conditions 
the presence of small traces of serum in the second protein-free culture could have 
caused the decrease in antibody quantified.
157
4.5.1 10 L Batch Fermenter Culture versus Hollow fibre Bioreactor
The hollow fibre bioeractor is the most commonly used method by which MAbs are 
cultured in projects where only gram quantities of antibody are required. However, 
when larger quantities are required, larger fermenter systems must be employed.
The main advantages of the hollow fibre bioreactor system over the 10L fermenter 
system are:
■ Higher cell densities of 107—108 are obtained.
■ The continuous supply of nutrients and removal of waste products ensures optimum 
growth conditions for the production of antibody.
■ The batch removal of the product every two days (depends on each cell line) 
decreases the possibility of antibody degradation, which may occur due to 
prolonged exposure to cellular proteases (Reuveny & Lazar, 1989).
■ The batch removal of the product ensures that dead cells and cellular debris are also 
removed, which results in increased space and new cell growth.
■ The hollow fibre bioreactor used in this work was much easier to set up and operate 
compared to fermenters, which required a number of days for preparation and 
testing.
■ The capital costs for the hollow fibre and associated equipment used in this work 
was much lower than fermenters and less space was required to house them.
■ Fermenters on the other hand require a large area to house the fermenter itself and 
its associated controls (Lipman & Jackson, 1998).
Fermenters however, have their advantages over hollow fibre bioreactors. They are 
more stringently controlled in terms of pH and DO2 concentrations in situ, which 
becomes more important as the culture period increases.
As can be seen from the Table 4.2 below the quantity of antibody produced in the 
fermenter far exceeds the alternative in the hollow fibre bioreactor. The table shows the 
cost per mg to produce antibody in each of the cell culture methods utilised throughout 
the course of this thesis.
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Table 4.2 Comparing antibody production in the 10L fermenter and in a hollow 
fibre bioreactor (cellmax artificial capillary module, Cellco Inc.). Total 
volume used in hollow fibre bioreactor was approximately 4500 ml.
10L
(mg)
HFB
(mg)
5C3 in SSM 290 45.97
5C3 in PFM 2965 116
4/2D in SSM 190
4/2D in PFM 200
Not surprisingly, the production of the 5C3 MAb in protein-free medium is the most 
cost effective of all methods. Its production (per mg) in the hollow fibre bioreactor is 
significantly more expensive than culture in the 10L fermenter. Interestingly the cost of 
production in the 10L fermenter is the same as that in the spinner flask. However, 
production of MAb in spinner flask at large scale could not be deemed feasible. 
Numerous units of flasks and associated magnetic stirrer bases would be required along 
with designated incubators. Spinner flasks are more prone to contamination due to the 
extra manipulations that must be carried out in the laminar flow cabinet and the 
movement of the flasks from the incubators to the flow cabinets.
Table 4.3 Shows comparison of the cost of production of two monoclonal antibody 
producing cell lines in serum-supplemented and protein-free medium by 
a variety of different methods.
Cell Line Static Flask 
€ /m g
Spinner Flask 
€ Img
10 L Bioreactor 
€  /mg
Hollow Fibre Unit 
€  /mg
5C3 in SSM 39.91 20.15 2.60 17.66
5C3 in PFM 0.44 0.26 0.26 0.313
4/2D in SSM 20.66 9.23 3.95
4/2D in PFM 63.00 16.85 3.88
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4.6 MININEPH (Nephelometer)
The “MININEPH” is a bench-top laser nephelometer capable of performing a range of 
quantitative serum protein assays. The basis behind nephelometry is the ability to 
measure changes to analyte concentration in proportion to turbidity resulting from 
immune complex formation in solution. It is ideal for replacing assays currently 
performed by Radial Immunodiffusion (RID) and other manual techniques such as the 
ELISA.
The advantages of the nephelometer over currently used methods are shown in table 4.4.
Table 4.4 Comparison of the most frequently used assays for the determination of 
human IgG subclass levels (Adapted from Baker et al., 2002).
Assay Sensitivity Intra assay 
variation
Inter assay 
variation
Automation Assay Tinte
RID ng/ml Small Small No 48-72  hours
Nephelometry ng/nil Very small Very small Complete 3-15 minutes
ELISA ng/ml Medium Medium Partly 3-4 hours
With assays completed in 3-15 minutes, this method is a logical choice for analysis of 
cell culture supernatants for the presence of antibodies. Real time analysis of the 
quantity of antibody will allow harvest of the antibody at peak times during 
fermentation runs. However as Table 3.23 shows nephelometry using the IgG anti sera 
is not specific for samples containing IgM. In such a case an assay using IgM anti 
serum will have to be employed and new assay criteria developed. Also in order to 
determine a standard a number would have to be analysed as the accuracy can vary from 
one to another (Section 3.10.3).
Throughout the course of this work, the nephelometer was used continuously as the 
method of choice for the quantification of antibody. As one can see from the results in 
section 3.10, validation work was carried out on the nephelometer to ensure that the 
procedure was fit for the purpose intended in that it ensured confidence that the correct 
results were obtained when assaying the test samples.
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The acceptable coefficient of variance for the validation of analytical techniques is 10%. 
Validation work involved carrying out assays to verify the precision and reliability of 
the assay. The results obtained for the intra and inter variation assay showed very little 
variation (CV < 10%) between the results obtained when the sample was consecutively 
measured on ten separate occasions throughout a day (Inter Assay Variation, Table 
3.18) and over a four day period (Intra Assay Variation, Table 3.19). This gave a 
reasonable indication of the repeatability of the instrument to yield similar results over 
time. However when the precision and reliability of the assay were considered it was 
found that the intra-assay variation was 10.2% and the inter assay variation was 
15,97%. These large %CV could be explained by the fact that the system was manual 
and there may be a large pipetting error. This would endorse the bid for a fully 
automated system, which are available on the market and might reduce the error 
involved in the automated system.
The results obtained for repeated determination of the standard curve all have regression 
coefficient values of greater than 0.9990 (Figure 3.36 and Table 3.20). The linear range 
of the assay was also determined and found that the lower and upper limits of detection 
were 9.75 and 600mg/L respectively.
The accuracy and specificity of the assay was determined using a variety of IgG 
antibodies of varying subtypes of IgG and IgM, measuring, them against the standard 
curve and comparing them to their know concentrations. It can be seen from Table 3.22 
that specificity and accuracy was not acceptable in each of the cases. In particular the 
results obtained for the anti-fodrin MAB1622 and the anti-Cytokeratin No. 18 were not 
as specific or accurate as those obtained for the other IgG samples. In terms of accuracy 
they was a difference of 16.67 and 26.65% between the know concentration of the 
standard and that obtained from nephelometric analysis. The results obtained for the 
IgM control, which had a coefficient of variance of 135.6 suggested that the specificity 
of the IgG anti sera did not include IgM.
Overall, as a method for quantifying MAb in supernatant the nephelometer appears to 
be the most efficient and reliable method used during the course of this work. RID 
analysis took three days and results were often difficult to read, ELISA was difficult to
perform and often-yielded non-reproducible and non-linear results in our hands.
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Advances in the area of nephelometry assay development are yielding fully automated 
96-well plate assays allowing multiple samples to be analysed in a shorter time. In 
addition, because of these investigations, it is recommended to use a range of standards 
to validate the nephelometric assay.
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Section 5 Conclusion and Future Work
5.1 Conclusions
1. The main findings of this thesis relate to the use of different hybridoma producing 
cell lines and their requirements for optimal cell growth and antibody productivity. 
It is clear that each cell line performs differently under different culture conditions. 
Therefore, it can be said that different cell lines cannot be cultured under the same 
process conditions. For example, the optimum conditions for the growth of the 
hybridoma producing cell lines 4/2D and 5C3 in serum supplemented and in the 
case of 5C3 in protein free medium were lOOrpm and 37°C. The culture of the 
hybridoma 4/2D in protein free medium yielded higher antibody yields when 
agitated at 200rpm.
2. Another point noted was the reduction in antibody production of the 4/2D cell line 
after day 3 in the large-scale process. This was observed in one of two runs under 
SSM conditions. At small-scale antibody levels increased consistently throughout 
the 6 day culture period. Although no evidence is available, it is possible that 
protease inhibitors may have had a role, but this needs to be clarified with future 
work.
3. A number of methods were examined in the production of MAb namely the hollow 
fibre bioreactor, 10L fermenter and spinner flasks. These three methods were 
compared in detail in terms of antibody productivity. However, the cost of using 
each method must also be taken into consideration when developing a cost effective 
production process. In general, the production of MAb in protein free medium has 
proven much cheaper than culture in serum-supplemented medium. This is mainly 
due to the huge increase in serum prices observed in the last two years due to a 
shortage in high quality serum. The price of sera used in this work has almost 
doubled. In terms of the most cost efficient method of production, it was found that 
culture of each of the cell lines was cheaper in the 10L fermenter.
4. A new system of quantifying MAb, the nephelometer has been introduced into the 
laboratory. This method has proven to be a reliable and efficient means of 
quantifying antibody. It replaced the more commonly used methods of RID and 
ELISA, which are both unreliable and time consuming. For example, a
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nephelometric assay takes 15 minutes to complete, RID takes three days and 
ELISAs approximately 5 hours.
5.2 Future W ork
1. An investigation into why a drop in antibody production was observed at large scale 
past day 3 and as to why these trends were not observed in spinner flasks should be 
carried out. It has been reported in the literature that antibody loss can occur in 
culture due to the action of acid proteases (Teige, 1994: Kratje et al., 1994). To 
prevent this from happening in the future it would be necessary to identify what 
factors are responsible for the development of the acid proteases and how it can be 
removed or reduced. According to the literature the traditional way to handle acid 
proteases is to run the culture at reduced temperatures (Enfors, 1992). In order to 
monitor protease activity in culture, an assay based on the measurement of 
trichloroacetic acid soluble peptides, which are released from isotypocally labelled 
protein substrates could be performed. Another assay based on characterisation 
with chromogenic substrates would involve testing culture supernatants with 
artifical chromogenic peptide substrates based on p-nitroanalide dihydrochloride 
conjugates. This will allow a partial characterisation of the protease because of the 
specificity of the derivatives to particular types of enzymes (Kratje et al., 1994). By 
monitoring the protease action under different operating conditions, one will be able 
to determine the most appropriate environment in which to culture the cells with 
reduced protease action.
Another explanation for the reduction in antibody could have been the decrease in 
glucose and increase in lactate concentrations, which would correspond with the 
decreases in antibody productivity. To examine this possibility further experiments 
looking at the effect of varying concentrations of lactate and glucose in culture 
medium on antibody productivity need to be examined.
2. In order to try and optimise MAb production further, fed batch cultures at the 10L 
scale should be carried out. Batch cultures last only 6 to 7 days depending on the 
cell line. With the lead in time and cost involved in setting up fermentation runs at 
this scale it would be more economical to utilise a fed-batch regime. From the work
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carried out in this thesis the growth, antibody productivity, glucose and lactate 
characteristics of the hybridoma producing cell lines 4/2D and 5C3 have been 
clearly determined. Using this information one can identify the appropriate times to 
harvest and re-feed each cell line. Figures 3.26, 3.27. 3.30 and 3.30 show the exact 
time after which lactate becomes inhibitory and glucose rate limiting. It is clear 
from these figures that this time line varies from cell line to cell line. Therefore, 
exact process conditions should be determined for each individual cell line.
3. Further investigation into why the hybridoma producing cell line 5C3 cultured in 
protein free medium yielded concentrations of MAb 10-15 fold in excess of that 
achieved in the serum supplemented control is required. In addition, an 
investigation into why similar results were not being obtained for the culture of the 
hybridoma producing cell line 4/2D in protein free conditions is necessary. In order 
to try to mimic the antibody productivity results achieved from the hybridoma 
producing cell line 5C3, it would be necessary to take a basal medium and add 
various growth factors or additives in an attempt to recreate the culture conditions 
that yielded such a positive result. With such a medium, it would be clear what it is 
comprised of and may reveal what exactly is having the positive effect on antibody 
productivity.
4. On reflection of this is work western blot analysis to give an exact determination of 
the presence of MAb in the cell culture supernatants. SDS-PAGE was used but 
interference particularly in the case of serum-supplemented samples leaves a 
question over the exact existence of IgG bands.
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Appendix I
Abbreviations
ABC/HRP Strep tavidin/biotin-horseradish peroxidase conjugate
ADCC antibody dependent cell mediated cytotoxicity
BSA Bovine serum albumin
CDM Chemically Defined Medium
CDR Complementary Determining Region
cGMP current Good Manufacturing Practice
CJD Creutzfeldt-Jakob Disease
CT Computed Tomographic
DAB Diaminobenzidine
dH20 Deionised distilled water
DMEM Dulbeccos Modified Eagles Medium
DMSO Dimethyl sulfoximide
DQ Design Qualification
EBV Epstein Barr Virus
ECS Extracapillary Space
EGF Epidermal Growth Factor
ELISA Enzyme linked Immunosorbent Assay
FBS Foetal Bovine Serum
FDA Federal Development Authority
FeCl3 Iron Chloride
FS Functional Specification
HAMA Human-Anti-Murine antibody
HEPES 4-(2-hydroxethyl-)-piperazine ethane sulphonic acid
HFB Hollow Fibre Bioreactor
ICS Intracapillary Space
IMDM Iscoves Modified Dubleccos Medium
IMS Industrial methylated spirits
IQ Installational Qualification
KDa Kilo Dalton
1
MAb Monoclonal Antibody
MCB Master Cell Bank
MDR1 MDR-1 encoded P-glycoprotein (170kDa)
NF National Formulary
NGF Necrosis Growth Factor
Ni Nickel
°C degrees Celcius
OQ Operational Qualification
PAGE Polyacrylamide gel electrophoresis
PAMA Polyethylmethanacrylate
PBS Phosphate buffered saline
PEG Polyethylene Glycol
PFM Protein Free Medium
PQ Performance Qualification
RAID RadioLmmunoDetection
RID Radiohnmunodiffusion
RNA RibonucleicAssay
RP-HPLC Reverse Phase High performance Liquid Chromatography 
RPMI Roswell Park Memorial Institute
SDS Sodium dodecyl sulphate
SEC Size Exclusion Chromatography
SFM Serum Free Medium
Si Silicon
SOP Standard Operating Procedure
SSM Serum Supplemented Medium
TBS Tris buffered saline
TEMED N,N,N,N,-tetramethyl-ethylenediamine
TNF Tumor Necrosis Factor
Topo I la  Topoisomerase 11a (170kDa)
Tris Tris (hydroxymethyl) aminomethane
TSE Transmissible spongiform cncepha-lopathies
TV Trypsin/versene
2
URS User requirement Specification
USP United States Pharmacopoeia
WCB Working Cell Bank
s Kolmogrov eddy
% Percentage
(v/v) volume per volume ratio
fig microgram
y average shear rate (s'1)
t average shear stress (Nm‘ )
Visocsity (Nsm~2)
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Appendix II
Graphical Representation of the culture of 5C3 in the 10L bioreactor
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Graphical demonstration of set point dissolved oxygen concentration 
versus actual dissolved oxygen concentrations during the 10 L batch 
run of 5C3 cultured in PFHMII.
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Graphical demonstration of set point pH versus actual pH 
concentrations during the 10 L batch run of 5C3 cultured in PFHM II.
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Graphical demonstration o f set point temperature versus actual 
temperature during the 10 L batch run of 5C3 cultured in PFHMII.
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Appendix III
List o f  Suppliers
■ Applikon Ltd De Brauwweg 13, 3125 AE, Schiedem, Holland.
■ Amersham International pic. Bucks HP7 9NA, UK.
■ BDH laboratory Supplies, Poole, BDH15 1TD, England.
■ Beckman Instruments (UK) Ltd, High Wycombe, Bucks HP 12 4YH, UK.
■ Bio Rad loboratories Ltd Hertz HP2 7TD, UK.
■ Becton Dickinson UK Ltd, Between towns Road, Crowley, Oxford 0X4 3LY, UK.
■ Boehringer Manneheim, Roche Diagnostics Ltd. Bell Lane, Lewes, East Sussex 
BN7 1LG, UK.
■ Cellon Ltd 204 route d'Arlon, L-8010 Strassen, Grand-Duche de Luxemberg.
■ Costar Cambridge MA, USA
■ Dako, 16 Manir Courtyard, Hughendon Avenue, High Wycombe, Bucks HP 13 5RE, 
UK.
■ Gelman, United Kingdom Pall Gelman Sciences, Brackmills Buisness park, Caswell 
Road, Northampton NN4 7EZ, UK.
■ Gibco, Life Technologies Ltd, 3 Fountain Drive, Inchinnan Buisness Park Paisley 
PA4 9RF, UK.
■ Hoefar. Hoefar Scientific Instruments, San Fransisco, USA.
■ Lennox John F Kennedy Drive, Naas Road Dublin 12.
■ Merck, Magna Park, Little-worth, Leicestershire, UK.
■ NUNC A/S. Roskilde, Denmark.
■ Nuaire, 2100 Fembrook Lane, Plymouth, Minnesota 55447, USA.
■ Pierce, Post Office Box 117, Rockford Illinois 61105 USA.
■ Sigma Diagnostics, St.Louis, MO 63178 usa.
■ Sigma, Sigma-Aldrich Company Ltd. Fancy Road, Poole, Dorest, BH12 4QH, UK.
■ Sterlin Ltd, Middlesex TW148QS, UK.
■ The Binding Site Ltd PO Box 4073, Birmingham, B29 6 AT, England.
■ Vector laboratories Ltd., 16 Wulfric Square, Bretton, Peterborough PE3 8 RF, UK.
■ Vector laboratories, Inc. Burlingame, CA 94010 USA.
■ AGB Scientific Dublin Industrial Estate, Dublin 9.
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A p p e n d ix  I V  
R ea cto r Headplate
1. Stirrer Motor 10. Head Space Outlet
2. Triplet 11. Basket Screws
3. Stopper 12. Long Harvest Line
4. Ph Electrode 13. Sample Line
5. Triplet 14. Stopper
6. 0 2 Probe 15. Stopper
7. Stopper 16. Basket Screws
8. Level (Low) 17. Temperature Probe
9. Level (Medium) 18. Stopper
19. Level (High)
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Appendix V 
Sample Calculation
T-test
t = X , - X , /  — i— ¡ f —  
n\n -  lj
,
t = t value 
Xi = Sample 1 
X2 = Sample 2 
d = Difference (X| - X2 ) 
n =  Sample Number
Subject Sample 1 
X,
Sample 2
x 2
Difference
(d)
Squared difference 
(<?)
1 0.720 0.693 0.027 0.0007
2 0.604 0.534 0.070 0.0049
3 0.482 0.396 0.086 0.0074
4 0.300 0.247 0.053 0.0028
5 0.195 0.131 0.064 0.0041
Xj =2.301 
X2  = 2.001 
d = 0.3 
d2  = 0.09 
n = 5
Inserting the figures into the formula: 
T = 6.11
Degrees of freedom = 4
1
The calculated value of t = 6 .11 is greater than the table value of 2.132 allows one to 
reject the null hypothesis at the p = 0.05 level of significance and one can conclude that 
the results obtained comparing the standard concentrations of IgG washing buffer and in 
serum supplemented are significantly different.
2
Sample C a lcu la tio n  fo r costing the p ro d uctio n  o f 1 mg o f a n tib od y fro m  the 
cu ltu re  o f 5C3 in  p rote in  free conditions in  a large-scale b io reacto r
Costings for 4/2D in SSM
Days post 
set-up
jig/ml mg Volume Cost of
medium
€
Cost of 
Production 
€
10 L 6 19 190 1 0 0 0 0 751.31 3.95
Spinner Flask 6 8 . 1 2 0.406 50 3.75 9.23
Static Flask 6 36.31 0.0363 1 0 0.75 2 0 . 6 6
Costings for 4/2D in PFM
Days post 
set-up
Hg/ml mg Volume Cost of
medium
€
Cost of
Production
€
10 L 6 2 0 2 0 0 1 0 0 0 0 777.4 3.89
Spinner Flask 6 46.015 0.2302 50 3.88 16.85
Static Flask 6 12.38 0.0124 1 0 0.78 63.00
Costings for 5C3 in SSM
Days post 
set-up
pg/ml mg Volume Cost of 
medium 
€
Cost of
Production
€
10 L 6 29 290 1 0 0 0 0 751.31 2.60
Spinner Flask 6 37.22 0.1861 50 3.75 20.15
Static Flask 6 18.79 0.01879 1 0 0.75 39.91
HFB 2 1 10.32 42.92 4450 812.1 18.92
Costings for 5C3 in PFM
Days post 
set-up
Mg/ml mg Volume Cost of
medium
€
Cost of 
Production 
€
10 L 6 296.46 2964.6 1 0 0 0 0 777.4 0.26
Spinner Flask 6 294 14.7 50 3.88 0.26
Static Flask 6 175.64 1.76 1 0 0.78 0.44
HFB 2 1 28.08 115.855 4125 370.41 3.20
Days 
post set­
up
Hg/ml mg Volume Cost of 
medium 
€
Cost of
Production
€
10 L 6 296.46 2964.6 1 0 0 0 0 777.4 0.26
2964.6 mg = 777.4 
1 mg=X
Therefore 777.4/2964.6 = 0.26 (Cost of producing 1 mg)
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A p p e n d ix  VI 
V ia b il i t y  Tables
Time
(Davs)
Viability (%) Viability (%) Viability (%)
50 rpm 100 rpm 200 rpm
0 100.00 100.00 100.00
1 93.75 95.72 95.19
2 82.10 94.38 95.24
3 84.10 93.06 89.64
4 77.73 96.23 66.51
5 53.45 78.59 51.74
6 43.64 61.22 33.45
T a b le  7.1 Cell viability's for 4/2D cells cultured in serum supplemented 
medium.
Time
(Davs)
Viability (%) Viability (%) Viability (%)
50 rpm 100 rpm 200 rpm
0 100.00 100.00 100.00
1 100.00 92.40 100.00
2 89.24 93.36 95.66
3 89.40 94.10 90.19
4 80.60 90.02 86.48
5 54.18 81.54 65.27
6 39.74 60.02 52.97
T a b le  7.2 Cell viability's for 4/2D in protein free medium.
Time
(Days)
Viability (%) Viability (%) Viability (%)
50 rpm 100 rpm 200 rpm
0 100.00 100.00 100.00
1 100.00 99.43 95.29
2 96.71 97.37 94.92
3 95.52 97.04 89.45
4 87.02 94.35 74.53
5 70.48 87.76 71.32
6 39.28 74.92 58.84
T a b le  7.3 Cell viability's for 5C3 cultured in serum supplemented 
medium.
1
Time
(Days)
Viability (%) Viability (%) Viability (%)
50 rpm 100 rpm 200 rpm
0 100.00 100.00 100.00
1 76.06 97.37 75.69
2 74.05 95.93 68.12
3 81.32 97.12 No growth
4 59.42 84.00 No growth
5 41.09 69.92 No growth
6 39.28 43.58 No growth
T a b le  7.4 Cell Viability's for 4 2D cell cultured in protein free medium.
Time
(Days)
Viability (%) Viability (%) Viability (%)
34°C 37°C 39°C
0 100.00 100.00 100.00
1 98.22 95.72 100.00
2 97.83 94.38 78.57
3 97.84 93.06 69.84
4 93.32 96.23 86.11
5 86.04 78.59 48.00
6 69.33 61.22 No growth
T a b le  7.5 4 2D in serum supplemented medium.
Time
(Days)
Viability (%) Viability (%) Viability (%)
34°C 37°C 39°C
0 100.00 100.00 100.00
1 100.00 92.40 8.26
2 93.27 93.36 2.91
3 92.82 94.10 No growth
4 85.62 90.02 No growth
5 78.24 81.54 No growth
6 54.35 60.02 No growth
T a b le  7.6 Cell viability's for 4 2D cultured in protein free medium.
Time
(Davs)
Viability
(%)
Viability (%) Viability (%)
34°C 37°C 39°C
0 100.00 100.00 100.00
1 100.00 99.43 93.91
2 97.59 97.37 83.84
3 95.50 97.04 80.89
4 89.90 94.35 78.33
5 76.46 87.76 No growth
6 53.14 74.92 No growth
2
Table 7.7 Cell viability's for 5C3 cultured in serum supplemented 
medium.
Time
(Davs)
Viability (%) Viability (%) Viability (%)
34°C 37°C 39°C
0 100.00 100.00 100.00
1 94.10 97.37 6.42
2 97.00 95.93 7.41
3 95.56 97.12 1.50
4 87.99 84.00 1.48
5 69.33 69.92 No growth
6 53.34 43.58 No growth
Table 7.8 Cell viability's for 5C3 in protein free medium.
Large Scale Culture:
Time
(Hours)
Viable cell count 
(xl 06 cells/ml)
Viability (%) Antibody 
Concentration 
(mg/L)
Antibody
Concentration
(mg/L)
0 0.10 100.00 Batch 1 Batch 2
1 0.23 93.66 14.158 8.24
2 0.7 91.91 25.86 11.40
3 2.67 90.71 72.91 12.30
4 3.78 85.00 23.44 14.60
5 2.24 64.21 14.92 18.90
6 1.555 49.61 13.45 28.37
Table 7.9 Average Viable cell count, % Viability and antibody
concentration for 4 2D cultured in serum supplemented 
medium.
Time
(Hours)
Viable cell count 
(xl 06 cells/ml)
Viability (%) Antibody
Concentration
(mg/L)
0 0.10 100.00 9.76
1 0.20 100.00 18.47
2 0.34 96.75 39.72
3 0.99 91.36 62.64
4 2.19 91.63 40.89
5 1.99 80.33 30.14
6 0.96 58.03 19.72
Table 7.10 Viable cell count, % Viability and antibody concentration for 
4 2D cultured in protein free medium.
3
Time
(Hours)
Viable cell count 
(xlO6 cells/ml)
Viability (%) Antibody
Concentration
(mg/L)
0 0.1 100.00
1 0.11 97.74 9.838
2 0.33 94.29 13.942
3 1.3 96.55 15.222
4 1.665 87.40 23.583
5 1.535 67.95 20.346
6 0.91 36.99 18.280
Table 7.11 Viable cell count, % Viability and antibody concentration for 
5C3 cultured in serum supplemented medium.
Time
(Hours)
Viable cell count 
(xlO6 cells/ml)
Viability (%) Antibody
Concentration
(ms/L)
0 0.10 100.00
1 0.10 100.00 48.78
2 0.42 96.59 177.28
3 0.74 90.11 273.20
4 1.64 86.51 405.95
5 1.23 68.89 475.35
6 0.83 32.73 652.45
Table 7.12 Viable cell count, % Viability and antibody concentration for 
5C3 cultured in protein free medium.
4
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1. Purpose:
The purpose of this Installation Qualification is to provide documented 
evidence that the Applikon 10 L Bioreactor and control units are installed as 
per design intent and to the manufacturer’s recommendations where 
applicable.
2. Scope
The scope of the Installation Qualification, includes the Applikon 10 L 
Bioreactor and control units. All other aspects of the mechanical and 
electrical installation of the unit and their assembly are included.
3. System Description
The ADI Bio Controller ADI 1060, the ADI 1035 Bioconsole and the ADI 
1040/25 are used in unison for the process control of the 10 L Applikon 
bioreactor. The purpose of the ADI 1060 is to control and monitor mammalian 
cell culture systems in a controlled environment where pH, temperature, 
dissolved oxygen and mixing can be controlled.
The ADI 1035 Bioconsole is an actuator console that is used in combination 
with the ADI 1060 Bio Controller. It supports gas flow regulation, stirrer 
speed, pH control, dissolved Oxygen control, level control, temperature 
control, and liquid addition/withdrawal via pumps.
The ADI 1040/25 functions by connecting the ADI 1060 Bio controller with the 
bioreactor and their actuator consoles. The measured sensor signals are 
amplified in the 1040/25 and are transmitted to the Bio Controller through 
serial communication.
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Depending on deviation from the set point, a controller output value is sent to 
an analog or digital output that will activate the actuator in the ADI 1035 in 
order to decrease the deviation from the set point. The control system is 
shown below (Fig. 1) and outlines the roles played by each component of the 
process system. The associated 10 L Bioreactor is a glass stirred tank 
reactor.
ADI 1060
Biocontroller
Actuator Console 
ADI 1035 □
Scada (Uiocxpert system)
Fig 1: Schematic overview of the Applikon “bioprocess” system.
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4. Pre Protocol Checks:
Have the appropriate representatives reviewed the Installation Qualification? 
Is the protocol approved and ready for execution?
Yes/No: File Location:_________________
Verified By: ___________  Date:
Have Standard Operating Procedures have been drafted for the operation of 
the Bioreactor & Control System?
Yes/No: File Location:_________________
Verified By: ___________  Date:
Detail relevant SOP numbers:
All recommended spare parts on order?
Yes/No: ____________ File Location
Verified By: ___________  Date:
Comments:
Siqned: Date:
Approved By: Date:
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5.0 Installation Qualification:
The Installation Qualification is the documentation process, which verifies that 
the physical components of a system have been installed according to design 
specifications. The IQ also serves as a final equipment audit prior to 
equipment operation. The installation of the system will be verified by 
reviewing the equipment installed and using the check sheets provided in this 
protocol to document that the system components conform to design 
specifications. In addition, where applicable, engineering documentation will 
be reviewed and compared to the installed system.
5.1 Specification & Purchase Documentation Review
Reference Attachment A 1
This section identifies a list of all specification and purchase documentation 
associated with the bioreactor and verifies that this documentation is complete 
and accurately describes the installed equipment.
5.2 Engineering & Safety Documentation Review
Reference Attachment A2
This section identifies a list of all engineering documentation associated with 
the bioreactor and verifies that this documentation is complete and accurately 
describes the installed equipment. The list should include the following 
documents: design specification, functional specification, P&ID's, electrical 
schematics, wiring diagrams, loop check documentation, equipment 
operation, maintenance manuals and spare parts lists.
List all safety valves, piping and ancillary equipment associated with this 
system, which need to be inspected for safety. Verification that inspection 
has been performed and is current must be recorded. (Include copies of this 
information in the validation file).
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5.3 Equipment List
Reference Attachment A3.
A list of all installed process and ancillary equipment based on information 
from the purchase orders and equipment specifications are included here. All 
items should be verified to ensure installation as specified. Equipment tag 
number, model number, serial number, location, manufacture, description, for 
each item should be indicated. Verification that preventative maintenance 
routines have been established for major equipment is also included.
5.4 Instrument List
Reference Attachment A4
A complete list of instruments designated critical or non- critical is included in 
this section.
Critical instruments pertain to those whose performance will affect the 
operation of the system or the quality attributes of the process material. 
Non-critical instruments are those provided for information or convenience 
purposes only. The information provided will include ID number, 
manufacturer, location, and description of each item.
These instruments should be uniquely identified and calibrated in accordance 
with Archport Ltd SOP’s. Copies of calibration documentation should be 
included or an indication provided of where it is located.
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5.5 Utilities Verification
Reference Attachment A5:
A complete list of utilities supplied to the equipment based on equipment 
specifications. The installation is inspected to verify that the correct utilities 
have been installed and that these meet specifications and equipment 
requirements.
5.6 Materials of Construction and lubricants list
Reference Attachment A6:
A complete list of materials of construction of equipment components and 
lubricants used is included in this section.
5.7 Control System Hardware
Reference Attachment A7
A complete list of major control hardware, including installed boards and 
communications cabling based on information from purchase orders and 
equipment specifications. Verification that the items have been installed as 
specified is included. Indication of hardware identification, location, 
manufacture, description for each item as is applicable. Also a system 
configuration drawing showing system architecture is included (if applicable).
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5.8 Input/ Output List I Loop Check Documentation
Reference Attachment A8
Verify existence and adequacy of loop checks performed by the installing 
contractor. Persons performing checks in field and console or operator 
interface should sign documentation. Loop checks should be used on P & 
ID’s. Include a reference as built copies of these in loop check documentation 
package.
5.9 Setpoints & Software Parameters
Reference Attachment A9:
Document set points and other operating parameter data installed in the 
control panel or on local instrumentation. Note the presence and adequacy of 
security measures against set point and software modification, if applicable.
5.10 Software Documentation
Reference Attachment A 10:
The revision of installed software is recorded. Record the installation location, 
including hardware model No., serial No., manufacturer, reference 
specifications, printed copy of annotated applications code (ladder logic etc.), 
including date and version, software functionality flowcharts and 
documentation of any modifications made to the software.
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5.11 Factory Acceptance Testing (FAT)
Reference Attachment A11:
List all audit and testing documentation including vendor audit report, test 
procedures and results of any testing performed on the system, including 
commissioning and Factory Acceptance Tests (FAT). Verify completeness of 
documentation and satisfactory resolution of any deviations or failed tests.
5.12 Standard Operating Procedures List
Reference Attachment A 12.
List all applicable SOP’s including procedures for operation, cleaning, 
maintenance, change control and calibration. Verify that these are in place, 
that they accurately describe the applicable equipment and that they are 
implemented by appropriate personnel. Training records should be available 
for all personnel operating the bioreactor.
5.13 Installation Qualification Discrepancy Summary
Reference Attachment A 13.
Document any discrepancies or variations noted during the execution of the 
Installation Qualification protocol. Include the resolution of these items and/or 
any item outstanding that will require resolution in the future.
If changes to the system are required, their implementation will follow the 
standard operating procedures. All such changes must be documented in this 
attachment and copies of other documentation relating to such changes must 
be referenced in this protocol.
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6. SUMMARY CONCLUSIONS
Signed Date
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Supplier : Vs o  ^ » i--—^
Type : U  ^ c r v v O i 'A .......... ,sJ..................
Type of process : C M  fL ita c f it -
Equipment Manual : xl^oece ec>sr \
...
...........iVwi..........
Manufacture, year : ....... .......................
Equipment no. : -?ó//OCX>G /C
■ \  -
......... ,>J....................
Archport Ltd information .
z i  i F )
Serial number :
••-=* ÌA ............ /w l.................
Facility :
t-f P ^ ^ y C r i > C - .  '  ^
Room location:
Supplier order reference.no.
/ ^ l A
External dimensions of 
equipment:
ft-?» p » S ■.'2. i
-  b - X 'Z .  -  O  > K
....... r> J ................
Internal dimensions of apparatus:
^ ¡ A
......... J f s t ..................
Preventive maintenance / O i  A ..........., r ^ .................
Certificate : ¿ !A
Comments;
z :
p g . _
Performed by: _'______ Dat8 l^>>.
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Name :
i t o l  tO lC
Supplier : PvpyH.iW<5-~=* .... .tA ......
Type : ¿2= .-=i t i - c o L e i ' i - .... ^ .......
Type of process :
G dA  cu>lk»u_ ... jìwI.......
Equipment Manual :
Manufacture, year : ... r*J........
Equipment no, . p-.tr/c>£ a c C /ó
Archport Ltd information : /Om ... ¡.o .......
Serial number Pui^& S  H S O S Z .  i ... .................
Facility : pfe "  "  ...... ........
Room location: ...... a ...........
Supplier order reference.no. .....
External dimensions of 
equipment:
.......................
Internal dimensions of apparatus:
H f ) ........In’...........
Preventive maintenance -o iQ ..... ...............
Certificate :
Comments:
T5f4L?  &
Performed by: C,
R ev iew ed  by: ■/.^  ^
Date [t>r ■$'( & 2_
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Description Identification Discrepancies
(Y /N )
Name : o iE O L ti I t ;  ¿>S ..........(Zt...... .
Supplier : .......Jirl........
Type : .........YSJ........
Type of process : QlW Cit, Hi.'Sfe- Xi*? ¡'iWii VcJkliX .........<>J...........
Equipment Manual : \I 10 see: ......J......
Manufacture, year : 1999
Equipment no. : Ì C 3 5 " ...................
Archport Ltd information : / 0 / 4 ...........£>...........
Serial number : V 16 ù é  O fZ9
\..........*»*...........
Facility : .........................
Room location: S  i 2 ^
\.........CiJ............
Supplier order reference.no. ........ i>A...........
External dimensions of 
equipment:
........../ i...........
Internal dimensions of apparatus: ........ /s?.........
Preventive maintenance ........ A ...........
Certificate :
Comments
Performed by: 
Reviewed by:
___________  ____  Date
A I , . A i
H tA ^  »AanAiAAc .______________ Date ï ï  H I " I  ¡L\,
■jaw s K ■' - tUi ;'^-j ;t ' *t?T '**•'" ' rV-
(M :e c o n f o r m it y
EU DECLARATION OF CONFORMITY
C€
The company Applikon Dependable Instruments B.V., 
Schiedam, The Netherlands, hereby certifies that the 
instrument:
ADI 1035 BSO CONSOLE
meets the requirements of 
89/336/EEC (Electromagnetic 
73/23/EEC (Low Voltage).
the LU Directives 
Compatibility) and
SOURCE OF THE SPECIFICATIONS:
89/336/EEC:
73/23/EEC
EN 50081-1 (1992) EMC Generic emission standard.
Residential, commercial and light industry.
EN 61000-3-2 (1995) EMC Limits for harmonic current 
emissions (equipment input current < 16A per phase).
EN 61000-3-3 (1995) EMC Limits concerning voltage
fluctuations and flicker for equipment having an input current 
up to and including 16 A per phase
EN 50082-1 (1992) EMC Generic immunity standard
Residential, commercial and light industry.
EN 50082-2 (1995) EMC Generic immunity standard.
Industrial environment (including table A.4).
EN 61010 Safety requirements for electrical equipment for 
measurement, control and laboratory use.
ing J. van Burg, President 23 .10 .96
Applikon Dependable Instruments De Brauwweg 13
3125 AE Schiedam The Netherlands
Tel.: (31 )(0)10-2983555 Fax.: (31 )(0)10-4379648
feU cp p lik o i
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Description Identification Discrepancies
(Y/N)
Name :
Supplier ..... /£>......
Type : c a  LCi "S. ..... *0 ......
Type of process : C e ll gaJ K ïtîî
Equipment Manual :
Manufacture, year : 3£jQO ...... ' / J .....
Equipment no. : ■p-. <r/ühttjïso ... ...........
Archport Ltd information :
Serial number : PU 1 OS’ o  I / ...... /O .....
Facility / k / : t ï p C î i^  f! .......¿j,.......
Room location: Sz-U
/ 0
Supplier order reference.no. <OiA
External dimensions of 
equipment:
Internal dimensions of apparatus kli A ........ J.?..........
Preventive maintenance AJ /A ........ ci.........
Certificate
Comments:
-  " -p^ ~—
Performed by: ___
Reviewed by: A
Date Æ/S-/C <r
o  òj.ìm ■, Date , 9  u
, ^ \Ca\\0() ?• 'pL1 ¿C l-t/'fâc:'
j  °tù.\J\€
'if
t f \c  1
AttAC'. n k'--* ~ ' f~). 2y
)E CONFORMITY
EU DECLARATION OF CONFORMITY
c c
The company Applikori Dependable Instruments B.V., 
Schiedam, The Netherlands, hereby certifies that the 
instrument:
AD! 1040/25 INTERFACE
89/336/EEC.
73/23/EEC
meets the requirements of the EU Directives 89/336/EEC 
(Electromagnetic Compatibility) and 73/23/EEC (Low 
Voltage).
SOURCE OF THE SPECIFICATIONS:
EN 50081=1 (1992) EMC Generic emission standard.
Residential, commercial and light industry 
EN 61000-3-2 (1995) EMC Limits for harmonic current
emissions (equipment input current < 16A per phase).
EN 61000-3-3 (1995) EMC Limits concerning voltage
fluctuations and flicker for equipment having an input current up 
to and including 16 A per phase.
EN 50082-1 (1992) EMC Generic immunity standard.
Residential, commercial and light industry.
EN 50082-2 (1995) EMC Generic immunity standard. Industrial 
environment (including table A .4 .1 , A .4 .2 , A .4 .3  and A .4.5).
EN 61010 Safety requirements for electrical equipment for 
measurement, control and laboratory use.
ing J. van Burg, President. December 13th 1999
Applikon Dependable Instruments De Brauwweg 13
3125 AE Schiedam The Netherlands
Tel.: (31 )(0)10-2983555 Fax.: (31)(0) 10-4379648
© ap p ik ofT
‘ DEPENDABLE INSTRUMENTS
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT : A3 Specification & Purchase 
Documentation Review
Pg S' of t f
D e s c r i p t i o n i d e n t i f i c a t i o n D i s c r e p a n c i e s
( Y / N )
Name :
.
.  .
......¿ W ..........
Supplier :
A p C i t - j  k
• V J
Type :
P m O O
.....* 3 ...........
Type of process :
t e l i  C l / l l c ' f C O
...... ¿ Ì ........
Equipment Manual : ..... s à ..........
Manufacture, year :
Equipment no. :
^  5 * \ O O C O C C  Ì
....................
Archport Ltd information :
y s i i A
....... ..............................
Serial number :
?  \ S \  7 9
%
................. ................................
Facility : ................. ................................
Room location: 1
. S \ z u
/ j
Supplier order reference.no. ................ 0 . ........................
External dimensions of 
equipment:
.................................................
Internal dimensions of apparatus: ...............< \ 3 .........................
Preventive maintenance .................* > . ......................
Certificate :
E CONFORM!
EU DECLARATION OF CONFORMITY
C€
89/336/EEC:
73/23/EEC
The company Applikon Dependable Instruments B.V., 
Schiedam, The Netherlands, hereby certifies that the 
instrument:
AD! 1032/1 STIRRER SPEED CONTROLLER
meets the requirements of the EU Directives 89/336/EEC 
(Electromagnetic Compatibility) and 73/23/EEC (Low 
Voltage).
SOURCE OF THE SPECIFICATIONS:
EN 50081-1 (1992) EMC Generic emission standard.
Residential, commercial and light industry.
EN 50081-2 (1993) EMC Generic emission standard. Industrial 
environment.
EN 50082-1 (1992) EMC Generic immunity standard. 
Residential, commercial and light industry.
EN 50082-2 (1995) EMC Generic immunity standard. Industrial 
environment (including table A.4.1, A.4.2 A.4.3 and A.4.5).
EN 61000-3-2 (1995) EMC Limits for harmonic current 
emissions (equipment input current < 16A per phase).
EN 61000-3-3 (1995) EMC Limits concerning voltage 
fluctuations and flicker for equipment having an input current up 
to and including 16 A per phase.
EN 61010 Safety requirements for electrical equipment for 
measurement, control and laboratory use.
ing J. van Burg, President. 14.10.96
Applikon Dependable Instruments 
3125 AE Schiedam 
Tel.: (31)(0)10-2983555 Fax.: (31)(0)10-4379648
De Brauwweg 13 
The Netherlands
I d  g p p K o rf
DEPENDABLE tNSTRMftfeK?S
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT : A4 Instrument List Pg ! of \
1 Critical Instruments
Component Function Type Tolerance Serial Last Discrepancies
No. Calibration (Y/N)
Date
................................... . 0 ; ; ^S j OCWpi ................................................. ...............
¿C V -J  TEC*
fentofd&  ù-.\k.?A. ............................. Nf
WveVb
Wxto&àfc. .C^piifô. û.r.\ç>.q%. 'Z7/Æ Q& ............................A
OF 0 * 1 0 0 * . *
\< £Ô fiÀ /^ s -
................................... '¿ Z M fà ç o l..................................a)..
Date /J /s jÙ Z  - 
Date ?J W  jo  L-
Performed by: 
Reviewed by:
' Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT : A4 Instrument List Pg I of i
2 Non-Critical Instruments
Component Function Type Range Tolerance Serial Last Discrepancies
no- Calibration (Y/N) 
Date
Performed by:
R ev iew ed  by: û
Date
D ate
li/s V o ^  -
5H l& l02 . 
(V Uil 7 Lj_
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT: A5 Utilities Verification Pg I of }
Utility Location / 
Source
Specified Actual Method Verified by / 
Date
O a SXZbr
•piScr/l AecHpef
0% & i6ie/r?s
¿ee
<5F *^ietv?
$zAP>^> S lZ k
fee-in PzciAfozr ' p • i ¿jpeoili eif
‘St’fe i/fljr.(Er)-7t6sj,
6 f-
■£*.iSTerv?
(S)d>.yb s a h
•pa>.-vi Ae 
COz BilSTErr?
■ -i - / 
iS(p@Ci (w? i
¿ ee  \!fli-iDpn& C ^ r
z i W o i
S \Z k
f^ XYiY)
(6,fsrervf
$ee i^wO^T/cS
O f QpfS=*
31/ SsTiii^
PoiieR- S^Pf1{i 5 \ z k z-z-oX i fyi £peaffecl
See \Jm-vDfrnc^
i’P
i3s<=> T & » v - \ ^ 1 ?  t o  z~ .
Performed by: , ___________  Date ?9/? /Q  cL '
a  1 V J  . ( | ^
Reviewed by: ___________  Date 2..-%\
Archport Ltd 
Protocol No.: 261G-29-IQ-004
ATTACHMENT : A6 Material of Construction / Lubricant List Pg I of Ì
Equipment As specified As Supplied / 
Installed
Acceptable (Y/N) Verified by
'fìc-.iC,'' a U C_A T6.' iVb
3 fe e u r i& D 4
Qieè-l
S éM î» Vfo
fW ’ p  • \_5pcA •Ittëi ( H
fcSï-
SncEéJC-
Ai6tïvUilv|
S red l . p • î 
ip 'C .V Æ '! i 6 4 -
1
Lubricant List:
Equipment As specified As Supplied / 
Installed
Acceptable (Y/N) Verified by
Spatri. Gefef><ie
+tefifc isW 
u-iL \ z a i* i i
6f*scA^‘—
CrîÇCkJr^ 3^'-' . 1
< %  .
Performed by:
R ev iew ed  by:
eàM i
A
Date
D ate
Archport Ltd 
Protoco! No,: 2610-29-1Q-004
ATTACHMENT: A7 Control System Hardware Pg I of I
Equipment ID #:
f in i  IQkts
Location:
_____S V t U _............
Description :
7gC-L_____ __________________
Manufacturer:
f c p p u k g  _________________
Model # /Serial #:
^  IQCOOO/O I U / ù ï  WÛZM
Equipment ID #:
BOX \CUïfz->
Location:
(W -rfP C ^ T  > ^ \Z U ________
Description :
6:,<±7£Ot-. ÙajiJ
Manufacturer:
Appu  kc ^ ______________
Model # /Serial #:
zs-icm co a zc i / P u ¡ Q S Q i i
Equipment ID #:
ÏÏlQ C_&r^hQL& P m  îCC^ S? 
Location:
A r c ^ p o î ^ t ________ ^ ¿ 4 ________________
Description :
¿cATgQL____iiûitX________
Manufacturer:
fìp ^ u lW d / ^ ______________
Model # /Serial #:
l ô ^ Ç T ____l f > i ^ U é O / £ cì
Performed by:
} ^ '
R ev iew ed  by: P ’ m i.,a .a D ate
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT : A8 Input/Output List /Loop Check 
Documentation
Pg ( of !
Input Listing Output Listing As Supplied / 
Installed
Acceptable (Y/N) Verified by
y
s '/
S'
t ,
r r
/
/
Loop Check Certifice 
Available (Y/N)
As Supplied / 
Installed
Acceptable (Y/N) Verified by
. .__ /  ..........
Performed by:__  , _____ __________  Date ^
A C d . L
Reviewed by: U- _____ _________  Date ( I  ?
National Celi & Tissue culture Centre 
Protocol No.: 2610-29-IQ-004
ATTACHMENT : A9 Set Points & Software Parameters Pg i of l
ln<îtri impnt/Fm linmpnt I n Ar>l io  t  o  L ^s-1 06 OC&Ï O )
Parameter/Setpoint: - c >3 1
Inspected bv: Date: /p jto jû ï 1Discrepancies (Y/NÌ ^
In.Qtrnmftnt/Fniiinmfint 1 R • do/JTPOJ^f*- (¿ /2  23)
Parameter/Setpoint: ^  ^  ^  v  /Cm fee&i ^  ,X*S> 09/
Inspected bv: Date: p j t o / o } Discreoancies (Y/N} a /
Comments :
Document any discrepancies on attachment A13, 
Performed by:______
¿7
CÌ-IkM M  i y t - ................. Date
. I
• si j~^ iC ¿..
Arch port Ltd 
Protocol No.: 2610-29-IQ-G04
ATTACHMENT: A10 Software Documentation Pg t of S
SOFTWARE
TITLE
REF.
No
VERSION DATE
PRINTED
COPY
LOCATION
INSTALLATION
MODEL
No.
SERIAL
No.
MANU
FACTURER
SOFTWARE
FLOWCHARTS
nar« vîlÜPi "2 - ficcBpcin A]A »IA- fW<?LÌ M
■vr 1 7-'^ i
f tVT ( c t  Ö
- 3 - 1 »0 / / 1 iO/fl !\ppu Iço'^ M- - r
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT:A11 Factory Acceptance Testing (FAT) Pg i of i
X
rM
Performed by:  _ Date
Reviewed by: A  ___ Date •- ^  ^( • " l
I Archport Ltd 
Protocol No.: 2610-29-IQ-Q04
ATTACHMENT : A12 Standard Operating Procedures List Pg 1 of 1
Operating Procedure Title SOP No. Rev. Date Responsible
Department
Verified
by
Ivi'i cJ ^ ^
3  cmficxOiK y
(£3 k b&m&ciGii- irs»<r«wpcM0,;ii5 a
\0 f^Oii(SCK~or-^ Tuze 3
Gèi-U t/iü Çj Wr>¡2’ r^ ì
■p|3C«.33^ge' toe ¿rmi/ùiî-üj CV: i-ä-'*
4
0 &  U_ ¿U I_ T U 2 _ C  S"r^/AO^E£) - f ë t K ^ r ô O ^ f c  i="C>R
¿Lv^Lcuo^Ti-^Oj -me kuA 'ofrì~v€. J%l th<? 
U- B\oIZC I^CT C'Vt
S'
Date >3/e r to  z.
Date X H \ l u }
Performed by:
R ev iew ed  by: £ L m .v ; .
Archport Ltd 
Protocol No.: 2610-29-IQ-004
ATTACHMENT: A13 Installation Qualification Discrepancy 
Summary
Pg 1 of I
Reference:
Discrepancy/Variation:
Resolution:
Satisfactorily completed? (Y/N):
Signature Date
Reference:
Discrepancy/Variation:
/
/
Resolution:
/
/4 
/ _
/
/
---------------------L------------ J P * ----------------------------------
Satisfactorily completed? (Y/N):-----J—
Reference:
Discrepancy/Variation:
Signature Date
Resolution:
Satisfactorily completed? (V/N):
Performed by:
Reviewed by: A 'A
Signature
VA-A. r^ ~—
Date
Date e
Date Ì H Î 1 L  ;
Appendix VIII Operational Qualification
Note: Operational Qualification has not been completely signed off see discrepancy 
summary for reasons.
Title: Operational Qualification
Applikon 10 L Bioreactor, 
Bio 4 and Control System.
Company Archport Ltd.. Page:
Protocol No. 
Issue:
Date:
1 of 15
2610-29-00-00'! 
0
25-02-02
Operational Qualification 
Applikon 10 L Bioreactor (Z611000010)
Pre Execution. Signature Title Date
Prepared By: 
Catherese Fahey G é d ÿ  •
Research Scientist
/Ô'/e/i/'Xfà* . 
'</ ;/
Approved by:
hUAjArJ
Cathal O Grady ’
P
J w , j
Cell Culture 
Manager S c ( i ja L
Approved by: 
Anne Hannigan Û 7j‘"'t eaa
Validation
Supervisor
1 -f ■; ij  i
Approved by: 
Irene Cleary
Validation
Manager ,3-a-ìl, l o i
Post Execution Signature Title Date
Prepared By: 
Catherese Fahey
Research Scientist
//. -  /Dotât/ ¿Cfi -XJQ2
Approved by: 
Cathal O Grady
Cell Culture 
Manager
Approved by: 
Anne Hannigan
Validation
Supervisor
Approved by: 
Irene Cleary
Validation
Manager
Com pany Archport Ltd.. Page: 2 o f 15
Protocol No.: 2610-29-OQ-004 
Title: Operational Qualification Issue: 0
Applikon 10 L Bioreactor, Date: 25-02-02
Bio 4  and Control System.
Contents:
Page Number
1. Purpose 3
2. Scope 3
3. System Description 3
4. Pre-Protocol Checks 4
5. Operational Qualification 5
5.1 Configuration Table ADI 1060 5
5.2 Temperature Control 8
5.2.1 Cultivation Mode 8
5.2.2 Test Mode 8
5.3 pH Control 10
5.3.1 Test Mode 10
5.4 Dissolved Oxygen 11
5.4.1 Test Mode 11
5.5 Level Control 13
5.5.1 Test Mode 13
6. Discrepancy Summary 14
7. Conclusion 15
Title: Operational Qualification
Applikon 10 L Bioreactor, 
Bio 4 and Control System
Company Archport Ltd.. Page: 3 o f 15
Protocol No.: 2610-29-OQ-004 
Issue: 0
Date: 25-02-02
1. Purpose:
The purpose of the Operational Qualification (OQ) is to demonstrate that the 
Applikon 10 L Bioreactor and control units operate according to the design 
intent and manufacturers recommendations.
2. Scope:
The scope of the Operational Qualification includes the Applikon 10 L 
Bioreactor and control units. All other aspects of the mechanical and 
electrical installation of the unit and its assembly are included.
3. System Description:
The ADI 1060 Bio Controller, the ADI 1035 Bioconsole and the ADI 1040/25 
are used in unison for the process control of the 10 L Applikon bioreactor. 
The purpose of the ADI 1060 (Software version V1.3) is to monitor 
mammalian cell culture systems in an environment where pH, temperature, 
dissolved oxygen and mixing can be controlled.
The ADI 1035 Bioconsole is an actuator console that is used in combination 
with the ADI 1060 Bio Controller. It supports gas flow regulation, stirrer 
speed, pH control, dissolved Oxygen control, level control, temperature 
control, and liquid addition/withdrawal via pumps.
The ADI 1040/25 functions by connecting the ADI 1060 Bio controller with the 
bioreactor and their actuator consoles. The measured sensor signals are 
amplified in the 1040/25 and are transmitted to the Bio Controller through 
serial communication. Depending on deviation from the set point, a controller 
output value is sent to an analog or digital output that will activate the actuator 
in the ADI 1035 in order to decrease the deviation from the set point.
The associated 10 L Bioreactor is a glass stirred tank reactor.
Title: Operational Qualification
Applikon 10 L Bioreactor, 
Bio 4 and Control System.
Company Archport Ltd. Page: 4 of 15
Protocol No. : 2610-29-GQ-004
issue: 0
Date: 25-02-02
4. Pre-protocol Checks:
Have QA representatives reviewed the iQ? Are ali critical discrepancy items 
resolved? Have outstanding discrepancy items been reviewed and have 
resolution actions put in place?
Yes/No: H e*  File Location; x o  st-x.u w>v...,
Verified By: _____  Date: ¿////Q2-________
Have Standard Operating Procedures been drafted for the operation of the 10 
L Bioreactor & Control System?
Yes/No: File Location: —
Verified By: ■ Date: ^
Detail relevant SOP numbers: —------
Has GMP training been provided to relevant maintenance and operational 
personnel? Have reports been completed and filed?
Yes/No: Do File Location — -
Verified By: _____  Date: ¿///Joz-
Is a maintenance program in place and has it been approved?
Yes/No: File Location —
Verified By: Date: \
Are all utility connections live and sufficient to support normal operation? Is 
unit prepared for start up and where applicable has basic first charges of oil 
etc. have been added to commence OQ attributes.
Yes/No: /£■?______  File Location - —
Verified By: Date: a / h / o  «
Comments:
Siqned:
à
Date:
Approved By: Date:
Com pany Archport Ltd.. Page: 5 of 15
Protocol No.: 2610-29-OQ-004 
Title: Operational Qualification Issue: 0
Applikon 10 L Bioreactor, Date: 25-02-02
Bio 4 and Control System.
5. Operation Qualification
5.1 Configuration Table AD11060
□  Fill in the settings from the ADI 1060 controller in the tables below. 
Sensor Cards
PH
Low Alarm ,2
High Alarm / X
P gain ZOÙ
I (time) 0
D (time) 0
Bias 0
Deadzone oto
TEMPERATURE
Low Alarm
High Alarm 3$'
P gain XÓ
I (time)
D (time) Ù
Bias Ù
Deadzone
0
Performed by: 
Reviewed by:
Date ¿f - U '02- 
D a t e _________
Com pany A rchport Ltd.. Page: 6 of 15
Protocol No.: 2610-29-OQ-004 
Title: O pera to ria ! Qualification Issue: 0
Applikon 10 L Bioreactor, Date: 25-02-02
Bio 4 and Control System.
D I S S O L V E D  O X Y G E N
L o w  A l a r m
se>
H i g h  A l a r m 55
P  g a i n ¡0
i  ( t i m e )
( )
D (time) 0
Bias 0
Deadzone 5'
Digital Outputs:
O U T P U T F U N C T I O N L O W  % H I G H  % C Y C L E  T I M E  
( S E C S )
D O S E
1,3 0 2  V a l v e 0 100 3 0 ---------------
1,4 C 0 2  V a l v e 0 100 5
2,1 B a s e  P u m p 0 100 /Ó
2,3 H e a t i n g 0 100
3 Ù
Analog Outputs:
OUTPUT FUNCTION MIN VALUE (MA) MAX VALUE (MA)
1 S t i r r e r <0
2 F e e d p u m p 90
3 F e e d p u m p  2 0 'AO
4 p H  R e c o r d e r 0 00
5 T e m p .  R e c o r d e r 0 ZO
6 D 0 2  R e c o r d e r
0 * 0
Titte: Operational Qualification
Applikon 10 L Bioreactor, 
Bio 4  and Control System.
Company Archport Ltd. Page: 7 of 15
Protocol No. ■ 2610-29-OQ-004
Issue: 0
Date: 25-02-02
Serial Communications:
AD11040/25 COMMUNICATION SETTINGS
Baudrate Parity Stobit Databit Device
1 / n o o /do (
HOST COMMUNICATIONS SETTINGS
RS //ÇÇ- Baudrate Parity Stobit Databit Device
1 / fx o o r3o / 1 -
Performed by: __* ______________ ___________ Date
Reviewed by: ____________________________________  Date __________
Company A rchport Ltd.. Page: 8 o f 15
Protocol No.' 2610-29-OQ-Q04 
Title: Operational Qualification Issue: 0
Applikon 10 L Bioreactor, Date: 25-02-02
Bio 4 and Control System
5.2 Temperature Control
5.2.1 Cultivation Mode
□  Control Temperature inside bioreactor at 37°C during cultivation, with a 
stirrer speed of 100 rpm for at least 3 hours.
PID Settings:
TEMPERATURE °C
P 3 0
1 US'
D O
Bias 0
5.2.2 Test Mode:
□  Start the temperature controller on ADI 1060.
□  Create "stepresponses" In Bioexpert changing the temperature setpoint 
using a profile as mentioned in the table below.
□  The criteria for overshoot during cooling and heating are 2°C and within an 
hour after reaching the set-point the temperature must be stable (+/- 
0.2°C).
□  Make a trend, record operator actions, alarms and periodical data. Report 
on the results.
Title: Operational Qualification
Applikon 10 L Bioreactor, 
Bio 4 and Control System.
Company Archport Ltd, Page: 9 of 15
Protocol No : 2610-29-QQ-004 
Issue: 0
Date: 25-02-02
SETPOINT CHANGE DATE SIGN INSPECTOR CHECK: PASS/FAIL
37°C •• >  31 °C
À -ft' 02
31 °C >35°C Û-//-Û2 fit&b
35°C ~ >37°C U-//Ô2
37°C >32°C U'K'0 2 ô iü h j
32°C ....>31°C L'H'0 2 a h i, PaSS
31°C >37°C k-tl-01 .— (■&£■/>— pùés
Comments:
QiMm Tesr u)o.z>i toc'V Ca z& o  ac-r M pezïüzty>£.o ._______
A ire ?  z u t \c w i* ^  r u e  5i£trc>//JT  ryyg re m ?  *qpt ‘J rM L t i  Y- ¿C<L )  I m-vx
arAW /»-^ uJfta. PACAIAGX> A)PTHt^> X / M ^  -, ¡G iii -3iU - HflVt? ~tC >V- f r i f g A T e iï  l l ï i ' j  
¿Jmrtt» O f V -Ù -b 'C ,  „ „ ___[ \ i .  T C P  Fflg 3C»7£ O f w
pci^ t__ç»ipna<u:£>
+
Performed by: 
Reviewed by:
Date ■ /!" '( '.} 
Date
T emp sTem  
degsC degsC  
40 40l
1 8
16 24
time
32 40
Time Temp sTem Time T e m p s T e m
h : m degs C degs C h:m d e g s  C d e g s  C
c://MONOCAL.frm
0 30 28.6 37 1:02 36.8 37
0:31 28.8 37 1:03 37 37
0:32 29 37 1 04 37.1 37
0 33 29.3 37 105 37.2 37
0 34 29.5 37 1:06 37.4 37
0'3f- 29.7 37 1 07 37.5 37
0:36 30 37 1 08 37.6 37
0 37 30.1 37 1:09 37.7 37
0 38 30.3 37 1:10 37.7 37
0 39 30.6 37 1:11 37.7 37
0 40 30.8 37 1.12 37.6 37
C41 30.9 37 1.13 37.6 37
0 42 31.2 37 1.14 37.6 37
0 43 31.5 37 1:15 37.5 37
<}£/.< 31.8 37 1.16 37.5 37
' i  45 32.1 37 1:17 37.5 37
' <15 32.3 37 1 18 37.4 37
‘ 4“ 32.5 37 1.19 37.4 37
'! 4r : 32.9 37 1:20 37.4 37
0-£C 33.2 37 1:21 37.4 37
•» ?* 33.5 37 1 22 37.4 37
•v 5 ' 33.8 37 1:23 37.5 37
-V 34.1 37 1 24 37.5 37
34.4 37 1:25 37.6 37
34.8 37 1 26 37.6 37
35.1 37 1.27 37.5 37
35.4 37 1:28 37.5 37
35.6 37 1:29 37.5 37
-V 35.9 37 1 30 37.4 37
• f;’; 36.1 37 1:31 37.4 37
364 37 1 32 37.4 37
36.6 37 1 33 37.4 37
lime Temp stem
h:m degs C degs C
1:34 37.4 37
1-35 37.4 37
1 36 37.5 37
1 37 37.5 37
1.38 37.6 37
1:39 37.6 37
1:40 37.6 37
1 41 37.5 37
1-42 37.5 37
1:43 37.5 37
1.44 37 4 37
1-45 37.4 37
1:46 37.4 37
1:47 37.4 37
1.48 37.4 37
1.49 37.4 37
1-50 37.4 37
V51 37.5 37
1-52 37.5 37
1 53 37.6 37
1:54 37.5 37
1.55 37.5 37
1:56 37.5 37
1:57 37.4 37
1 58 37.4 37
1 59 37.4 37
2:00 37.4 37
2:0; 37.4 37
2:02 37.4 37
2:03 37.5 37
2:04 37.5 37
2:05 37.5 37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37
37.5 37 2:41 37.4
37.5 37 2:42 37.5
37.5 37 2:43 37.5
37.4 37 2:44 37.5
37.4 37 2:45 37.5
37.4 37 2:46 37.5
37.4 37 2:47 37.4
37.4 37 2:48 37.4
37.4 37 2:49 37.4
37.4 37 2:50 37.4
37.5 37 2:51 37.4
37.5 37 2:52 37.4
37.5 37 2:53 37.4
37.5 37 2:54 37.4
37.5 37 2:55 37.4
37.5 37 2:56 37.5
37.4 37 2:57 37.5
37.4 37 2:58 37.5
37.4 37 2:59 37.5
37.4 37 3:00 37.4
37.4 37 3:01 37.4
374 37 3:02 37.4
37.4 37 3:03 37.4
37.5 37 3:04 37.4
37.5 37 3:05 37.4
37.5 37 3:06 37.4
37.5 37 3:07 37.4
37.5 37 3:08 37.4
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5.3 pH control:
PID settings:
PH CONTROL
P
¡ 0 0
1
0
D 0
Bias A
5.3.1 Test Mode:
□  Start the pH control on the AD11060.
□  Connect a pH simulator (setpoint 7,0 pH).
□  Check the CO (control outputs), which are mentioned in table below and 
fill out the results.
□  Check the correct function of the actuators.
inc •îjtA'Zt t'A iû  Aafto>v>fc ¿— ¡4 •
SET POINT 
CHANGE
CO/VALUE 
(CO %)
CHECK
ACTUATOR
PASS/FAIL
SET
POINT
CHANGE
CO 1 PUMP 
BASE
CHECK
ACTUATOR
PASS/FAIL
S® /oo pas*? 4 TOO /ài? 5
7  9tfrùlntn . /ÛO Pash
5
/OO
'till/H $7 ¡00 PaS*, 6 /O Q Pa^5
/OO 9 fOO fo t o
AO jj
C& “Y
J ,  -H-V 7
/oo Fa*} 10 /0 0 Pa&s
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5.4 DO control
PID settings:
d o 2 c o n t r o l
p /O
1 0
D 0
BIAS
0
5.4.1 Test Mode
□  Start the DO controlier in the AD11060
□  Connect a DO-simulator (setpoint 25%)
□  Check the CO (control output and fill out the results in the table below).
□  Check the right function of the actuator.
SIMULATOR AIR
VALVEM
(CO)%‘
CHECK
ACTUATOR
PASS/FAIL
STIRRER SPEED
(CO%)
CHECK
ACTUATOR
PASS/FAIL
0 JOO Fa
I50 Ò
SIMULATOR N2 VALVE (CO%) CHECK ACTUATOR PASS/FAIL
0 0
5°
fOO feaS
Comments: Qp> s&o________£)F-f ^
_____________  ______
ríteC~ í
ù4r
*tßfc£. .
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%
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5.5 Level Control:
5.5.1 Test Mode
□  Setpoint level: contact
□  Move the level detector on the vessel in and out the medium
□  Check if the level card is reaching from contact to no contact showing on 
the AD11060 screen and fill out the results in the table below.
LEVEL READING SCREEN  ADI1060 PASS/FAIL
Contact Contact
No Contact No Contact 9(kbb
Comments:
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